

5-30-00

A

Please type a plus sign (+) inside this box. → ☒

PTO/SB/05 (2/98)

JC833 U.S. PTO  
05/26/00UTILITY  
PATENT APPLICATION  
TRANSMITTAL

Only for new nonprovisional applications under 37 C.F.R. § 1.53(b)

Attorney Docket No.	LUD 5353.5 DIV (10016355)
First Inventor or Application Identifier	Boon et al.
Title	ISOLATED NUCLEIC ACID MOLECULES CODING FOR TUMOR REJECTON ANTIGEN PRECURSOR MAGE-3 AND USES THEREOF
Express Mail Label No.	EL227321857US

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. ☒ \*Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original and a duplicate for fee processing)
2. ☒ Specification (preferred arrangement set forth below) Total Pages 85
- Descriptive title of the Invention
  - Cross References to Related Applications
  - Reference of Microfiche Appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
3. ☒ Drawing(s) (35 U.S.C. 113) Total Sheets 16
4. ☒ Oath or Declaration Total Pages 3
- a. ☐ Newly executed (original or copy)
  - b. ☒ Copy from a prior application (37 C.F.R. § 1.63(d))  
(for continuation/divisional with Box 17 completed)
  - i. ☐
- DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s)  
named in the prior application, see 37 C.F.R. §§  
1.63(d)(2) and 1.33 (b)
5. ☒ Incorporation By Reference (useable if Box 4b is checked)  
The entire disclosure of the prior application, from which a copy of the oath or  
declaration is supplied under Box 4b, is considered to be a part of the disclosure of  
the accompanying application and is hereby incorporated by reference therein

ADDRESS TO: Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

6. ☐ Microfiche Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)
- a. ☐ Computer Readable Copy
  - b. ☒ Paper Copy (identical to computer copy)
  - c. ☒ Statement verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 C.F.R. § 3.73(b) Statement (when there is an assignee) ☒ Power of Attorney
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☒ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
14. ☐ \*Small Entity Statement(s) (PTO/SB/09-12) ☐ Statement filed in prior application,  
Status is proper and desired
15. ☐ Certified Copy of Priority Document(s)
16. ☐ Other.

\* NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY  
FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF  
ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28)

## 17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:


☐ Continuation ☒ Divisional ☐ Continuation-in-part (CIP) of prior application No: 09/404,026 (9/23/99)

Prior application information: Examiner: Group / Art Unit:

## 18. CORRESPONDENCE ADDRESS

☐ Customer Number or bar code label (Insert Customer No. or Attach bar code label here) or ☒ Correspondence address below

Name	FULBRIGHT & JAWORSKI LLP				
Address	666 FIFTH AVENUE				
City	NEW YORK	State	NEW YORK	ZIP Code	10103
Country	USA	Telephone	212-318-3000	Fax	212-752-5958

Name (Print/Type)	NORMAN D. HANSON	Registration No. (Attorney/Agent)	30,946
Signature		Date	May 26, 2000

VIA EXPRESS MAIL

"Express Mail" mailing label Number EL227321857US

Date of Deposit May 26, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under CFR 1.10 on the date indicated above, and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

FULBRIGHT & JAWORSKI L.L.P.

By:

*[Signature]*

ATTY. DOCKET NO: LUD 5353.5 (10016355)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Boon, et al

Serial No. : TO BE ASSIGNED

Filed : HEREWITH

For : Isolated Nucleic Acid Molecules Coding For Tumor Rejection Antigen Precursor Mage-4 and 41 And Uses Thereof

Group Art Unit : NOT YET ASSIGNED

Examiner : NOT YET ASSIGNED

May 26, 2000

Hon. Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

**PRELIMINARY AMENDMENT**

Prior to examination, please amend this application as follows:

**IN THE TITLE**

Change "MAGE-3" to -- MAGE-4 and 41 -- .

**IN THE SPECIFICATION**

Page 1, line 6: after "is" add -- a divisional of Serial No.09/404,026, filed September 23, 1999, which is a divisional of Serial No. 08/967,727, filed on November 27, 1997, now U.S. Patent No.6,025, 474, which is a divisional of Serial No. 08/037,230, filed March 26, 1993, now U.S. patent No. \_\_\_\_\_ which --

line 9: after "1991" add -- now U.S. Patent No. 5,342,774 --

Page 44, line 33: change "TRA" to -- TRAP --.

**IN THE CLAIMS**

CANCEL claims 1-21 without prejudice

ADD claims 22-37 which follow:

Claim 22. An isolated nucleic acid molecule which encodes a tumor rejection antigen precursor, or a fragment thereof, the complementary sequence of which hybridizes, under stringent conditions, to the nucleotide sequence set forth in SEQ ID NO:13, 14 or 15.

Claim 23. The isolated nucleic acid molecule of claim 22, wherein said isolated nucleic acid molecule is genomic DNA.

Claim 24. The isolated nucleic acid molecule of claim 23, consisting of SEQ ID NO:13 or 14.

Claim 25. The isolated nucleic acid molecule of claim 22, wherein said isolated nucleic acid molecule is cDNA.

Claim 26. The isolated nucleic acid molecule of claim 25, comprising the nucleotide sequence of SEQ ID NO:15.

Claim 27. The isolated nucleic acid molecule of claim 22, comprising mRNA.

Claim 28. An expression vector comprising the isolated nucleic acid molecule of claim 22, operably linked to a promoter.

Claim 29. The expression vector of claim 28, wherein said promoter is an inducible promoter.

Claim 30. An expression vector comprising the isolated nucleic acid molecule of claim 25, operably linked to a promoter.

Claim 31. The expression vector of claim 30, wherein said promoter is inducible.

Claim 32. A host cell transfected or transformed with the isolated nucleic acid molecule of claim 22.

Claim 33. The host cell of claim 32, wherein said cell is a fibroblast.

Claim 34. A host cell transfected or transformed with the isolated nucleic acid of claim 25.

Claim 35. The host cell of claim 32, wherein said host cell is a mammalian cell.

Claim 36. The host cell of claim 34, wherein said host cell is a mammalian cell.

Claim 37. An isolated protein encoded by the isolated nucleic acid molecule of claim 22.

### **REMARKS**

Entry of the foregoing amendment is requested. The changes to the specification are minor. For example, review of page 44 will show that, on line 30, "TRAP fragments" is recited, so the change to line 33 is appropriate.

This application properly claims priority to, inter alia, Serial No. 807,043, filed December 12, 1991. A review of that application will show that the examiner required applicants




to elect a species of MAGE, and applicants elected MAGE-1. In the present case, MAGE-4 and 41 are elected. In view of the examiner's action, double patenting does not lie.

Claim 22, and hence all other claims, are supported via, e.g., page 34, lines 24-28 of the specification.

Entry of the foregoing amendment is requested.

Respectfully submitted,

FULBRIGHT & JAWORSKI L.L.P.

By   
Norman D. Hanson  
Reg. No. 30,946

666 Fifth Avenue  
New York, New York 10103  
(212) 318-3000

009250" E452560

ISOLATED NUCLEIC ACID MOLECULES CODING FOR  
TUMOR REJECTION ANTIGEN PRECURSOR MAGE-3  
AND USES THEREOF

5 RELATED APPLICATION

This application is a continuation-in-part of PCT Application PCT/US92/04354 filed on May 22, 1992 designating the United States, which is a continuation-in-part of Serial Number 807,043, filed December 12, 1991, which is a  
10 continuation-in-part of Serial Number 764,364, filed September 23, 1991, which is a continuation-in-part of Serial Number 728,838, filed July 9, 1991, which is a continuation-in-part of Serial Number 705,702, filed May 23, 1991, and now abandoned.

15 FIELD OF THE INVENTION

This invention relates in general to the field of immunogenetics as applied to the study of oncology. More specifically, it relates to the study and analysis of mechanisms by which tumors are recognized by the organism's immune system such as through the presentation of so-called tumor rejection antigens, and the expression of what will be referred to herein as "tumor rejection antigen precursors" or "TRAPs". Most specifically, it refers to nucleic acid  
20 molecules coding for one such TRAP, i.e., MAGE-3, which is processed to a tumor rejection antigen or "TRA" presented by HLA-A1 molecules.

25 BACKGROUND AND PRIOR ART

30 The study of the recognition or lack of recognition of cancer cells by a host organism has proceeded in many different directions. Understanding of the field presumes some understanding of both basic immunology and oncology.

Early research on mouse tumors revealed that these  
35 displayed molecules which led to rejection of tumor cells when transplanted into syngeneic animals. These molecules are "recognized" by T-cells in the recipient animal, and provoke

5 a cytolytic T-cell response with lysis of the transplanted  
cells. This evidence was first obtained with tumors induced  
in vitro by chemical carcinogens, such as methylcholanthrene.  
The antigens expressed by the tumors and which elicited the T-  
cell response were found to be different for each tumor. See  
Prehn, et al., J. Natl. Canc. Inst. 18: 769-778 (1957); Klein  
et al., Cancer Res. 20: 1561-1572 (1960); Gross, Cancer Res.  
3: 326-333 (1943), Basombrio, Cancer Res. 30: 2458-2462 (1970)  
10 for general teachings on inducing tumors with chemical  
carcinogens and differences in cell surface antigens. This  
class of antigens has come to be known as "tumor specific  
transplantation antigens" or "TSTAs". Following the  
observation of the presentation of such antigens when induced  
by chemical carcinogens, similar results were obtained when  
tumors were induced in vitro via ultraviolet radiation. See  
Kripke, J. Natl. Canc. Inst. 53: 333-1336 (1974).

While T-cell mediated immune responses were observed for  
the types of tumor described supra, spontaneous tumors were  
thought to be generally non-immunogenic. These were therefore  
believed not to present antigens which provoked a response to  
the tumor in the tumor carrying subject. See Hewitt, et al.,  
Brit. J. Cancer 33: 241-259 (1976).

009250 2456255  
25 The family of tum<sup>-</sup> antigen presenting cell lines are  
immunogenic variants obtained by mutagenesis of mouse tumor  
cells or cell lines, as described by Boon et al., J. Exp. Med.  
152: 1184-1193 (1980), the disclosure of which is incorporated  
by reference. To elaborate, tum<sup>-</sup> antigens are obtained by  
mutating tumor cells which do not generate an immune response  
in syngeneic mice and will form tumors (i.e., "tum<sup>+</sup>" cells).  
30 When these tum<sup>+</sup> cells are mutagenized, they are rejected by  
syngeneic mice, and fail to form tumors (thus "tum<sup>-</sup>"). See  
Boon et al., Proc. Natl. Acad. Sci. USA 74: 272 (1977), the  
disclosure of which is incorporated by reference. Many tumor  
types have been shown to exhibit this phenomenon. See, e.g.,  
35 Frost et al., Cancer Res. 43: 125 (1983).

It appears that tum<sup>-</sup> variants fail to form progressive  
tumors because they elicit an immune rejection process. The

evidence in favor of this hypothesis includes the ability of "tum<sup>-</sup>" variants of tumors, i.e., those which do not normally form tumors, to do so in mice with immune systems suppressed by sublethal irradiation, Van Pel et al., Proc. Natl. Acad. Sci. USA 76: 5282-5285 (1979); and the observation that intraperitoneally injected tum<sup>-</sup> cells of mastocytoma P815 multiply exponentially for 12-15 days, and then are eliminated in only a few days in the midst of an influx of lymphocytes and macrophages (Uyttenhove et al., J. Exp. Med. 152: 1175-1183 (1980)). Further evidence includes the observation that mice acquire an immune memory which permits them to resist subsequent challenge to the same tum<sup>-</sup> variant, even when immunosuppressive amounts of radiation are administered with the following challenge of cells (Boon et al., Proc. Natl. Acad. Sci. USA 74: 272-275 (1977); Van Pel et al., supra; Uyttenhove et al., supra). Later research found that when spontaneous tumors were subjected to mutagenesis, immunogenic variants were produced which did generate a response. Indeed, these variants were able to elicit an immune protective response against the original tumor. See Van Pel et al., J. Exp. Med. 157: 1992-2001 (1983). Thus, it has been shown that it is possible to elicit presentation of a so-called "tumor rejection antigen" in a tumor which is a target for a syngeneic rejection response. Similar results have been obtained when foreign genes have been transfected into spontaneous tumors. See Fearson et al., Cancer Res. 48: 2975-1980 (1988) in this regard.

A class of antigens has been recognized which are presented on the surface of tumor cells and are recognized by cytotoxic T cells, leading to lysis. This class of antigens will be referred to as "tumor rejection antigens" or "TRAs" hereafter. TRAs may or may not elicit antibody responses. The extent to which these antigens have been studied, has been via cytolytic T cell characterization studies, in vitro i.e., the study of the identification of the antigen by a particular cytolytic T cell ("CTL" hereafter) subset. The subset proliferates upon recognition of the presented tumor rejection

antigen, and the cells presenting the antigen are lysed. Characterization studies have identified CTL clones which specifically lyse cells expressing the antigens. Examples of this work may be found in Levy et al., Adv. Cancer Res. 24: 1-59 (1977); Boon et al., J. Exp. Med. 152: 1184-1193 (1980); Brunner et al., J. Immunol. 124: 1627-1634 (1980); Maryanski et al., Eur. J. Immunol. 124: 1627-1634 (1980); Maryanski et al., Eur. J. Immunol. 12: 406-412 (1982); Palladino et al., Canc. Res. 47: 5074-5079 (1987). This type of analysis is required for other types of antigens recognized by CTLs, including minor histocompatibility antigens, the male specific H-Y antigens, and a class of antigens, referred to as "tum-" antigens, and discussed herein.

A tumor exemplary of the subject matter described supra is known as P815. See DePlaen et al., Proc. Natl. Acad. Sci. USA 85: 2274-2278 (1988); Szikora et al., EMBO J 9: 1041-1050 (1990), and Sibille et al., J. Exp. Med. 172: 35-45 (1990), the disclosures of which are incorporated by reference. The P815 tumor is a mastocytoma, induced in a DBA/2 mouse with methylcholanthrene and cultured as both an in vitro tumor and a cell line. The P815 line has generated many tum<sup>-</sup> variants following mutagenesis, including variants referred to as P91A (DePlaen, supra), 35B (Szikora, supra), and P198 (Sibille, supra). In contrast to tumor rejection antigens - and this is a key distinction - the tum<sup>-</sup> antigens are only present after the tumor cells are mutagenized. Tumor rejection antigens are present on cells of a given tumor without mutagenesis. Hence, with reference to the literature, a cell line can be tum<sup>+</sup>, such as the line referred to as "P1", and can be provoked to produce tum<sup>-</sup> variants. Since the tum<sup>-</sup> phenotype differs from that of the parent cell line, one expects a difference in the DNA of tum<sup>-</sup> cell lines as compared to their tum<sup>+</sup> parental lines, and this difference can be exploited to locate the gene of interest in tum<sup>-</sup> cells. As a result, it was found that genes of tum<sup>-</sup> variants such as P91A, 35B and P198 differ from their normal alleles by point mutations in the coding regions of the gene. See Szikora and Sibille, supra, and Lurquin et

al., Cell 58: 293-303 (1989). This has proved not to be the case with the TRAs of this invention. These papers also demonstrated that peptides derived from the tum<sup>-</sup> antigen are presented by the L<sup>d</sup> molecule for recognition by CTLs. P91A is presented by L<sup>d</sup>, P35 by D<sup>d</sup> and P198 by K<sup>d</sup>.

Prior patent applications PCT/US92/04354, U.S. Serial No. 807,043; 764,364; 728,838 and 707,702, all of which are incorporated by reference, describe inventions involving, inter alia, genes and other nucleic acid molecules which code for various TRAPs, which are in turn processed to tumor rejection antigen, or "TRAs".

The genes are useful as a source for the isolated and purified tumor rejection antigen precursor and the TRA themselves, either of which can be used as an agent for treating the cancer for which the antigen is a "marker", as well as in various diagnostic and surveillance approaches to oncology, discussed infra. It is known, for example, that tum<sup>-</sup> cells can be used to generate CTLs which lyse cells presenting different tum<sup>-</sup> antigens as well as tum<sup>+</sup> cells. See, e.g., Maryanski et al., Eur. J. Immunol 12: 401 (1982); and Van den Eynde et al., Modern Trends in Leukemia IX (June 1990), the disclosures of which are incorporated by reference. The tumor rejection antigen precursor may be expressed in cells transfected by the gene, and then used to generate an immune response against a tumor of interest.

In the parallel case of human neoplasms, it has been observed that autologous mixed lymphocyte-tumor cell cultures ("MLTC" hereafter) frequently generate responder lymphocytes which lyse autologous tumor cells and do not lyse natural killer targets, autologous EBV-transformed B cells, or autologous fibroblasts (see Anichini et al., Immunol. Today 8: 385-389 (1987)). This response has been particularly well studied for melanomas, and MLTC have been carried out either with peripheral blood cells or with tumor infiltrating lymphocytes. Examples of the literature in this area including Knuth et al., Proc. Natl. Acad. Sci. USA 86: 2804-2802 (1984); Mukherji et al., J. Exp. Med. 158: 240 (1983);

Hérin et al., Int. J. Canc. 39: 390-396 (1987); Topalian et al., J. Clin. Oncol 6: 839-853 (1988). Stable cytotoxic T cell clones ("CTLs" hereafter) have been derived from MLTC responder cells, and these clones are specific for the tumor cells. See Mukherji et al., supra, Hérin et al., supra, Knuth et al., supra. The antigens recognized on tumor cells by these autologous CTLs do not appear to represent a cultural artifact, since they are found on fresh tumor cells. Topalian et al., supra; Degiovanni et al., Eur. J. Immunol. 20: 1865-1868 (1990). These observations, coupled with the techniques used herein to isolate the genes for specific murine tumor rejection antigen precursors, have led to the isolation of nucleic acid sequences coding for tumor rejection antigen precursors of TRAs presented on human tumors. It is now possible to isolate the nucleic acid sequences which code for tumor rejection antigen precursors, including, but not being limited to those most characteristic of a particular tumor, with ramifications that are described infra.

Additional work has focused upon the presentation of TRAs by the class of molecules known as human leukocyte antigens, or "HLAs". This work has resulted in several unexpected discoveries regarding the field. Specifically in U.S. patent application Serial Number 938,334, the disclosure of which is incorporated by reference, nonapeptides are taught which are presented by the HLA-A1 molecule. The reference teaches that given the known specificity of particular peptides for particular HLA molecules, one should expect a particular peptide to bind one HLA molecule, but not others. This is important, because different individuals possess different HLA phenotypes. As a result, while identification of a particular peptide as being a partner for a specific HLA molecule has diagnostic and therapeutic ramifications, these are only relevant for individuals with that particular HLA phenotype. There is a need for further work in the area, because cellular abnormalities are not restricted to one particular HLA phenotype, and targeted therapy requires some knowledge of the phenotype of the abnormal cells at issue.

In U.S. Patent Application Serial Number 008,446, filed January 22, 1993 and incorporated by reference, the fact that the MAGE-1 expression product is processed to a second TRA is disclosed. This second TRA is presented by HLA-C10-molecules. The disclosure shows that a given TRAP can yield a plurality of TRAs.

In U.S. Patent Application Serial Number 994,928, filed December 22, 1992, and incorporated by reference herein, tyrosinase is described as a tumor rejection antigen precursor. This reference discloses that a molecule which is produced by some normal cells (e.g., melanocytes), is processed in tumor cells to yield a tumor rejection antigen that is presented by HLA-A2 molecules.

It was mentioned, supra, that different individuals possess different HLA types. It has also been found that the expression of particular MAGE genes is not always linked to particular disorders, or individuals of particular HLA types. Thus, one cannot state, e.g., that all melanoma patients will express MAGE-1 TRAP nor could one say categorically that MAGE-1 expression is limited to melanoma patients of type HLA-A1. Further, one cannot state that only one type of TRAP is expressed in individuals of a particular HLA type. No rules or guidelines can be pointed to which correlate any of these factors.

Thus, it is not expected that a second TRAP is processed to a TRAP which is presented by HLA-A1 molecules. It has now been found that in addition to MAGE-1, a TRA derived from MAGE-3 TRAP is presented by HLA-A1 molecules. This is shown in examples 37-40, which follow, together with a discussion of the ramifications of this discovery.

These and various other aspects of the invention are elaborated upon in the disclosure which follows.

#### **BRIEF DESCRIPTION OF THE FIGURES**

Figure 1 depicts detection of transfectants expressing antigen P815A.

Figure 2 shows the sensitivity of clones P1.HTR, PO.HTR, genomic transfectant P1A.T2 and cosmid transfectant P1A.TC3.1



to lysis by various CTLs, as determined by chromium release assays.

Figure 3 is a restriction map of cosmid C1A.3.1.

Figure 4 shows Northern Blot analysis of expression of gene P1A.

Figure 5 sets forth the structure of gene P1A with its restriction sites.

Figure 6 shows the results obtained when cells were transfected with the gene from P1A, either isolated from P815 or normal cells and then tested with CTL lysis.

Figure 7 shows lytic studies using mast cell line L138.8A.

Figure 8 is a map of subfragments of the 2.4 kb antigen E fragment sequence which also express the antigen.

Figure 9 shows homology of sections of exon 3 from genes mage 1, 2 and 3.

Figure 10 shows the result of Northern blots for MAGE genes on various tissues.

Figure 11 presents the data of Figure 13 in table form. Figure 12 shows Southern Blot experiments using the various human melanoma cell lines employed in this application.

Figure 13 is a generalized schematic of the expression of MAGE 1, 2 and 3 genes by tumor and normal tissues.

Figure 14 shows results from a chromium release assay using CTL clone 20/38 on various cell lines.

Figure 15 presents the result of assays undertaken to determine antigenic specificity of CTL clone 20/38.

Figure 16 shows the results obtained when a TNF release assay was carried out on various transfected cells.

#### **BRIEF DESCRIPTION OF SEQUENCES**

SEQ ID NO: 1 is cDNA for part of gene P1A.

SEQ ID NO: 2 presents coding region of cDNA for gene P1A.

SEQ ID NO: 3 shows non coding DNA for P1A cDNA which is 3' to the coding region of SEQ ID NO: 2.

SEQ ID NO: 4 is the entire sequence of cDNA for P1A.

SEQ ID NO: 5 is the genomic DNA sequence for P1A.

SEQ ID NO: 6 shows the amino acid sequence for the

antigenic peptides for P1A TRA. The sequence is for cells which are A<sup>+</sup> B<sup>+</sup>, i.e., express both the A and B antigens.

SEQ ID NO: 7 is a nucleic acid sequence coding for antigen E.

5 SEQ ID NO: 8 is a nucleic acid sequence coding for MAGE-1.

SEQ ID NO: 9 is the gene for MAGE-2.

SEQ ID NO: 10 is the gene for MAGE-21.

SEQ ID NO: 11 is cDNA for MAGE-3.

10 SEQ ID NO: 12 is the gene for MAGE-31.

SEQ ID NO: 13 is the gene for MAGE-4.

SEQ ID NO: 14 is the gene for MAGE-41.

SEQ ID NO: 15 is cDNA for MAGE-4.

SEQ ID NO: 16 is cDNA for MAGE-5.

SEQ ID NO: 17 is genomic DNA for MAGE-51.

SEQ ID NO: 18 is cDNA for MAGE-6.

SEQ ID NO: 19 is genomic DNA for MAGE-7.

SEQ ID NO: 20 is genomic DNA for MAGE-8.

SEQ ID NO: 21 is genomic DNA for MAGE-9.

SEQ ID NO: 22 is genomic DNA for MAGE-10.

SEQ ID NO: 23 is genomic DNA for MAGE-11.

SEQ ID NO: 24 is genomic DNA for smage-I.

SEQ ID NO: 25 is genomic DNA for smage-II.

#### DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

25 Many different "MAGE" genes have been identified, as will be seen from the sequences which follow the application. The protocols described in the following examples were used to isolate these genes and cDNA sequences.

"MAGE" as used herein refers to a nucleic acid sequence isolated from human cells. The acronym "smage" is used to describe sequences of murine origin.

When "TRAP" or "TRAs" are discussed herein as being specific to a tumor type, this means that the molecule under consideration is associated with that type of tumor, although not necessarily to the exclusion of other tumor types.

#### Example 1

In order to identify and isolate the gene coding for

antigen P815A, gene transfection was used. This approach requires both a source of the gene, and a recipient cell line. Highly transfectable cell line P1.HTR was the starting material for the recipient, but it could not be used without further treatment, as it presents "antigen A", one of four recognized P815 tumor antigens. See Van Pel et al., Molecular Genetics 11: 467-475 (1985). Thus, screening experiments were carried out to isolate cell lines which did not express the antigen and which nonetheless possessed P1.HTR's desirable qualities.

To do this, P1.HTR was screened with CTLs which were specific for each of tumor antigens A, B, C and D. Such CTLs are described by Uyttenhove et al., J. Exp. Med. 157: 1040-1052 (1983).

To carry out the selection,  $10^6$  cells of P1.HTR were mixed with  $2-4 \times 10^6$  cells of the CTL clone in a round bottom tube in 2 ml of medium, and centrifuged for three minutes at 150xg. After four hours at 37°C, the cells were washed and resuspended in 10 ml of medium, following Maryanski et al., Eur. J. Immunol. 12: 406-412 (1982). Additional information on the CTL assay and screening protocol, in general may be found in Boon et al., J. Exp. Med. 152: 1184-1193 (1980), and Maryanski et al., Eur. J. Immunol. 12: 406-412 (1982), the disclosure of which are incorporated by reference.

When these selections were carried out, a cell line variant was found which expressed neither antigen A or B. Additional selections with CTLs specific for antigen C then yielded a variant which also lacked antigen C. Please see figure 2 for a summary of the results of these screenings. The variant PO.HTR is negative for antigens A, B and C, and was therefore chosen for the transfection experiments.

The cell line PO.HTR has been deposited in accordance with the Budapest Treaty at the Institute Pasteur Collection Nationale De Cultures De Microorganismes, 28, Rue de Docteur Roux, 75724 Paris France, and has accession number I-1117.

This methodology is adaptable to secure other cell lines which are variants of a cell type which normally presents at

least one of the four recognized P815 tumor antigens, i.e.,  
antigens A, B, C and D, where the variants present none of  
antigens A, B and C. P1.HTR is a mastocytoma cell line, so it  
will be seen that the protocol enables the isolation of  
biologically pure mastocytoma cell lines which express none of  
P815 antigens A, B and C, but which are highly transfectable.  
Other tumor types may also be screened in this fashion to  
secure desired, biologically pure cell lines. The resulting  
cell lines should be at least as transfectable with foreign  
DNA as is P1.HTR, and should be selected so as to not express  
a specific antigen.

### Example 2

Previous work reported by DePlaen et al., Proc. Natl.  
Acad. Sci. USA 85: 2274-2278 (1988) the disclosure of which is  
incorporated by reference herein had shown the efficacy of  
using cosmid library transfection to recover genes coding for  
tumor antigens.

Selective plasmid and genomic DNA of P1.HTR were  
prepared, following Wölfel et al., Immunogenetics 26: 178-187  
(1987). The transfection procedure followed Corsaro et al.,  
Somatic Cell Molec. Genet 7: 603-616 (1981), with some  
modification. Briefly, 60  $\mu$ g of cellular DNA and 3  $\mu$ g of DNA  
of plasmid pHMR272, described by Bernard et al., Exp. Cell.  
Biol. 158: 237-243 (1985) were mixed. This plasmid confers  
hygromycin resistance upon recipient cells,  
and therefore provides a convenient way to screen for  
transfectants. The mixed DNA was combined with 940  $\mu$ l of 1 mM  
Tris-HCl (pH 7.5), 0.1 mM EDTA; and 310  $\mu$ l 1M  $\text{CaCl}_2$ . The  
solution was added slowly, and under constant agitation to  
1.25 ml of 50 mM Hepes, 280 mM NaCl, 1.5 mM  $\text{Na}_2\text{HPO}_4$ , adjusted  
to pH 7.1 with NaOH. Calcium phosphate - DNA precipitates  
were allowed to form for 30-45 minutes at room temperature.  
Following this, fifteen groups of PO.HTR cells ( $5 \times 10^6$ ) per  
group were centrifuged for 10 minutes at 400 g. Supernatants  
were removed, and pellets were resuspended directly into the  
medium containing the DNA precipitates. This mixture was  
incubated for 20 minutes at 37°C, after which it was added to

an 80 cm<sup>2</sup> tissue culture flask containing 22.5 ml DMEM, supplemented with 10% fetal calf serum. After 24 hours, medium was replaced. Forty-eight hours after transfection, cells were collected and counted. Transfected cells were selected in mass culture using culture medium supplemented with hygromycin B (350 ug/ml). This treatment selected cells for hygromycin resistance.

For each group, two flasks were prepared, each containing 8x10<sup>6</sup> cells in 40 ml of medium. In order to estimate the number of transfectants, 1x10<sup>6</sup> cells from each group were plated in 5 ml DMEM with 10% fetal calf serum (FCS), 0.4% bactoagar, and 300 ug/ml hygromycin B. The colonies were then counted 12 days later. Two independent determinations were carried out and the average taken. This was multiplied by 5 to estimate the number of transfectants in the corresponding group. Correction had to be made for the cloning efficiency of P815 cells, known to be about 0.3.

### Example 3

Eight days after transfection as described in example 2, supra, antibiotic resistant transfectants were separated from dead cells, using density centrifugation with Ficoll-Paque. These cells were maintained in non-selective medium for 1 or 2 days. The cells were plated in 96 well microplates (round bottom), at 30 cells/microwell in 200 ul of culture medium. Anywhere from 100-400 microwells were prepared, depending on the number of transfectants prepared. Agar colony tests gave estimates of 500-3000. After 5 days, the wells contained about 6x10<sup>4</sup> cells and replicate plates were prepared by transferring 1/10 of the wells to microplates which were then incubated at 30°C. One day later, master plates were centrifuged, medium removed, and 750 CTLs against P815 antigen A (CTL-P1:5) were added to each well together with 10<sup>6</sup> irradiated syngeneic feeder spleen cells in CTL culture medium containing 40 U/ml recombinant human IL-2, and HAT medium to kill stimulator cells. Six days later, plates were examined visually to identify wells where CTLs had proliferated. Where plates showed proliferating microcultures, aliquots of 100 ul

of the wells were transferred to another plate containing  $^{51}\text{Cr}$  labeled P1.HTR target cells ( $2 \times 10^3$  -  $4 \times 10^3$  per well), and chromium release was measured after 4 hours. Replicate microcultures corresponding to those showing high CTL activity were expanded and cloned by limited dilution in DMEM with 10% FCS. Five days later, about 200 clones were collected and screened with the CTL.P1:5 cell line, described supra, in a visual lysis assay. See figure 1A for these results.

In these experiments, three of the fifteen groups of transfectants yielded a few positive microcultures. These microcultures were tested for lytic activity against P1.HTR, as described supra. Most of the microcultures where proliferation was observed showed lytic activity. This activity was well above background, as shown in figure 1B. This figure summarizes data wherein two groups of cells (groups "5" and "14"), 400 and 300 microwells were seeded with 30 hygromycin resistant transfected cells. Amplification and duplication of the microcultures was followed by addition of anti-A CTL P1:5. Six days later, lytic activity against P1.HTR was tested. In the figure, each point represents lytic activity of a single microculture.

Duplicate microcultures corresponding to several positive wells were subcloned, and more than 1% of the subclones were found to be lysed by anti-A CTL. Thus, three independent transfectants expressing P815A were obtained from 33,000 hygromycin resistant transfectants. One of these lines, referred to hereafter as P1A.T2 was tested further.

The relevant antigen profile of P1A.T2 is shown in figure 2, this being obtained via anti-CTL assays of the type described supra.

#### Example 4

The CTL assays carried out for P1A.T2 demonstrated that it presented antigen A ("P815A"), and therefore had received the gene from P1.HTR. To that end, this cell line was used as a source for the gene for the antigen precursor in the following experiments.

Prior work had shown that genes coding for tum<sup>-</sup> antigens

could be recovered directly from transfectants obtained with a cosmid library. See DePlaen et al., Proc. Natl. Acad. Sci. USA 85: 2274-2278 (1988). This procedure was followed for recovery of the P815 gene.

5 Total genomic DNA of P1A.T2 was partially digested with restriction endonuclease Sau 3A1, and fractionated by NaCl density gradient ultracentrifugation to enrich for 35-50 kb DNA fragments, following Grosveld et al., Gene 10: 6715-6732 (1982). These fragments were ligated to cosmid arms of C2RB, 10 described by Bates et al., Gene 26: 137-146 (1983), the disclosure of which is incorporated by reference. These cosmid arms had been obtained by cleavage with SmaI and treatment with calf intestinal phosphatase, followed by digestion with BamHI. Ligated DNA was packaged into lambda phage components, and titrated on E. coli ED 8767, following Grosveld et al., supra. Approximately  $9 \times 10^5$  ampicillin resistant colonies were obtained per microgram of DNA insert.

15 The cosmid groups were amplified by mixing 30,000 independent cosmids with 2 ml of ED 8767 in 10 mM  $MgCl_2$ , incubated 20 minutes at 37°C, diluted with 20 ml of Luria Bertani ("LB") medium, followed by incubation for one hour. This suspension was titrated and used to inoculate 1 liter of LB medium in the presence of ampicillin (50 ug/ml). At a bacterial concentration of  $2 \times 10^8$  cells/ml ( $OD_{600}=0.8$ ), a 10 ml 20 aliquot was frozen, and 200 ug/ml chloramphenicol was added to the culture for overnight incubation. Total cosmid DNA was isolated by alkaline lysis procedure, and purified on CsCl gradient.

25 In these experiments, a library of 650,000 cosmids was prepared. The amplification protocol involved the use of 21 groups of approximately 30,000 cosmids.

#### Example 5

30 Using the twenty-one groups of cosmids alluded to supra, (60 ug) and 4 ug of pHMR272, described supra, groups of  $5 \times 10^6$  PO.HTR cells were used as transfectant hosts. Transfection was carried out in the same manner as described in the preceding experiments. An average of 3000 transfectants per 35

group were tested for antigen presentation, again using CTL assays as described. One group of cosmids repeatedly yielded positive transfectants, at a frequency of about 1/5,000 drug resistant transfectants. The transfectants, as with P1A.T2, also showed expression of both antigen A and B. The pattern of expression of transfectant P1A.TC3.1 is shown in figure 2.

#### Example 6

As indicated in Example 5, supra, three independent cosmid transfected cells presenting P815A antigen were isolated. The DNA of these transfectants was isolated and packaged directly with lambda phage extracts, following DePlaen et al., Proc. Natl. Acad. Sci. USA 85: 2274-2278 (1988). The resulting product was titrated on E. coli ED 8767 with ampicillin selection, as in Example 5. Similarly, amplification of the cosmids and transfection followed Example 5, again using PO.HTR.

High frequencies of transfection were observed, as described in Table 1, which follows:

**Table 1.** Transfer of the expression of antigen P815A by cosmids obtained by direct packaging

Transfectant obtained with the cosmid library	No. of cosmids obtained by direct packaging of 0.5 µg of DNA	No. of transfectants expressing P815A / no. of HmB <sup>r</sup> transfectants
TC3.1	32	87/192
TC3.2	32000	49/384
TC3.3	44	25/72

The cosmids were analyzed with restriction enzymes and it was found that directly packaged transfectant P1A.TC3.1 contained 32 cosmids, 7 of which were different. Each of these 7 cosmids was transfected into PO.HTR, in the manner described supra, and again, following the protocols described above, transfectants were studied for presentation of P815A.



Four of the cosmid transfectants showed P815A presentation and, as with all experiments described herein, P815B was co-expressed.

Of the four cosmids showing presentation of the two antigens, cosmid C1A.3.1 was only 16.7 kilobases long, and was selected for further analysis as described infra.

The cosmid C1A.3.1 was subjected to restriction endonuclease analysis, yielding the map shown in Figure 3.

All EcoRI fragments were transfected, again using the above described protocols, and only the 7.4 kilobase fragment produced a transfectant that anti-A CTLs could lyse. Similar experiments were carried out on the PstI fragments, and only a 4.1 kb fragment fully contained within the 7.4 kb EcoRI fragment produced lysable transfectants.

This fragment (i.e., the 4.1 kb PstI fragment), was digested with SmaI, giving a 2.3 kb fragment which also yielded host cells presenting antigens A and B after transfection. Finally, a fragment 900 bases long, secured with SmaI/XbaI, also transferred expression of the precursors of these two antigens, i.e., the transfected host cell presented both antigen A and antigen B.

#### Example 7

The 900 base fragment described above was used as a probe to detect the expression of the P815A gene in parent cell line P1.HTR. To accomplish this, total cellular RNA was first isolated using the guanidine-isothiocyanate procedure of Davis et al., Basic Methods In Molecular Biology (Elsevier Science Publishing Co, New York) (1986). The same reference was the source of the method used to isolate and purify polyA<sup>+</sup> mRNA using oligodT cellulose column chromatography.

Samples were then subjected to Northern Blot analysis. RNA samples were fractionated on 1% agarose gels containing 0.66 M formaldehyde. The gels were treated with 10xSSC (SSC: 0.15 M NaCl; 0.015 M sodium citrate, pH 7.0) for 30 minutes before overnight blotting on nitrocellulose membranes. These were baked for two hours at 80°C, after which the membranes

were prehybridized for 15 minutes at 60°C in a solution containing 10% dextran sulfate, 1% SDS and 1M NaCl. Hybridization was then carried out using denatured probe (the 900 base fragment), together with 100 ug/ml salmon sperm DNA.

When this protocol was carried out using P1.HTR poly A<sup>+</sup> RNA, a band of 1.2 kb and two fainter bands were identified, as shown in Figure 4, lane 1 (6 ug of the RNA).

The same probe was used to screen a cDNA library, prepared from poly-A<sup>+</sup> RNA from the cell line. This yielded a clone with a 1kb insert, suggesting a missing 5' end. The Northern blots for the cDNA are not shown.

Hybridization experiments in each case were carried out overnight at 60°C. The blots were washed twice at room temperature with 2xSSC and twice at 60°C with 2xSSC supplemented with 1% SDS.

The foregoing experiments delineated the DNA expressing the P815A antigen precursor sufficiently to allow sequencing, using the well known Sanger dideoxy chain termination method. This was carried out on clones generated using a variety of restriction endonucleases and by specific priming with synthetic oligonucleotide primers. The results for exons of the gene are set forth in sequence id no: 4.

#### Example 8

The Northern analysis described supra suggested that the 5' end of the cDNA was missing. To obtain this sequence, cDNA was prepared from P1.HTR RNA using a primer corresponding to positions 320-303. The sequence was then amplified using the polymerase chain reaction using a 3' primer corresponding to positions 286-266 and a 5' primer described by Frohman et al., Proc. Natl. Acad. Sci. USA 85: 8998-9002 (1988). A band of the expected size (270 bases) was found, which hybridized to the 900 bp SmaI/XbaI fragment described supra on a Southern blot. Following cloning into m13tg 130 λ tg 131, the small, 270 bp fragment was sequenced. The sequence is shown in sequence id no: 1.

#### Example 9

Following the procurement of the sequences described in Examples 7 and 8 and depicted in seq id no: 4, a 5.7 kb region of cosmid C1A.3.1 was sequenced. This fragment was known to contain the 900 base fragment which expressed P815A in transfectants. This experiment permitted delineation of introns and exons, since the cosmid is genomic in origin.

The delineated structure of the gene is shown in figure 5. Together with seq id no: 4, these data show that the gene for the antigen precursor, referred to as "P1A" hereafter, is approximately 5 kilobases long and contains 3 exons. An ORF for a protein of 224 amino acids starts in exon 1, ending in exon 2. The 900 base pair fragment which transfers expression of precursors for antigens A and B only contains exon 1. The promoter region contains a CAAT box, as indicated in seq. id no: 1, and an enhancer sequence. This latter feature has been observed in promoters of most MHC class I genes, as observed by Geraghty et al., J. Exp. Med 171: 1-18 (1990); Kimura et al., Cell 44: 261-272 (1986).

A computer homology search was carried out, using program FASTA with K-triple parameters of 3 and 6, as suggested by Lipman et al., Science 227: 1435-1441 (1985), and using Genbank database release 65 (October 1990). No homology was found except for a stretch of 95 bases corresponding to part of an acid region coded by exon 1 (positions 524-618), which is similar to sequences coding for acidic regions in mouse nucleolar protein NO38/B23, as described by Bourbon et al., Mol. Biol. 200: 627-638 (1988), and Schmidt-Zachmann et al., Chromosoma 96: 417-426 (1988). Fifty six of 95 bases were identical. In order to test whether these homologies were the reason for cross hybridizing, experiments were carried out using a mouse spleen cDNA library screened with the 900 base fragment. cDNA clones corresponding closely to the sizes of the cross hybridizing bands were obtained. These were partially sequenced, and the 2.6 kb cDNA was found to correspond exactly to reported cDNA sequence of mouse nucleolin, while the 1.5 kb cDNA corresponded to mouse nucleolar protein NO38/B23.

Analysis of the nucleotide sequence of the gene, referred to as "P1A" hereafter, suggests that its coded product has a molecular mass of 25 kd. Analysis of the sequence id no: 4 shows a potential nuclear targeting signal at residues 5-9 (Dingwall et al., Ann. Rev. Cell Biol. 2: 367-390 (1986)), as well as a large acidic domain at positions 83-118. As indicated supra, this contains the region of homology between P1A and the two nucleolar proteins. A putative phosphorylation site can be found at position 125 (serine). Also, a second acidic domain is found close to the C-terminus as an uninterrupted stretch of 14 glutamate residues. A similar C-terminal structure has been found by Kessel et al. Proc. Natl. Acad. Sci. USA 84: 5306-5310 (1987), in a murine homeodomain protein having nuclear localization.

In studies comparing the sequence of gene P1A to the sequences for P91A, 35B and P198, no similarities were found, showing that P1A is indicative of a different class of genes and antigens.

#### Example 10

With the P1A probe and sequence in hand, investigations were carried out to determine whether the gene present in normal tissue was identical to that expressed by the tumor. To do this, phage libraries were prepared, using lambda zapII 10 and genomic DNA of DBA2 murine kidney cells. P1A was used as a probe. Hybridization conditions were as described supra, and a hybridizing clone was found. The clone contained exons one and two of the P1A gene, and corresponded to positions - 0.7 to 3.8 of figure 5. Following localization of this sequence, PCR amplification was carried out to obtain the sequence corresponding to 3.8 to 4.5 of figure 5.

Sequence analysis was carried out, and no differences were found between the gene from normal kidneys and the P1A gene as obtained from the P815 tumor cells.

In further experiments, the gene as found in DBA/2 kidney cells was transfected into PO.HTR, as described supra. These experiments, presented pictorially in figure 7, showed that antigens A and B were expressed as efficiently by the kidney

gene isolated from normal kidney cells as with the P1A gene isolated from normal kidney cells.

These experiments lead to the conclusion that the gene coding for the tumor rejection antigen precursor is a gene that does not result from a mutation; rather, it would appear that the gene is the same as one present in normal cells, but is not expressed therein. The ramifications of this finding are important, and are discussed infra.

In studies not elaborated upon herein, it was found that variants of the gene were available. Some cells were "P1A-B+", rather than the normal "P1A". The only difference between these is a point mutation in exon 1, with the 18th triplet coding for Ala in the variant instead of Val.

#### Example 11

Additional experiments were carried out with other cell types. Following the protocols described for Northern blot hybridizations supra, RNA of normal liver and spleen cells was tested to determine if a transcript of the P1A gene could be found. The Northern blot data are presented in figure 4 and, as can be seen, there is no evidence of expression.

The murine P815 cell line from which P1A was isolated is a mastocytoma. Therefore, mast cell lines were studied to determine if they expressed the gene. Mast cell line MC/9, described by Nabel et al., Cell 23: 19-28 (1981), and short term cultures of bone marrow derived mast cells were tested in the manner described supra (Northern blotting), but no transcript was found. In contrast when a Balb/C derived IL-3 dependent cell line L138.8A (Hültner et al., J. Immunol. 142: 3440-3446 (1989)) was tested, a strong signal was found. The mast cell work is shown in figure 4.

It is known that both BALB/C and DBA/2 mice share H-2<sup>d</sup> haplotype, and thus it was possible to test sensitivity to lysis using the CTLs described supra. Figure 8 shows these results, which essentially prove that anti-A and anti-B CTLs lysed the cells strongly, whereas anti-C and anti-D lines did not.

Further tests were carried out on other murine tumor cell

lines, i.e., teratocarcinoma cell line PCC4 (Boon et al., Proc. Natl. Acad. Sci. USA 74: 272-275 (1977), and leukemias LEC and WEH1-3B. Expression could not be detected in any of these samples.

#### Example 12

The actual presentation of the P1A antigen by MHC molecules was of interest. To test this, cosmid C1A.3.1 was transfected into fibroblast cell line DAP, which shows phenotype H-2<sup>k</sup>. The cell lines were transfected with genes expressing one of the K<sup>d</sup>, D<sup>d</sup>, and L<sup>d</sup> antigen. Following transfection with both the cosmid and the MHC gene, lysis with CTLs was studied, again as described supra. These studies, summarized in Table 2, show that L<sup>d</sup> is required for presentation of the P1A antigens A and B.

Table 2. H-2-restriction of antigens P815A and P815B

Recipient cell*	No. of clones lysed by the CTL/ no. of HmB <sup>r</sup> clones <sup>#</sup>	
	CTL anti-A	CTL anti-B
DAP (H-2 <sup>k</sup> )	0/208	0/194
DAP + K <sup>d</sup>	0/165	0/162
DAP + D <sup>d</sup>	0/157	0/129
DAP + L <sup>d</sup>	25/33	15/20

\*Cosmid C1A.3.1 containing the entire P1A gene was transfected in DAP cells previously transfected with H-2<sup>d</sup> class I genes as indicated.

<sup>#</sup>Independent drug-resistant colonies were tested for lysis by anti-A or anti-B CTL in a visual assay.

The observation that one may associate presentation of a tumor rejection antigen with a particular MHC molecule was confirmed in experiments with human cells and HLA molecules, as elaborated upon infra.

#### 5 Example 13

Using the sequence of the P1A gene as well as the amino acid sequence derivable therefrom, antigenic peptides which were A<sup>+</sup> B<sup>+</sup> (i.e., characteristic of cells which express both the A and B antigens), and those which are A<sup>+</sup>B<sup>+</sup> were identified. The peptide is presented in Figure 10. This peptide when administered to samples of PO.HTR cells in the presence of CTL cell lines specific to cells presenting it, led to lysis of the PO.HTR cells, lending support to the view that peptides based on the product expressed by the gene can be used as vaccines.

#### 15 Example 14

The human melanoma cell line referred to hereafter as MZ2-MEL is not a clonal cell line. It expresses four stable antigens recognized by autologous CTLs, known as antigens "D, E, F, and A". In addition, two other antigens "B" and "C" are expressed by some sublines of the tumor. CTL clones specific for these six antigens are described by Van den Eynde et al., Int. J. Canc. 44: 634-640 (1989). Among the recognized subclones of MZ2-MEL are MEL.43, MEL3.0 and MEL3.1. (Van den Eynde et al., supra). Cell line MEL3.1 expresses antigen E, as determined by CTL studies as described for P815 variants, supra, so it was chosen as a source for the nucleic acid sequence expressing the antigen precursor.

In isolating the pertinent nucleic acid sequence for a tumor rejection antigen precursor, the techniques developed supra, showed that a recipient cell is needed which fulfills two criteria: (i) the recipient cell must not express the TRAP of interest under normal conditions, and (ii) it must express the relevant class I HLA molecule. Also, the recipient cell must have a high transfection frequency, i.e., it must be a "good" recipient.

In order to secure such a cell line, the clonal subline

ME3.1 was subjected to repeated selection with anti-E CTL 82/30 as described by Van den Eynde, supra. The repeated cycles of selection led to isolation of subclone MZ2-MEL-2.2 isc E<sup>-</sup>. This subclone is also HPRT<sup>-</sup>, (i.e., sensitive to HAT medium: 10<sup>-4</sup> M hypoxanthine, 3.8 x 10<sup>-7</sup> aminopterin, 1.6 x 10<sup>-5</sup> M 2-deoxythymidine). The subclone is referred to as "MEL-2.2" for simplicity hereafter.

#### Example 15

The genomic DNA of MEL3.0 was prepared following Wölfel et al., Immunogenetics 26: 178-187 (1987), the disclosure of which is incorporated by reference. The plasmid pSVtkneoß, as described by Nicolas et al., Cold Spring Harb., Conf. Cell Prolif. 10: 469-485 (1983) confers geneticin resistance, so it can be used as a marker for cotransfection, as it was in this experiment.

Following a procedure similar but not identical to that of Corsao et al., Somatic Cell Molec. Genet 7: 603-616 (1981), total genomic DNA and the plasmid were cotransfected. The genomic DNA (60 µg) and plasmid DNA (6 µg) were mixed in 940 µl of 1 mM Tris·HCl (pH 7.5), 0.1 mM EDTA, after which 310 µl of 1M CaCl<sub>2</sub> was added. This solution was slowly added, under constant agitation, to 1.25 ml of 2xHBS (50 mM HEPES, 280 mM NaCl 1.5 mM Na<sub>2</sub>HPO<sub>4</sub>, adjusted to pH 7.1 with NaOH). The calcium phosphate DNA precipitates were allowed to form for 30-45 minutes at room temperature, after which they were applied to 80 cm<sup>2</sup> tissue culture flasks which had been seeded 24 hours previously with 3x10<sup>6</sup> MEL2.2 cells, in 22.5 ml of melanoma culture medium (Dulbecco's Modified Eagle's Medium) supplemented with 10% fetal calf serum. After 24 hours, the medium was replaced. Forty eight hours after transfection, the cells were harvested and seeded at 4x10<sup>6</sup> cells per 80 cm<sup>2</sup> flask in melanoma culture medium supplemented with 2 mg/ml of geneticin. The geneticin serves as a selection marker.

#### Example 16

Thirteen days after transfection, geneticin-resistant colonies were counted, harvested, and cultured in nonselective



medium for 2 or 3 days. Transfected cells were then plated in 96-well microplates at 200 cells/well in 200  $\mu$ l of culture medium with 20% fetal calf serum (FCS) in order to obtain approximately 30 growing colonies per well. The number of microcultures was aimed at achieving redundancy, i.e., such that every independent transfectant should be represented at least four times.

After 10 days, wells contained approximately  $6 \times 10^4$  cells. These cells were detached, and 1/3 of each microculture was transferred to a duplicate plate. After 6 hours, i.e., after readherence, medium was removed and 1500 anti-E CTL (CTL 82/30), were added to each well in 100  $\mu$ l of CTL culture medium with 35 U/ml of IL-2. One day later, the supernatant (50  $\mu$ l) was harvested and examined for TNF concentration, for reasons set forth in the following example.

#### Example 17

The size of the mammalian genome is  $6 \times 10^6$  kb. As the average amount of DNA integrated in each drug-resistant transfectant was expected to be about 200 kb, a minimum of 30,000 transfectants would need to be examined to ascertain whether antigen E had been transfected. Prior work with murine cells had shown that when a CTL stimulation assay was used, groups containing only 3% of cells expressing the antigen of interest could be identified. This should reduce the number of assays by a factor of 30. While an anti-E CTL assay, as described supra, in mixed E<sup>+</sup>/E<sup>-</sup> cells was helpful, it was not sufficient in that consistent results could not be obtained.

As a result, an alternative test was devised. Stimulation of CTLs was studied by release of tumor necrosis factor ("TNF") using well known methodologies which need not be repeated here. As described in Example 15, 1500 CTL 82/30 cells had been added per well of transfectants. These CTLs were collected 6 days after stimulation. As indicated supra, after 1/3 of the cells in each well had been removed and the remaining 2/3 ( $4 \times 10^4$ ) had readhered, the CTLs and IL-2 were added thereto. The 50  $\mu$ l of supernatant was removed 24 hours

later and transferred to a microplate containing  $3 \times 10^4$  W13 (WEHI-164 clone 13; Espevik et al., J. Immunol. Meth. 95: 99-105 (1986)) cells in 50  $\mu$ l of W13 culture medium (RPMI-1640, supplemented with L-arginine (116 mg/l), L-asparagine (36 mg/l), L-glutamine (216 mg/l), and 10% FCS supplemented with 2  $\mu$ g of actinomycin D at 37% in an 8% CO<sub>2</sub> atmosphere. The cell line W13 is a mouse fibrosarcoma cell line sensitive to TNF. Dilutions of recombinant TNF- $\beta$  in RPMI 1640 were added to target cell controls.

The W13 cultures were evaluated after 20 hours of incubation, and dead cell percentage was measured using an adaptation of the colorimetric assay of Hansen et al., J. Immunol. Meth. 119: 203-210 (1989). This involved adding 50  $\mu$ l of (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide at 2.5 mg/ml in PBS, followed by two hours of incubation at 37°C. Dark blue formazan crystals were dissolved by adding 100  $\mu$ l of lysis solution (1 volume N,N dimethyl formamide mixed at 37°C with two volumes of water containing 30% (w/v) sodium dodecyl sulphate, at pH 4.7 from 1.6% acetic acid and 2.5% 1N HCl). Plates were incubated at 37°C overnight, and ODs were taken at 570 nm using 650 nm as control. Dead cell percentage was determined via the formula:

$$100 \times \left[ 1 - \frac{100 - (\text{OD}_{570} \text{ sample well})}{\text{OD}_{570} \text{ well} + \text{medium}} \right]$$

following Espevik et al., J. Immunol. Meth. 95: 99-105 (1986). The results showed that even when the ratio of E<sup>+</sup>/E<sup>-</sup> cells was as low as 1/45, significant production of TNF was observed, thus showing active CTLs. This led to the decision to test the drug resistant transfectants in groups of 30.

#### Example 18

Cells were tested for TNF production as discussed in Example 17, supra. A total of 100 groups of E<sup>-</sup> cells ( $4 \times 10^6$  cells/group) were tested following transfection, and  $7 \times 10^4$  independent geneticin resistant transfectants were obtained, for an average of 700 per group. Only one group of

transfected cells led to a microculture which caused anti-E antigen CTL clone 82/30 to produce TNF. Of 300 clones tested, 8 were positive. These clones were then tested for lysis by anti-E CTL, using the standard  $^{51}\text{Cr}$  release assay, and were found to be lysed as efficiently as the original E<sup>+</sup> cell line. The transfectant E.T1, discussed herein, had the same lysis pattern as did MEL2.2 for CTLs against antigens B,C,D and F.

The fact that only one transfectant presented the antigen out of 70,000 geneticin resistance transfectants may at first seem very low, but it is not. The work described supra for P815 showed an average frequency of 1/13,000. Human DNA recipient MEL2.2 appears to integrate 5 times less DNA than P1.HTR.

#### Example 19

Once transfectant E.T1 was found, analysis had to address several questions including whether an E<sup>+</sup> contaminant of the cell population was the cause. The analysis of antigen presentation, described supra, shows that E.T1 is B<sup>-</sup> and C<sup>-</sup>, just like the recipient cell MEL2.2. It was also found to be HPRT<sup>-</sup>, using standard selection procedures. All E<sup>+</sup> cells used in the work described herein, however, were HPRT<sup>+</sup>.

It was also possible that an E<sup>+</sup> revertant of MEL2.2 was the source for E.T1. To test this, the observation by Perucho et al., Cell 22: 309-317 (1980), that cotransfected sequences usually integrate together at a single location of recipient genome was employed. If antigen E in a transfectant results from cotransfection with pSVtkneo $\beta$ , then sequences should be linked and deletion of the antigen might also delete the neighboring pSVtkneo $\beta$  sequences. Wölfel et al., supra, has shown this to be true. If a normally E<sup>-</sup> cell is transfected with pSVtkneo $\beta$ , then sequences should be linked and deletion of the antigen might also delete the neighboring pSVtkneo $\beta$  sequences. If a normally E<sup>+</sup> cell transfected with pSVtkneo $\beta$  is E.T1, however, "co-deletion" should not take place. To test this, the transfectant E.T1 was subjected to immunoselection with 82/30, as described supra. Two antigen loss variants were obtained, which resisted lysis by this CTL.

Neither of these had lost geneticin resistance; however, Southern blot analysis showed loss of several neo<sup>r</sup> sequences in the variants, showing close linkage between the E gene and neo<sup>r</sup> gene in E.T1, leading to the conclusion that E.T1 was a transfectant.

#### Example 20

The E<sup>+</sup> subclone MZ2-MEL 4B was used as a source of DNA for preparation of a cosmid library. This library of nearly 700,000 cosmids was transfected into MZ2-MEL 2.2 cells, following the cosmid transfection protocols described supra.

By packaging the DNA of cosmid transfectants directly into lambda phase components, it is sometimes possible to retrieve cosmids that contain the sequences of interest. This procedure was unsuccessful here, so we rescued the transfected sequence by ligating DNA of the transfectant to appropriate restriction fragments of cosmid vector pTL6. This was tried with two transfectants and was successful with one of them. One cosmid, referred to as B3, was recovered from this experiment, and subjected to restriction endonuclease digestion via XmaI, or by BamHI digestion of a large, 12 kb XmaI transfected fragment. The fragments were cloned into vector pTZ 18R, and then transfected into MEL2.2. Again, TNF production was the measure by which successful transfection was determined. The experiments led to the determination of a gene sequence capable of transfecting antigen E on the 12 kb XmaI fragment, and then on the 2.4 kb fragment of BamHI digestion of the 12 kb segment.

The 2.4 kb fragment hybridizes with a 2.4 kb fragment from MZ2-MEL and with a T cell clone of patient MZ-2, as determined by Southern Blots (BamHI/SmaI digested DNA). The band is absent from E<sup>-</sup> antigen loss variants of MZ2-MEL, as seen in Figure 12.

The sequence for the E antigen precursor gene has been determined, and is presented herein:

	10	20	30	40	50	60
1	GGATCCAGGC	CCTGCCAGGA	AAAATATAAG	GGCCCTGCGT	GAGAACAGAG	GGGGTCAATCC 60
61	ACTGCATGAG	AGTGGGGATG	TCACAGAGTC	CAGCCCACCC	TCCTGGTAGC	ACTGAGAAGC 120
121	CAGGGCTGTG	CTTGCGGTCT	GCACCCTGAG	GGCCCGTGGA	TTCTCTTCC	TGGAGCTCCA 180
181	GGAAACCAGGC	AGTGAGGCCT	TGGTCTGAGA	CAGTATCCTC	AGGTCACAGA	GCAGAGGATG 240
241	CACAGGGTGT	GCCAGCAGTG	AATGTTTGCC	CTGAATGCAC	ACCAAGGGCC	CCACCTGCCA 300
301	CAGGACACAT	AGGACTCCAC	AGAGTCTGGC	CTCACCTCCC	TACTGTCACT	CCTGTAGAAT 360
361	CGACCTCTGC	TGGCCGGCTG	TACCCTGAGT	ACCCTCTCAC	TTCTCTTTC	AGGTTTTCAG 420
421	GGGACAGGCC	AACCCAGAGG	ACAGGATTCC	CTGGAGGCCA	CAGAGGAGCA	CCAAGGAGAA 480
481	GATCTGTAAG	TAGGCCTTTG	TTAGAGTCTC	CAAGGTTTCT	TTCTCAGCTG	AGGCCCTCTCA 540
541	CACACTCCCT	CTCTCCCCAG	GCCTGTGGGT	CTTCATTGCC	CAGCTCCTGC	CCCACTCCT 600
601	GCCTGCTGCC	CTGACGAGAG	TCATCATGTC	TCTTGAGCAG	AGGAGTCTGC	ACTGCAAGCC 660
661	TGAGGAAGCC	CTTGAGGCC	AACAAGAGGC	CCTGGGCCTG	GTGTGTGTGC	AGGCTGCCAC 720
721	CTCCTCCTCC	TCTCCTCTGG	TCCTGGGCAC	CCTGGAGGAG	GTGCCCCACTG	CTGGGTCAAC 780
781	AGATCCTCCC	CAGAGTCCTC	AGGGAGCCTC	CGCCTTTCCC	ACTACCATCA	ACTTCACTCG 840
841	ACAGAGGCCA	CCCAGTGAGG	GTTCCAGCAG	CCGTGAAGAG	GAGGGGCCAA	GCACCTCTTG 900
901	TATCCTGGAG	TCCTTGTTCC	GAGCAGTAAT	CACCTAAGAAG	GTGGCTGATT	TGGTTGGTTT 960
961	TCTGCTCCTC	AAATATCGAG	CCAGGGAGCC	AGTCACAAAG	GCAGAAATGC	TGGAGAGTGT 1020
1021	CATCAAAAAT	TACAAGCACT	GTTTTCTCTGA	GATCTTCGGC	AAAGCCTCTG	AGTCTTTGCA 1080
1081	GCTGGTCTTT	GGCATTGACG	TGAAGGAAGC	AGACCCACC	GGCCACTCCT	ATGTCCTTGT 1140
1141	CACCTGCCTA	GGTCTCTCCT	ATGATGGCCT	GCTGGGTGAT	AATCAGATCA	TGCCCAAGAC 1200
1201	AGGCTTCCTG	ATAATTGTCC	TGGTCATGAT	TGCAATGGAG	GGCGGCCATG	CTCCTGAGGA 1260
1261	GGAAATCTGG	GAGGAGCTGA	GTGTGATGGA	GGTGTATGAT	GGGAGGGAGC	ACAGTGCCTA 1320
1321	TGGGGAGCCC	AGGAAGCTGC	TCACCCAAGA	TTTGGTGCAG	GAAAAGTACC	TGGACTACCG 1380
1381	GCAGGTGCCG	GACAGTGATC	CCGCACGCTA	TGAGTTCCTG	TGGGGTCCAA	GGGCCCTCGC 1440
1441	TGAAACCAGC	TATGTGAAAG	TCCTTGAGTA	TGTGATCAAG	GTCAGTGCAA	GAGTTCGCTT 1500
1501	TTTCTTCCCA	TCCCTGCGTG	AAGCAGCTTT	GAGAGAGGAG	GAAGAGGGAG	TCTGAGCATG 1560
1561	AGTTGCAGCC	AAGGCCAGTG	GGAGGGGGAC	TGGGCCAGTG	CACCTTCCAG	GGCCCGCTCC 1620
1621	AGCAGCTTCC	CCTGCCCTCGT	GTGACATGAG	GCCCCATTCTT	CACCTCTGAAG	AGAGCGGTCA 1680
1681	GTGTTCTCAG	TAGTAGGTTT	CTGTTCTATT	GGGTGACTTG	GAGATTTATC	TTTGTCTCT 1740
1741	TTTGGAATTG	TTCAAATGTT	TTTTTTTAAG	GGATGGTTGA	ATGAACTTCA	GCATCCAAGT 1800
1801	TTATGAATGA	CAGCAGTCAC	ACAGTTCTGT	GTATATAGTT	TAAGGGTAAG	AGTCTTGTGT 1860
1861	TTTATTGAGA	TTGGGAAATC	CATTCTATTT	TGTGAATTGG	GATAATAACA	GCAGTGGAAAT 1920
1921	AAGTACTTAG	AAATGTGAAA	AATGAGCAGT	AAAATAGATG	AGATAAAGAA	CTAAAGAAAT 1980
1981	TAAGAGATAG	TCAATTCTTG	CCTTATACCT	CAGTCTATTC	TGTAAAATTT	TTAAAGATAT 2040
2041	ATGCATACCT	GGATTTCCCTT	GGCTTCTTTG	AGAATGTAAG	AGAAATTAAA	TCTGAATAAA 2100
2101	GAATTCCTCC	TGTTCACTGG	CTCTTTTCTT	CTCCATGCAC	TGAGCATCTG	CTTTTTGGAA 2160
2161	GGCCCTGGGT	TAGTAGTGGA	GATGCTAAGG	TAAGCCAGAC	TCATACCCAC	CCATAGGGTC 2220
2221	GTAGAGTCTA	GGAGCTGCAG	TCACGTAATC	GAGGTGGCAA	GATGTCCTCT	AAAGATGTAG 2280
2281	GGAAAAGTGA	GAGAGGGGTG	AGGGTGTGGG	GCTCCGGGTG	AGAGTGGTGG	AGTGTCAATG 2340
2341	CCCTGAGCTG	GGGCATTTTG	GGCTTTGGGA	AACTGCAGTT	CCTTCTGGGG	GAGCTGATTG 2400
2401	TAATGATCTT	GGGTGGATCC				2420

**Example 21**

After the 2.4 kb genomic segment had been identified, studies were carried out to determine if an "E" subline expressed any homologous DNA. Cell line MZ2-MEL 3.0 was used as a source, and a cDNA library was prepared from its mRNA, using art known techniques. The 2.4 kb segment was used as a probe, and mRNA of about 1.8 kb was identified as homologous, using Northern blot analysis. When cDNA was screened, clones were obtained showing almost complete identity to parts of the 2.4 kb fragment. Two exons were thus identified. An additional exon was located upstream of these, via sequencing segments of cosmid B3 located in front of the 2.4 kb BamHI fragment. The gene extends over about 4.5 kb, as shown in Figure 8. The starting point of the transcribed region was confirmed using PCR for the 5' end of the cDNA. The three exons comprise 65, 73, and 1551 base pairs. An ATG is located at position 66 of exon 3, followed by an 828 base pair reading frame.

**Example 22**

To determine if smaller segments of the 2.4 kb fragment could transfer the expression of antigen E, smaller pieces corresponding to the larger gene were prepared, using art recognized techniques, and transferred into E<sup>-</sup> cells. Figure 8 shows the boundaries of the three segments.

Transfer of antigen expression in this manner indicates that the gene codes for the antigen precursor, rather than coding for a protein which activates the antigen.

**Example 23**

The probing of cDNA described supra revealed, surprisingly, two different but closely related cDNAs. These cDNAs, when tested, did not transfer expression of antigen E, but they do show substantial homology to the first cDNA segment. The three segments, appear to indicate a newly recognized family of genes, referred to as "MAGE" for "melanoma antigen". In Figure 9, "mage-1" directs expression of the antigen from MZ2 cells. Portions of the third exon of each gene are presented in Figure 9. The second and third

sequences are more closely related to each other than the first (18.1 and 18.9% difference compared to the first; 12% with each other). Out of 9 cDNA clones obtained, three of each type were obtained, suggesting equal expression. "MAGE" as used hereafter refers to a family of molecules, and the nucleic acids coding for them. These nucleic acids share a certain degree of homology and are expressed in tumor cells including several types of human tumor cells as well as in human tumors. The family is referred to as "MAGE" because the first members were identified in human melanoma cells. As the experiments which follow indicate, however, the members of the MAGE family are not at all restricted to melanoma tumors; rather, MAGE refers to a family of tumor rejection antigen precursors and the nucleic acid sequences coding therefore. The antigens resulting therefrom are referred to herein as "MAGE TRAs" or "melanoma antigen tumor rejection antigens"

#### Example 24

Experiments with mouse tumors have demonstrated that new antigens recognized by T cells can result from point mutations that modify active genes in a region that codes for the new antigenic peptide. New antigens can also arise from the activation of genes that are not expressed in most normal cells. To clarify this issue for antigen MZ2-E, the mage-1 gene present in the melanoma cells was compared to that present in normal cells of patient MZ2.

Amplification by polymerase chain reaction (PCR) of DNA of phytohemagglutinin-activated blood lymphocytes using primers surrounding a 1300 bp stretch covering the first half of the 2.4 kb fragment was carried out. As expected, a PCR product was obtained whereas none was obtained with the DNA of the E<sup>-</sup> variant. The sequence of this PCR product proved identical to the corresponding sequence of the gene carried by the E<sup>+</sup> melanoma cells. Moreover, it was found that antigen MZ2-E was expressed by cells transfected with the cloned PCR product. This result suggests that the activation of a gene normally silent is responsible for the appearance of tumor rejection antigen MZ2-E.

**Example 25**

In order to evaluate the expression of gene mage-1 by various normal and tumor cells, Northern blots were hybridized with a probe covering most of the third exon. In contrast with the result observed with human tumor cell line MZ2-MEL 3.0, no band was observed with RNA isolated from a CTL clone of patient MZ2 and phytohemagglutinin-activated blood lymphocytes of the same patient. Also negative were several normal tissues of other individuals (Figure 10 and Figure 11). Fourteen melanoma cell lines of other patients were tested. Eleven were positive with bands of varying intensities. In addition to these culture cell lines, four samples of melanoma tumor tissue were analyzed. Two samples, including a metastasis of patient MZ2 proved positive, excluding the possibility that expression of the gene represented a tissue culture artefact. A few tumors of other histological types, including lung tumors were tested. Most of these tumors were positive (Figures 10 and 11). These results indicated that the MAGE gene family is expressed by many melanomas and also by other tumors. However, they provided no clear indication as to which of genes mage-1, 2 or 3 were expressed by these cells, because the DNA probes corresponding to the three genes cross-hybridized to a considerable extent. To render this analysis more specific, PCR amplification and hybridization with highly specific oligo- nucleotide probes were used. cDNAs were obtained and amplified by PCR using oligonucleotide primers corresponding to sequences of exon 3 that were identical for the three MAGE genes discussed herein. The PCR products were then tested for their ability to hybridize to three other oligonucleotides that showed complete specificity for one of the three genes (Figure 9). Control experiments carried out by diluting RNA of melanoma MZ2-MEL 3.0 in RNA from negative cells indicated that under the conditions used herein the intensity of the signal decreased proportionally to the dilution and that positive signals could still be detected at a dilution of 1/300. The normal cells (lymphocytes) that were tested by PCR were confirmed to be negative for the



expression of the three MAGE genes, suggesting therefore a level of expression of less than  $1/300^{\text{th}}$  that of the MZ2 melanoma cell line (Figure 11). For the panel of melanoma cell lines, the results clearly showed that some melanomas expressed MAGE genes mage 1, 2 and 3 whereas other expressed only mage-2 and 3 (Figures 11 and 10). Some of the other tumors also expressed all three genes whereas others expressed only mage-2 and 3 or only mage-3. It is impossible to exclude formally that some positive PCR results do not reflect the expression of one of the three characterized MAGE genes but that of yet another closely related gene that would share the sequence of the priming and hybridizing oligonucleotides. It can be concluded that the MAGE gene family is expressed by a large array of different tumors and that these genes are silent in the normal cells tested to this point.

#### Example 26

The availability of a sequence that transfects at high efficiency and efficiently expresses a TRAP made it possible to search for the associated major histocompatibility complex (MHC) class I molecule. The class I specificities of patient MZ2 are HLA-A1, A29, B37, B44 and C6. Four other melanomas of patients that had A1 in common with MZ2 were cotransfected with the 2.4 kb fragment and pSVtkneo $\beta$ . Three of them yielded neo $^r$  transfectants that stimulated TNF release by anti-E CTL clone 82/30, which is CD8 $^+$  (Figure 10). No E- transfectant was obtained with four other melanomas, some of which shared A29, B44 or C6 with MZ2. This suggests that the presenting molecule for antigen MZ2-E is HLA-A1. In confirmation, it was found that, out of 6 melanoma cell lines derived from tumors of HLA-A1 patients, two stimulated TNF release by anti-E CTL clone 82/30 of patient MZ2. One of these tumor cell lines, MI13443-MEL also showed high sensitivity to lysis by these anti-E CTL. These two melanomas were those that expressed mage-1 gene (Figure 13). Eight melanomas of patients with HLA haplotypes that did not include A1 were examined for their sensitivity to lysis and for their ability to stimulate TNF release by the CTL. None was found to be positive. The

ability of some human anti-tumor CTL to lyse allogeneic tumors sharing an appropriate HLA specificity with the original tumor has been reported previously (Darrow, et al., J. Immunol. 142: 3329 (1989)). It is quite possible that antigenic peptides encoded by genes mage 2 and 3 can also be presented to autologous CTL by HLA-A1 or other class I molecules, especially in view of the similar results found with murine tumors, as elaborated upon supra.

#### Example 27

As indicated supra, melanoma MZ2 expressed antigens F, D and A', in addition to antigen E. Following the isolation of the nucleic acid sequence coding for antigen E, similar experiments were carried out to isolate the nucleic acid sequence coding for antigen F.

To do this, cultures of cell line MZ2-MEL2.2, an E<sup>-</sup> cell line described supra, were treated with anti-F CTL clone 76/6, in the same manner described for treatment with anti-E CTL clones. This resulted in the isolation of an F antigen loss variant, which was then subjected to several rounds of selection. The resulting cell line, "MZ2-MEL2.2.5" was completely resistant to lysis by anti-F CTLs, yet proved to be lysed by anti-D CTLs.

Again, following the protocols set forth for isolation of antigen -E precursor DNA, the F<sup>-</sup> variant was transfected with genomic DNA from F<sup>+</sup> cell line MZ2-MEL3.0. The experiments yielded 90,000 drug resistant transfectants. These were tested for MZ2-F expression by using pools of 30 cells in the TNF detection assay elaborated upon supra. One pool stimulated TNF release by anti-F CTLs, and was cloned. Five of 145 clones were found to stimulate anti-F CTLs. Lysis assays, also following protocols described supra, confirmed (i) expression of the gene coding for antigen F, and (ii) presentation of antigen F itself.

#### Example 28

Following identification of F<sup>+</sup> cell lines, the DNA therefrom was used to transfect cells. To do this, a cosmid library of F<sup>+</sup> cell line MZ2-MEL.43 was prepared, again using

the protocols described supra. The library was divided into 14 groups of about 50,000 cosmids, and DNA from each group was transfected into MZ2-MEL2.2.5. Transfectants were then tested for their ability to stimulate TNF release from anti-F CTL clone 76/6. Of 14 groups of cosmids, one produced two independent transfectants expressing antigen F; a yield of two positives out of 17,500 genitacin resistant transfectants.

#### Example 29

The existence of a gene family was suggested by the pattern observed on the Southern blot (Figure 12). To do this, the 2.4 kb BamHI fragment, which transferred the expression of antigen M22-E, was labelled with  $^{32}\text{p}$  and used as a probe on a Southern Blot of BamHI digested DNA of E + cloned subclone M22-MEL2.2. Hybridization conditions included  $50\ \mu\text{l}/\text{cm}^2$  of  $3.5\times\text{SSC}$ ,  $1\times\text{Denhardt's}$  solution; 25 mM sodium phosphate buffer (pH 7.0), 0.5% SDS, 2mM EDTA, where the 2.4 kb probes had been labelled with  $[\alpha^{32}\text{p}]\text{dCTP}$  (2-3000 Ci/mole), at  $3\times 10^6$  cpm/ml. Hybridization was carried out for 18 hours at  $65^\circ\text{C}$ . After this, the membranes were washed at  $65^\circ\text{C}$  four times for one hour each in  $2\times\text{SSC}$ , 0.1% SDS, and finally for 30 minutes in  $0.1\times\text{SSC}$ , 0.1% SDS. To identify hybridization, membranes were autoradiographed using Kodak X-AR film and Kodak X-Omatic fine intensifying screens.

In the following examples, whenever "hybridization" is referred to, the stringency conditions used were similar to those described supra. "Stringent conditions" as used herein thus refers to the foregoing conditions; subject to routine, art recognized modification.

#### Example 30

The cDNA coding for mage 4 was identified from a sample of the human sarcoma cell line LB23-SAR. This cell line was found to not express mage 1, 2 or 3, but the mRNA of the cell line did hybridize to the 2.4 kb sequence for mage 1. To study this further, a cDNA library was prepared from total LB23-SAR mRNA, and was then hybridized to the 2.4 kb fragment. A cDNA sequence was identified as hybridizing to this probe, and is identified hereafter as mage 4.

**Example 31**

Experiments were carried out using PHA-activated lymphocytes from patient "MZ2", the source of the "MZ" cells discussed supra. An oligonucleotide probe which showed homology to mage 1 but not mage 2 or 3 was hybridized with a cosmid library derived from the PHA activated cells. The size of the hybridizing BamHI cosmid fragment, however, was 4.5 kb, thus indicating that the material was not mage 1; however, on the basis of homology to mage 1-4, the fragment can be referred to as "mage 5". The sequence of MAGE 5 is presented in SEQ ID NO: 16.

**Example 32**

Melanoma cell line LB-33-MEL was tested. Total mRNA from the cell line was used to prepare cDNA, which was then amplified with oligos CHO9: (ACTCAGCTCCTCCCAGATTT), and CHO10: (GAAGAGGAGGGGCCAAG). These oligos correspond to regions of exon 3 that are common to previously described mage 1, 2 and 3.

To do this, 1  $\mu$ g of RNA was diluted to a total volume of 20  $\mu$ l, using 2  $\mu$ l of 10x PCR buffer, 2  $\mu$ l of each of 10 mM dNTP, 1.2  $\mu$ l of 25 mM  $MgCl_2$ , 1  $\mu$ l of an 80 mM solution of CHO9, described supra, 20 units of RNAsin, and 200 units of M-MLV reverse transcriptase. This was followed by incubation for 40 minutes at 42°C. PCR amplification followed, using 8  $\mu$ l of 10x PCR buffer, 4.8  $\mu$ l of 25 mM  $MgCl_2$ , 1  $\mu$ l of CHO10, 2.5 units of *Thermus aquaticus* ("Taq") polymerase, and water to a total volume of 100  $\mu$ l. Amplification was then carried out for 30 cycles (1 minute 94°C; 2 minutes at 52°C, 3 minutes at 72°C). Ten  $\mu$ l of each reaction were then size fractionated on agarose gel, followed by nitrocellulose blotting. The product was found to hybridize with oligonucleotide probe CHO18 (TCTTGATCCTGGAGTCC). This probe identified mage 1 but not mage 2 or 3. However, the product did not hybridize to probe SEQ 4 (TTGCCAAGATCTCAGGAA). This probe also binds mage 1 but not 2 and 3. This indicated that the PCR product contained a sequence that differed from mage 1, 2 and 3. Sequencing of this fragment also indicated differences with

respect to mage 4 and 5. These results indicate a sequence differing from previously identified mage 1, 2, 3, 4 and 5, and is named mage 6.

#### Example 33

5 In additional experiments using cosmid libraries from PHA-activated lymphocytes of MZ2, the 2.4 kb mage 1 fragment was used as a probe and isolated a complementary fragment. This clone, however, did not bind to oligonucleotides specific for mage 1, 2, 3 or 4. The sequence obtained shows some  
10 homology to exon 3 of mage 1, and differs from mages 1-6. It is referred to as mage 7 hereafter. Additional screenings yielded mage 8-11.

#### Example 34

The usefulness of the TRAPs, as well as TRAs derived therefrom, was exemplified by the following.

Exon 3 of mage 1 was shown to transfer expression of antigen E. As a result, it was decided to test whether synthetic peptides derived from this exon 3 could be used to confer sensitivity to anti-E CTL.

20 To do this, and using standard protocols, cells normally insensitive to anti-E/CTLs were incubated with the synthetic peptides derived from Exon 3.1. Using the CTL lytic assays described supra on P815A, and a peptide concentration of 3 mM, the peptide Glu-Ala-Asp-Pro-Thr-Gly-His-Ser-Tyr was shown to  
25 be best. The assay showed lysis of 30%, indicating conferring of sensitivity to the anti-E CTL.

#### Example 35

Nucleic acid sequences referred to as "smage" were isolated from murine cells. Using the protocols described  
30 supra, a cosmid library was prepared from the DNA of normal DBA/2 kidney cells, using cosmid vector C2RB. As a probe, the 2.4 kb BamHI fragment of MAGE-1 was used. The DNA was blotted to nylon filters, and these were washed in 2xSSC at 65°C to identify the smage material.

#### Example 36

35 Further tissue samples were tested for the presence of MAGE genes, using the protocols discussed supra. Some of

these results follow.

There was no expression of the MAGE genes in brain or kidney tumor tissue. Colon tumor tissue showed expression of MAGE 1, 2, 3 and 4, although not all tumors tested showed expression of all MAGE genes. This is also true for pancreatic tumor (MAGE 1); non-small cell lung (MAGE 1, 2, 3 and 4), prostate (MAGE 1), sarcomas (MAGE 1, 2, 3 and 4), breast (MAGE 1, 2 and 3), and larynx (MAGE 1 and 4).

#### Example 37

A cytolytic CTL clone "20/38" was obtained from peripheral blood lymphocytes of melanoma patient MZ2. This clone is described by Van den Eynde et al., Int. J. Cancer 44: 634-640 (1989), the disclosure of which is incorporated by reference. The CTL clone has isolated following Herin et al., Int. J. Cancer 39: 390-396 (1987), which is incorporated by reference. The assay is described herein, however. Autologous melanoma cells were grown in vitro, and then resuspended at  $10^7$  cells/ml in DMEM, supplemented with 10% HEPES and 30% FCS, and incubated for 45 minutes at  $37^\circ\text{C}$  with  $200\text{ }\mu\text{Ci/ml}$  of  $\text{Na}^{51}\text{Cr}\text{O}_4$ . Labelled cells were washed three times with DMEM, supplemented with 10 mM HEPES. These were then resuspended in DMEM supplemented with 10 mM HEPES and 10% FCS, after which  $100\text{ }\mu\text{l}$  aliquots containing  $10^3$  cells, were distributed into 96 well microplates. Samples of the CTL clone were added in 100  $\mu\text{l}$  of the same medium, and assays were carried out in duplicate. Plates were centrifuged for four minutes at 100g, and incubated for four hours at  $37^\circ\text{C}$  in a 5.5%  $\text{CO}_2$  atmosphere.

Plates were centrifuged again, and 100  $\mu\text{l}$  aliquots of supernatant were collected and counted. Percentage of  $^{51}\text{Cr}$  release was calculated as follows:

$$\% \text{ } ^{51}\text{Cr release} = \frac{(\text{ER}-\text{SR})}{(\text{MR}-\text{SR})} \times 100$$

where ER is observed, experimental  $^{51}\text{Cr}$  release, SR is spontaneous release measured by incubating  $10^3$  labeled cells in 200  $\mu\text{l}$  of medium alone, and MR is maximum release, obtained

by adding 100 ul 0.3% Triton X-100 to target cells.

Those mononuclear blood samples which showed high CTL activity were expanded and cloned via limiting dilution, and were screened again, using the same methodology.

5 The same method was used to test target K562 cells. When EBV-B cells were used, the only change was the replacement of DMEM medium by Hank's medium, supplemented with 5% FCS.

These experiments led to isolation of CTL clone 20/38.

10 Figure 1 presents the results of these assays. Specifically, it will be seen that the CTL clone lysed autologous melanoma cell line MZ2-MEL.3.0, but did not lyse EBV-B cell lines, fibroblasts, K562 or non-autologous melanoma cell line SK-MEL-29.

#### Example 38

Once the CTL clone was recognized as being specific for the autologous cell line, it was tested for antigenic specificity. To do this, antigen loss variants derived from patient MZ2 were tested in the same type of chromium release assay described above. These target lines were MZ2-MEL 3.0, which is D<sup>+</sup>, E<sup>+</sup>, F<sup>+</sup>, A<sup>+</sup>, MZ2-MEL.61, which is D<sup>-</sup>, MZ2-MEL 2.2, which is E<sup>-</sup>, and MZ2-MEL.4, which is F<sup>-</sup>. In addition to CTL clone 20/38, clones which are known to be anti-A (CTL 28/336), anti-F (CTL 76/6), and anti-E (CTL 22/13) were tested.

25 These results are set forth in figure 15. It will be seen that CTL clone 20/38 lysed all the cell lines leading to chromium release except D<sup>-</sup> cell line MZ2-MEL.61, thus indicating that the CTL clone is anti-D. This result was confirmed, in experiments not included herein, by experiments  
30 where TNF release by the CTL clone was observed only in the presence of melanoma lines presenting antigen D.

#### Example 39

Once antigen D was identified as the target molecule, studies were carried out to determine the HLA type which  
35 presented it. The experiments described in example A showed that antigen D was presented by MZ2-MEL, and this cell line's HLA specificity is known (i.e., A1, A29, B37, B44, Cw6,

C.cl.10). It was also known, however, that a variant of MZ2-MEL which had lost HLA molecules A29, B44 and C.cl.10 still expressed antigen D, so these could be eliminated from consideration. Studies were not carried out on lines expressing B37, as none could be found.

In all, 13 allogeneic lines were tested, which expressed either HLA-A1 (10 of 13), or Cw6 (3 of 13). The cell lines were tested for their ability to stimulate release of TNF by CTL clone 20/38, using the method of Traversari et al., Immunogenetics 35: 145-152 (1992), the disclosure of which is incorporated by reference. This assay measures TNF release via testing toxicity of supernatants on WEHI 164-13 cells.

In the assays, cell samples (3000, 10,000 or 30,000 cells) from the allogeneic lines were cultured in the presence of 1500 cells of the CTL clone, and 25 u/ml of IL-2. Twenty-four hours later, the supernatant from the culture was tested against the WEHI cells for toxicity. The results are presented in Table 3, which follows.

Eight cell lines were found to stimulate TNF release from the CTL clone 20/38. All of these lines were HLA-A1. None of the Cw6 presenting lines did so.

The cell lines were also assayed to determine MAGE expression. All eight of the lines which stimulated TNF release expressed MAGE-3, whereas the two HLA-A1 lines which were negative did not.



**Example 40**

In view of the results set forth in example C, experiments were carried out to determine if antigen D was in fact a tumor rejection antigen derived from MAGE-3. To do this, recipient COS7 cells were transfected with 100ng of the gene for HLA-A1 cloned into pcDNA I/Amp, and 100 ng of one of (a) cDNA for MAGE-1 cloned into pcDNA I/Amp, (b) cDNA for MAGE-2 cloned into pcDSR $\alpha$ , or (c) cDNA for MAGE-3 cloned into pcDSR $\alpha$ . The transfecting sequences were ligated into the plasmids in accordance with manufacturer's instructions. Samples of COS-7 cells were seeded, at 15,000 cells/well into tissue culture flat bottom microwells, in Dulbecco's modified Eagles Medium ("DMEM") supplemented with 10% fetal calf serum. The cells were incubated overnight at 37°C, medium was removed and then replaced by 30  $\mu$ l/well of DMEM medium containing 10% Nu serum, 400  $\mu$ g/ml DEAE-dextran, 100  $\mu$ M chloroquine, and the plasmids described above. Following four hours of incubation at 37°C, the medium was removed, and replaced by 50  $\mu$ l of PBS containing 10% DMSO. This medium was removed after two minutes and replaced by 200  $\mu$ l of DMEM supplemented with 10% of FCS.

Following this change in medium, COS cells were incubated for 24 hours at 37°C. Medium was then discarded, and 1500 cells of CTL clones 20/38 were added, in 100  $\mu$ l of Iscove medium containing 10% pooled human serum, supplemented with 25 u/ml of IL-2. Supernatant was removed after 24 hours, and TNF content was determined in an assay on WEHI cells, as described by Traversari et al., Immunogenetics 35: 145-152 (1992), the disclosure of which is incorporated by reference. These results are shown in Figure 16.

It will be seen that the CTL clone was strongly stimulated by COS7 cells transfected with HLA-A1 and MAGE-3, but not by the cells transfected with the other mage genes. This leads to the conclusion that antigen D is a tumor rejection antigen derived from the tumor rejection antigen precursor coded by gene MAGE-3, and that this TRA is presented

by HLA-A1 molecules.

5 The foregoing disclosure, including the examples, places many tools of extreme value in the hands of the skilled artisan. To begin, the examples identify and provide a methodology for isolating nucleic acid molecules which code for tumor rejection antigen precursors as well as the nucleic acid molecules complementary thereto. It is known that DNA exists in double stranded form, and that each of the two strands is complementary to the other. Nucleic acid hybridization technology has developed to the point where, given a strand of DNA, the skilled artisan can isolate its complement, or synthesize it.

10 "Nucleic acid molecule" as used herein refers to all species of DNA and RNA which possess the properties discussed supra. Genomic and complementary DNA, or "cDNA" both code for particular proteins, and as the examples directed to isolation of MAGE coding sequences show, this disclosure teaches the artisan how to secure both of these.

15 Similarly, RNA molecules, such as mRNA can be secured. Again, with reference to the skilled artisan, once one has a coding sequence in hand, mRNA can be isolated or synthesized.

20 Complementary sequences which do not code for TRAP, such as "antisense DNA" or mRNA are useful, e.g., in probing for the coding sequence as well as in methodologies for blocking its expression.

25 It will also be clear that the examples show the manufacture of biologically pure cultures of cell lines which have been transfected with nucleic acid sequences which code for or express the TRAP molecules. Such cultures can be used as a source for tumor rejection antigens, e.g., or as therapeutics. This aspect of the invention is discussed infra.

30 Cells transfected with the TRAP coding sequences may also be transfected with other coding sequences. Examples of other coding sequences include cytokine genes, such as interleukins (e.g., IL-2 or IL-4), or major histocompatibility complex (MHC) or human leukocyte antigen (HLA) molecules.

Cytokine gene transfection is of value because expression of these is expected to enhance the therapeutic efficacy of the biologically pure culture of the cells in vivo. The art is well aware of therapies where interleukin transfectants have been administered to subjects for treating cancerous conditions. In a particularly preferred embodiment, cells are transfected with sequences coding for each of (i) a TRAP molecule, (ii) an HLA/MHC molecule, and (iii) a cytokine.

Transfection with an MHC/HLA coding sequence is desirable because certain of the TRAS may be preferentially or specifically presented only by particular MHC/HLA molecules. Thus, where a recipient cell already expresses the MHC/HLA molecule associated with presentation of a TRA, additional transfection may not be necessary although further transformation could be used to cause over-expression of the antigen. On the other hand, it may be desirable to transfect with a second sequence when the recipient cell does not normally express the relevant MHC/HLA molecule. It is to be understood, of course, that transfection with one additional sequence does not preclude further transfection with other sequences.

The term "biologically pure" as used in connection with the cell line described herein simply means that these are essentially free of other cells. Strictly speaking, a "cell line" by definition is "biologically pure", but the recitation will establish this fully.

Transfection of cells requires that an appropriate vector be used. Thus, the invention encompasses expression vectors where a coding sequence for the TRAP of interest is operably linked to a promoter. The promoter may be a strong promoter, such as those well known to the art, or a differential promoter, i.e., one which is operative only in specific cell types. The expression vectors may also contain all or a part of a viral or bacterial genome, such as vaccinia virus or BCG. Such vectors are especially useful in preparing vaccines.

The expression vectors may incorporate several coding sequences, as long as the TRAP sequence is contained therein.

The cytokine and/or MHC/HLA genes discussed supra may be included in a single vector with the TRAP sequence. Where this is not desired, then an expression system may be provided, where two or more separate vectors are used where each coding sequence is operably linked to a promoter. Again, the promoter may be a strong or differential promoter. Co-transfection is a well known technique, and the artisan in this field is expected to have this technology available for utilization. The vectors may be constructed so that they code for the TRA molecule directly, rather than the TRAP molecule. This eliminates the need for post-translational processing.

As the foregoing discussion makes clear, the sequences code for "tumor rejection antigen precursors" ("TRAPs") which, in turn, are processed into tumor rejection antigens ("TRAs"). Isolated forms of both of these categories are described herein, including specific examples of each. Perhaps their most noteworthy aspect is as vaccines for treating various cancerous conditions. The evidence points to presentation of TRAs on tumor cells, followed by the development of an immune response and deletion of the cells. The examples show that when various TRAs are administered to cells, a CTL response is mounted and presenting cells are deleted. This is behavior characteristic of vaccines, and hence TRAPs, which are processed into TRAs, and the TRAs themselves may be used, either alone or in pharmaceutically appropriate compositions, as vaccines. Similarly, presenting cells may be used in the same manner, either alone or as combined with ingredients to yield pharmaceutical compositions. Additional materials which may be used as vaccines include isolated cells which present the TRA molecule on their surface, as well as TRAP fragments, mutated viruses, especially etioloated forms, and transfected bacteria. "Fragments" as used herein refers to peptides which are smaller than the TRA, but which possess the properties required of a vaccine, as discussed supra. Another vaccine comprises or consists of complexes of TRA and HLA molecule. Vaccines of the type described herein may be used preventively, i.e., via administration to a subject in an

amount sufficient to prevent onset of a cancerous condition.

The generation of an immune response, be it T-cell or B-cell related, is characteristic of the effect of the presented tumor rejection antigen. With respect to the B-cell response, this involves, inter alia, the generation of antibodies to the TRA, i.e., which specifically bind thereto. In addition, the TRAP molecules are of sufficient size to render them immunogenic, and antibodies which specifically bind thereto are a part of this invention. These antibodies may be polyclonal or monoclonal, the latter being prepared by any of the well recognized methodologies for their preparation which need not be repeated here. For example, mAbs may be prepared using an animal model, e.g., a Balb/C mouse or in a test tube, using, e.g., EBV transformants. In addition, antiserum may be isolated from a subject afflicted with a cancerous condition where certain cells present a TRA. Such antibodies may also be generated to epitopes defined by the interaction of TRA and HLA/MHC molecules.

Review of the foregoing disclosure will show that there are a number of facets to the system which may be referred to as "tumor rejection antigen presentation and recognition". Recognition of these phenomena has diagnostic consequences. For example, the existence of specific CTL clones, or antibodies to the TRA makes it possible to diagnose or monitor cancerous conditions (explained infra), by monitoring the CTLs in a sample from a subject, binding of antibodies to TRAs, or the activity of anti-TRA CTLs in connection with subject samples. Similarly, the expression of nucleic acid molecules for TRAPs can be monitored via amplification (e.g., "polymerase chain reaction"), anti-sense hybridization, probe technologies, and so forth. Various subject samples, including body fluids (blood, serum, and other exudates, e.g.), tissues and tumors may be so assayed.

A particular manner of diagnosis is to use an adaptation of the standard "tuberculin test" currently used for diagnosis of tuberculosis. This standard skin test administers a stable form of "purified protein derivative" or "PPD" as a diagnostic

aid. In a parallel fashion, TRAs in accordance with this invention may be used in such a skin test as a diagnostic aid or monitoring method.

5 The term "cancerous condition" is used herein to embrace all physiological events that commence with the initiation of the cancer and result in final clinical manifestation. Tumors do not spring up "ab initio" as visible tumors; rather there are various events associated with the transformation of a normal cell to malignancy, followed by development of a growth  
10 of biomass, such as a tumor, metastasis, etc. In addition, remission may be conceived of as part of "a cancerous condition" as tumors seldom spontaneously disappear. The diagnostic aspects of this invention include all events involved in carcinogenesis, from the first transformation to malignancy of a single cell, through tumor development and metastasis, as well as remission. All are embraced herein.

Where "subject" is used, the term embraces any species which can be afflicted with a cancerous condition. This includes humans and non-humans, such as domesticated animals, breeding stock, and so forth.  
20

There are therapeutic aspects of this invention as well. The efficacy of administration of effective amounts of TRAPs and TRAs as vaccines has already been discussed supra. Similarly, one may develop the specific CTLs in vitro and then  
25 administer these to the subject. Antibodies may be administered, either polyclonal or monoclonal, which specifically bind to cells presenting the TRA of interest. These antibodies may be coupled to specific antitumor agents, including, but not being limited to, methotrexate radio-iodinated compounds, toxins such as ricin, other cytostatic or  
30 cytolytic drugs, and so forth. Thus, "targeted" antibody therapy is included herein, as is the application of deletion of the cancerous cells by the use of CTLs.

The data from examples 37-40 show that a tumor rejection antigen derived from MAGE-3 is presented by HLA-A1 molecules. As such, in addition to the nucleic acid molecules coding for this TRAP, the TRAP itself as coded for by the sequences,  
35

vectors, cell lines, etcetera which incorporate this nucleic acid molecule, the invention also encompasses combination of the molecules coding for the MAGE-3 TRAP and HLA-A1. Thus, co-transfectants, vectors containing coding sequences for both, expression systems such as kits, or separate vectors, and so forth, are all embraced by the invention. Similarly, the vaccines discussed supra can be made by incorporating the TRAP from MAGE-3 and an adjuvant.

It is to be understood that a given TRAP may yield more than one TRA. In the case of MAGE-3, it has been shown that antigen D, as the term is used herein, derives therefrom, and one aspect of the invention is this isolated tumor rejection antigen. Another is isolated complexes of the TRA and its presenting molecule, i.e., HLA-A1.

The identification of MAGE-3 derived TRAs as being presented by HLA-A1 molecules suggests various therapeutic and diagnostic approaches. In a therapeutic context, e.g., the treatment of a disorder characterized by MAGE-3 expression may be treated in a number of ways, "disorder" being used to refer to any pathological condition where MAGE-3 TRAP is expressed, such as cancer (e.g., melanoma).

Therapeutic approaches based upon the disclosure are premised on a response by a subject's immune system, leading to lysis of TRA presenting cells, such as HLA-A1 cells. One such approach is the administration of CTLs specific to the complex to a subject with abnormal cells of the phenotype at issue. it is within the skill of the artisan to develop such CTLs in vitro. Specifically, a sample of cells, such as blood cells, are contacted to a cell presenting the complex and capable of provoking a specific CTL to proliferate. The target cell can be a transfectant, such as a COS cell of the type described supra. These transfectants present the desired complex on their surface and, when combined with a CTL of interest, stimulate its proliferation. COS cells, such as those used herein are widely available, as are other suitable host cells.

To detail the therapeutic methodology, referred to as

adoptive transfer (Greenberg, J. Immunol. 136(5): 1917 (1986); Reddel et al., Science 257: 238 (7-10-92); Lynch et al., Eur. J. Immunol. 21: 1403-1410 (1991); Kast et al., Cell 59: 603-614 (11-17-89)), cells presenting the desired complex are combined with CTLs leading to proliferation of the CTLs specific thereto. The proliferated CTLs are then administered to a subject with a cellular abnormality which is characterized by certain of the abnormal cells presenting the particular complex. The CTLs then lyse the abnormal cells, thereby achieving the desired therapeutic goal.

The foregoing therapy assumes that at least some of the subject's abnormal cells present the HLA/TRA complex. This can be determined very easily, as the art is very familiar with methods for identifying cells which present a particular HLA molecule, as well as how to identify cells expressing DNA containing the indicated sequences. Once isolated, such cells can be used with a sample of a subject's abnormal cells to determine lysis in vitro. If lysis is observed, then the use of specific CTLs in such a therapy may alleviate the condition associated with the abnormal cells. A less involved methodology examines the abnormal cells for HLA phenotyping, using standard assays, and determines expression via amplification using, e.g., PCR.

Adoptive transfer is not the only form of therapy that is available in accordance with the invention. CTLs can also be provoked in vivo, using a number of approaches. One approach, i.e., the use of non-proliferative cells expressing the complex, has been elaborated upon supra. The cells used in this approach may be those that normally express the complex, such as irradiated melanoma cells or cells transfected with one or both of the genes necessary for presentation of the complex. Chen et al., Proc. Natl. Acad. Sci. USA 88: 110-114 (January, 1991) exemplifies this approach, showing the use of transfected cells expressing HPVE7 peptides in a therapeutic regime. Various cell types may be used. Similarly, vectors carrying one or both of the genes of interest may be used. Viral or bacterial vectors are especially preferred. In these



systems, the gene of interest is carried by, e.g., a Vaccinia virus or the bacteria BCG, and the materials de facto "infect" host cells. The cells which result present the complex of interest, and are recognized by autologous CTLs, which then proliferate. A similar effect can be achieved by combining the tumor rejection antigen or the precursor itself with an adjuvant to facilitate incorporation into HLA-A1 presenting cells which present the HLA molecule of interest. The TRAP is processed to yield the peptide partner of the HLA molecule while the TRA is presented without the need for further processing. Thus, one may treat disorders where a MAGE-3 derived TRA is presented by HLA-A1 molecules, or by any HLA molecule.

In a diagnostic context, one may determine a disorder, as the term is used herein, by assaying for expression of the TRAP. This can be done directly (via, e.g., a PCR assay for TRAP sequences), or indirectly, via assaying for a MAGE-3 derived TRA, as the TRA's presence means that the TRAP is or was expressed.

It will be noted that two nucleic acid molecules are presented herein, i.e., MAGE-3 and MAGE-31, each of which code for TRAP MAGE-3. It is to be understood that when the expression "nucleic acid molecule which codes for MAGE-3 TRAP" is used, all molecules are covered which yield this molecule upon expression. Any number of variations, such as those showing codon degeneracy within the coding region, or variation within the introns, are covered by the invention.

The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, it being recognized that various modifications are possible within the scope of the invention.

## (1) GENERAL INFORMATION:

- (i) APPLICANTS: Gaugler, Béatrice; Van den Eynde, Benoît;  
van der Bruggen, Pierre; Boon-Falleur, Thierry
- (ii) TITLE OF INVENTION: Isolated Nucleic Acid Molecules Coding For  
Tumor Rejection Antigen Precursor Mage-3 And Uses Thereof
- (iii) NUMBER OF SEQUENCES: 26
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Felfe & Lynch
  - (B) STREET: 805 Third Avenue
  - (C) CITY: New York City
  - (D) STATE: New York
  - (F) ZIP: 10022
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
  - (B) COMPUTER: IBM
  - (C) OPERATING SYSTEM: PC-DOS
  - (D) SOFTWARE: Wordperfect
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER: 08/037,230
  - (B) FILING DATE: 26-MARCH-1993
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: PCT/US92/04354
  - (B) FILING DATE: 22-MAY-1992
- (viii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: 07/807,043
  - (B) FILING DATE: 12-DECEMBER-1991
- (ix) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: 07/764,364
  - (B) FILING DATE: 23-SEPTEMBER-1991
- (x) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: 07/728,838
  - (b) FILING DATE: 9-JULY-1991
- (xi) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: 07/705,702
  - (B) FILING DATE: 23-MAY-1991
- (xii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Hanson, Norman D.
  - (B) REGISTRATION NUMBER: 30,946
  - (C) REFERENCE/DOCKET NUMBER: LUD 253.5
- (xiii) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: (212) 688-9200
  - (B) TELEFAX: (212) 838-3884

- (2) INFORMATION FOR SEQUENCE ID NO: 1:  
 (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 462 base pairs  
     (B) TYPE: nucleic acid  
     (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: genomic DNA  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

```

ACCACAGGAG AATGAAAAGA ACCCGGGACT CCCAAAGACG CTAGATGTGT GAAGATCCTG   60
ATCACTCATT GGGTGTCTGA GTTCTGCGAT ATTCATCCCT CAGCCAATGA GCTTACTGTT  120
CTCGTGGGGG GTTTGTGAGC CTTGGGTAGG AAGTTTTGCA AGTTCCGCCT ACAGCTCTAG  180
CTTGTGAATT TGTACCCTTT CACGTAAAAA AGTAGTCCAG AGTTTACTAC ACCCTCCCTC  240
CCCCCTCCCA CCTCGTGCTG TGCTGAGTTT AGAAGTCTTC CTTATAGAAG TCTTCCGTAT  300
AGAACTCTTC CGGAGGAAGG AGGGAGGACC CCCCCCTTT GCTCTCCAG CATGCATTGT  360
GTCAACGCCA TTGCACTGAG CTGGTCGAAG AAGTAAGCCG CTAGCTTGCG ACTCTACTCT  420
TATCTTAACT TAGCTCGGCT TCCTGCTGGT ACCCTTTGTG CC                               462

```

009250" E4562560

- (2) INFORMATION FOR SEQUENCE ID NO: 2:  
 (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 675 base pairs  
     (B) TYPE: nucleic acid  
     (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: genomic DNA  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

ATG TCT GAT AAC AAG AAA CCA GAC AAA GCC CAC AGT GGC TCA GGT GGT	48
Met Ser Asp Asn Lys Lys Pro Asp Lys Ala His Ser Gly Ser Gly Gly	
	5 10 15
GAC GGT GAT GGG AAT AGG TGC AAT TTA TTG CAC CGG TAC TCC CTG GAA	96
Asp Gly Asp Gly Asn Arg Cys Asn Leu Leu His Arg Tyr Ser Leu Glu	
	20 25 30
GAA ATT CTG CCT TAT CTA GGG TGG CTG GTC TTC GCT GTT GTC ACA ACA	144
Glu Ile Leu Pro Tyr Leu Gly Trp Leu Val Phe Ala Val Val Thr Thr	
	35 40 45
AGT TTT CTG GCG CTC CAG ATG TTC ATA GAC GCC CTT TAT GAG GAG CAG	192
Ser Phe Leu Ala Leu Gln Met Phe Ile Asp Ala Leu Tyr Glu Glu Gln	
	50 55 60
TAT GAA AGG GAT GTG GCC TGG ATA GCC AGG CAA AGC AAG CGC ATG TCC	240
Tyr Glu Arg Asp Val Ala Trp Ile Ala Arg Gln Ser Lys Arg Met Ser	
	65 70 75 80
TCT GTC GAT GAG GAT GAA GAC GAT GAG GAT GAT GAG GAT GAC TAC TAC	288
Ser Val Asp Glu Asp Glu Asp Asp Glu Asp Asp Glu Asp Asp Tyr Tyr	
	85 90 95
GAC GAC GAG GAC GAC GAC GAC GAT GCC TTC TAT GAT GAT GAG GAT GAT	336
Asp Asp Glu Asp Asp Asp Asp Asp Ala Phe Tyr Asp Asp Glu Asp Asp	
	100 105 110
GAG GAA GAA GAA TTG GAG AAC CTG ATG GAT GAT GAA TCA GAA GAT GAG	384
Glu Glu Glu Glu Leu Glu Asn Leu Met Asp Asp Glu Ser Glu Asp Glu	
	115 120 125
GCC GAA GAA GAG ATG AGC GTG GAA ATG GGT GCC GGA GCT GAG GAA ATG	432
Ala Glu Glu Glu Met Ser Val Glu Met Gly Ala Gly Ala Glu Glu Met	
	130 135 140
GGT GCT GGC GCT AAC TGT GCC TGT GTT CCT GGC CAT CAT TTA AGG AAG	480
Gly Ala Gly Ala Asn Cys Ala Cys Val Pro Gly His His Leu Arg Lys	
	145 150 155 160
AAT GAA GTG AAG TGT AGG ATG ATT TAT TTC TTC CAC GAC CCT AAT TTC	528
Asn Glu Val Lys Cys Arg Met Ile Tyr Phe Phe His Asp Pro Asn Phe	
	165 170 175
CTG GTG TCT ATA CCA GTG AAC CCT AAG GAA CAA ATG GAG TGT AGG TGT	576
Leu Val Ser Ile Pro Val Asn Pro Lys Glu Gln Met Glu Cys Arg Cys	
	180 185 190
GAA AAT GCT GAT GAA GAG GTT GCA ATG GAA GAG GAA GAA GAA GAA GAG	624
Glu Asn Ala Asp Glu Glu Val Ala Met Glu Glu Glu Glu Glu Glu	
	195 200 210
GAG GAG GAG GAG GAA GAG GAA ATG GGA AAC CCG GAT GGC TTC TCA CCT	672
Glu Glu Glu Glu Glu Glu Glu Met Gly Asn Pro Asp Gly Phe Ser Pro	
	220 225 230 235
TAG	675

009250" 64562560

- (2) INFORMATION FOR SEQUENCE ID NO: 3:  
(i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 228 base pairs  
    (B) TYPE: nucleic acid  
    (D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: genomic DNA  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

```
GCATGCAGTT GCAAAGCCCA GAAGAAAGAA ATGGACAGCG GAAGAAGTGG TTGTTTTTTT    60
TTCCCCTTCA TTAATTTTCT AGTTTTTAGT AATCCAGAAA ATTTGATTTT GTTCTAAAGT   120
TCATTATGCA AAGATGTCAC CAACAGACTT CTGACTGCAT GGTGAACTTT CATATGATAC   180
ATAGGATTAC ACTTGTACCT GTTAAAAATA AAAGTTTGAC TTGCATAC    228
```

009250 "CHS250"

- (2) INFORMATION FOR SEQUENCE ID NO: 4:  
 (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 1365 base pairs  
     (B) TYPE: nucleic acid  
     (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: genomic DNA  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

ACCACAGGAG AATGAAAAGA ACCCGGGACT CCCAAAGACG CTAGATGTGT 50  
 GAAGATCCTG ATCACTCATT GGGTGTCTGA GTTCTGCGAT ATTCATCCCT 100  
 CAGCCAATGA GCTTACTGTT CTCGTGGGGG GTTTGTGAGC CTTGGGTAGG 150  
 AAGTTTTGCA AGTTCCGCCT ACAGCTCTAG CTTGTGAATT TGTACCCTTT 200  
 CACGTAAAAA AGTAGTCCAG AGTTTACTAC ACCCTCCCTC CCCCCTCCCA 250  
 CCTCGTGCTG TGCTGAGTTT AGAAGTCTTC CTTATAGAAG TCTTCCGTAT 300  
 AGAACTCTTC CGGAGGAAGG AGGGAGGACC CCCCCCTTT GCTCTCCCAG 350  
 CATGCATTGT GTCAACGCCA TTGCACTGAG CTGGTCGAAG AAGTAAGCCG 400  
 CTAGCTTGCG ACTCTACTCT TATCTTAACT TAGCTCGGCT TCCTGCTGGT 450  
 ACCCTTTGTG CC 462  
 ATG TCT GAT AAC AAG AAA CCA GAC AAA GCC CAC AGT GGC TCA 504  
 GGT GGT GAC GGT GAT GGG AAT AGG TGC AAT TTA TTG CAC CGG 546  
 TAC TCC CTG GAA GAA ATT CTG CCT TAT CTA GGG TGG CTG GTC 588  
 TTC GCT GTT GTC ACA ACA AGT TTT CTG GCG CTC CAG ATG TTC 630  
 ATA GAC GCC CTT TAT GAG GAG CAG TAT GAA AGG GAT GTG GCC 672  
 TGG ATA GCC AGG CAA AGC AAG CGC ATG TCC TCT GTC GAT GAG 714  
 GAT GAA GAC GAT GAG GAT GAT GAG GAT GAC TAC TAC GAC GAC 756  
 GAG GAC GAC GAC GAC GAT GCC TTC TAT GAT GAT GAG GAT GAT 798  
 GAG GAA GAA GAA TTG GAG AAC CTG ATG GAT GAT GAA TCA GAA 840  
 GAT GAG GCC GAA GAA GAG ATG AGC GTG GAA ATG GGT GCC GGA 882  
 GCT GAG GAA ATG GGT GCT GGC GCT AAC TGT GCC TGT GTT CCT 924  
 GGC CAT CAT TTA AGG AAG AAT GAA GTG AAG TGT AGG ATG ATT 966  
 TAT TTC TTC CAC GAC CCT AAT TTC CTG GTG TCT ATA CCA GTG 1008  
 AAC CCT AAG GAA CAA ATG GAG TGT AGG TGT GAA AAT GCT GAT 1050  
 GAA GAG GTT GCA ATG GAA GAG GAA GAA GAA GAG GAG GAG 1092  
 GAG GAG GAA GAG GAA ATG GGA AAC CCG GAT GGC TTC TCA CCT 1134  
 TAG 1137  
 GCATGCAGTT GCAAAGCCCA GAAGAAAGAA ATGGACAGCG GAAGAAGTGG 1187  
 TTGTTTTTTT TTCCCCTTCA TTAATTTTCT AGTTTTTAGT AATCCAGAAA 1237  
 ATTTGATTTT GTTCTAAAGT TCATTATGCA AAGATGTCAC CAACAGACTT 1287  
 CTGACTGCAT GGTGAACCTT CATATGATAC ATAGGATTAC ACTTGTACCT 1337  
 GTTAAAAATA AAAGTTTGAC TTGCATAC 1365

009250" E4562560

- (2) INFORMATION FOR SEQUENCE ID NO: 5:  
 (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 4698 base pairs  
     (B) TYPE: nucleic acid  
     (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: genomic DNA  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

ACCACAGGAG AATGAAAAGA ACCCGGGACT CCCAAAGACG CTAGATGTGT 50  
 GAAGATCCTG ATCACTCATT GGGTGTCTGA GTTCTGCGAT ATTCATCCCT 100  
 CAGCCAATGA GCTTACTGTT CTCGTGGGGG GTTTGTGAGC CTGGGGTAGG 150  
 AAGTTTTGCA AGTTCGGCCT ACAGCTCTAG CTTGTGAATT TGTACCCCTT 200  
 CACGTAAAAA AGTAGTCCAG AGTTTACTAC ACCCTCCCTC CCCCCTCCCA 250  
 CCTCGTGCTG TGCTGAGTTT AGAAGTCTTC CTTATAGAAG TCTTCCGTAT 300  
 AGAACTCTTC CGGAGGAAGG AGGGAGGACC CCCCCCTTT GCTCTCCAG 350  
 CATGCATTGT GTCAACGCCA TTGCACTGAG CTGGTCGAAG AAGTAAGCCG 400  
 CTAGCTTGCG ACTCTACTCT TATCTTAACT TAGCTCGGCT TCCTGCTGGT 450  
 ACCCTTTGTG CC 462  
 ATG TCT GAT AAC AAG AAA CCA GAC AAA GCC CAC AGT GGC TCA 504  
 GGT GGT GAC GGT GAT GGG AAT AGG TGC AAT TTA TTG CAC CGG 546  
 TAC TCC CTG GAA GAA ATT CTG CCT TAT CTA GGG TGG CTG GTC 588  
 TTC GCT GTT GTC ACA ACA AGT TTT CTG GCG CTC CAG ATG TTC 630  
 ATA GAC GCC CTT TAT GAG GAG CAG TAT GAA AGG GAT GTG GCC 672  
 TGG ATA GCC AGG CAA AGC AAG CGC ATG TCC TCT GTC GAT GAG 714  
 GAT GAA GAC GAT GAG GAT GAT GAG GAT GAC TAC TAC GAC GAC 756  
 GAG GAC GAC GAC GAC GAT GCC TTC TAT GAT GAT GAG GAT GAT 798  
 GAG GAA GAA GAA TTG GAG AAC CTG ATG GAT GAT GAA TCA GAA 840  
 GAT GAG GCC GAA GAA GAG ATG AGC GTG GAA ATG GGT GCC GGA 882  
 GCT GAG GAA ATG GGT GCT GGC GCT AAC TGT GCC T 916  
 GTGAGTAACC CGTGGTCTTT ACTCTAGATT CAGGTGGGGT GCATTCTTTA 966  
 CTCTTGCCCA CATCTGTAGT AAAGACCACA TTTTGTTGG GGGTCATTGC 1016  
 TGGAGCCATT CCTGGCTCTC CTGTCCACGC CTATCCCCGC TCCTCCCATC 1066  
 CCCCCTCCT TGCTCCGCTC TCTTTCCTTT TCCCACCTTG CCTCTGGAGC 1116  
 TTCAGTCCAT CCGTCTCTGC TCCCTTTCCC CTTGCTCTC CTTGCTCCCC 1166  
 TCCCCCTCGG CTCAACTTTT CGTGCCTTCT GCTCTCTGAT CCCCACCTC 1216  
 TTCAGGCTTC CCCATTTGCT CTTCTCCCGA AACCTTCCC TTCTGTTC 1266  
 CCTTTTCGCG CCTTTTCTTT CTTGCTCCCC TCCCCCTCCC TATTTACCTT 1316  
 TCACCAGCTT TGCTCTCCCT GCTCCCCTCC CCCTTTTGCA CCTTTTCTTT 1366  
 TCCTGCTCCC CTCCCCCTCC CCTCCCTGTT TACCCTTCAC CGCTTTTCTT 1416  
 CTACCTGCTT CCCTCCCCCT TGCTGCTCCC TCCCTATTG CATTTTCCGG 1466  
 TGCTCCTCCC TCCCCCTCCC CCTCCCTCCC TATTTGCATT TTCGGGTGCT 1516  
 CCTCCCTCCC CCTCCCCAGG CCTTTTTTTT TTTTTTTTTT TTTTTTTTTT 1566  
 TTGGTTTTTC GAGACAGGGT TTCTCTTTGT ATCCCTGGCT GTCCTGGCAC 1616  
 TCACTCTGTA GACCAGGCTG GCCTCAAAC CAGAAATCTG CCTGCCTCTG 1666  
 CTCCCAAAT GCTGGGATTA AAGGCTTGCA CCAGGACTGC CCCAGTGCAG 1716  
 GCCTTTCTTT TTTCTCCTCT CTGGTCTCCC TAATCCCTTT TCTGCATGTT 1766  
 AACTCCCTTT TTGGCACCTT TCCTTTACAG GACCCCTCC CCCTCCCTGT 1816  
 TTCCCTTCCG GCACCTTCC TAGCCCTGCT CTGTTCCCTC TCCCTGCTCC 1866  
 CCTCCCCCTC TTTGCTCGAC TTTTAGCAGC CTTACCTCTC CCTGCTTTCT 1916  
 GCCCCGTTCC CCTTTTTTGT GCCTTTCTC CTGGCTCCCC TCCACCTTCC 1966  
 AGCTCACCTT TTTGTTTGT TGGTTGTTT GTTGTGTTGTT TTGCTTTTTT 2016  
 TTTTTTTTTT GCACCTTGTT TTCCAAGATC CCCCTCCCC TCCGGCTTCC 2066  
 CCTCTGTGT CCTTTCCTGT TCCCTCCCC TCGCTGGCTC CCCCCTCCCT 2116  
 TCTGCCTTTC CTGTCCCTGC TCCCTTCTCT GCTAACCTTT TAATGCCTTT 2166  
 CTTTTCTAGA CTCCCCCTC CAGGCTTGCT GTTTGCTTCT GTGCACTTTT 2216  
 CCTGACCCTG CTCCCCCTCC CCTCCCAGCT CCCCCCTCTT TTCCCACCTC 2266  
 CCTTTCTCCA GCCTGTCACC CCTCCTTCTC TCCTCTCTGT TTCTCCCACT 2316  
 TCCTGCTTCC TTTACCCCTT CCTCTCCCT ACTCTCCTCC CTGCCTGCTG 2366  
 GACTTCCTCT CCAGCCGCCC AGTTCCTGC AGTTCCTGGAG TCTTTCCTGC 2416  
 CTCTCTGTCC ATCACTTCCC CCTAGTTTCA CTTCCTTTC ACTCTCCCT 2466  
 ATGTGTCTCT CTTCCTATCT ATCCCTTCC TTCTGTCCCC TCTCCTCTGT 2516  
 CCATCACCTC TCTCCTCCCT TCCCTTTCCT CTCTCTTCCA TTTTCTTCCA 2566  
 CCTGCTTCTT TACCCTGCCT CTCCCATTGC CCTCTTACCT TTATGCCCAT 2616  
 TCCATGTCCC CTCTCAATTC CCTGTCCCAT TGTGCTCCCT CACATCTTCC 2666

009250" E4562560

ATTTCCCTCT	TTCTCCCTTA	GCCTCTTCTT	CCTCTTCTCT	TGTATCTCCC	2716
TTCCCTTTGC	TTCTCCCTCC	TCCTTTCCCC	TTCCCTATG	CCCTCTACTC	2766
TACTTGATCT	TCTCTCCTCT	CCACATACCC	TTTTTCCTTT	CCACCCTGCC	2816
CTTTGTCCCC	AGACCCTACA	GTATCCTGTG	CACAGGAAGT	GGGAGGTGCC	2866
ATCAACAACA	AGGAGGCAAG	AAACAGAGCA	AAATCCCAAA	ATCAGCAGGA	2916
AAGGCTGGAT	GAAAAATAAGG	CCAGGTTCTG	AGGACAGCTG	GAATCTAGCC	2966
AAGTGGCTCC	TATAACCCTA	AGTACCAAGG	GAGAAAAGTGA	TGGTGAAGTT	3016
CTTGATCCTT	GCTGCTTCTT	TTACATATGT	TGGCACATCT	TTCTCAAATG	3066
CAGGCCATGC	TCCATGCTTG	GCGCTTGCTC	AGCGTGTTA	AGTAATGGGA	3116
GAATCTGAAA	ACTAGGGGCC	AGTGGTTTGT	TTTGGGGACA	AATTAGCACG	3166
TAGTGATATT	TCCCCCTAAA	AATTATAACA	AACAGATTCA	TGATTTGAGA	3216
TCCTTCTACA	GGTGAGAAGT	GGAAAAATTG	TCACTATGAA	GTTCTTTTAA	3266
GGCTAAAGAT	ACTTGGAACC	ATAGAAGCGT	TGTTAAAATA	CTGCTTTCTT	3316
TTGCTAAAAAT	ATTCTTTTCTC	ACATATTCAT	ATTCTCCAG		3355
GT GTT CCT	GGC CAT CAT	TTA AGG	AAG AAT GAA	GTG AAG TGT	3396
AGG ATG ATT	TAT TTC	TTC CAC GAC	CCT AAT TTC	CTG GTG TCT	3438
ATA CCA GTG	AAC CCT	AAG GAA CAA	ATG GAG TGT	AGG TGT GAA	3480
AAT GCT GAT	GAA GAG	GTT GCA ATG	GAA GAG GAA	GAA GAA GAA	3522
GAG GAG GAG	GAG GAG	GAA GAG	ATG GGA AAC	CCG GAT GGC	3564
TTC TCA CCT	TAG				3576
GCATGCAGGT	ACTGGCTTCA	CTAACCAACC	ATTCCTAACA	TATGCCTGTA	3626
GCTAAGAGCA	TCTTTTTTAA	AAATATTATT	GGTAAACTAA	ACAATTGTGA	3676
TCTTTTTTACA	TTAATAAGTA	TTAAATTAAAT	CCAGTATACA	GTTTTAAGAA	3726
CCCTAAGTTA	AACAGAAGTC	AATGATGTCT	AGATGCCTGT	TCTTTAGATT	3776
GTAGTGAGAC	TACTTACTAC	AGATGAGAAG	TTGTTAGACT	CGGGAGTAGA	3826
GACCAGTAAA	AGATCATGCA	GTGAAATGTG	GCCATGGAAA	TCGCATATTG	3876
TTCTTATAGT	ACCTTTGAGA	CAGCTGATAA	CAGCTGACAA	AAATAAGTGT	3926
TTCAAGAAAG	ATCACACGCC	ATGGTTCACA	TGCAAAATTAT	TATTTTGTCTG	3976
TTCTGATTTT	TTTCATTTCT	AGACCTGTGG	TTTTAAAGAG	ATGAAAATCT	4026
CTTAAAATTT	CCTTCATCTT	TAATTTTCCT	TAACTTTAGT	TTTTTTTCACT	4076
TAGAATTCAA	TTCAAATTCT	TAATTCAATC	TTAATTTTTTA	GATTTCTTAA	4126
AATGTTTTTT	AAAAAAAATG	CAAATCTCAT	TTTTAAGAGA	TGAAAGCAGA	4176
GTAAGTGGGG	GGCTTAGGGG	ATCTGTAGGG	TTGCGGTATA	GCAATAGGGA	4226
GTTCTGGTCT	CTGAGAAGCA	GTCAGAGAGA	ATGGAAAACC	AGGCCCTTGC	4276
CAGTAGGTTA	GTGAGGTTGA	TATGATCAGA	TTATGGACAC	TCTCCAAATC	4326
ATAAATACTC	TAACAGCTAA	GGATCTCTGA	GGGAAACACA	ACAGGGAAAT	4376
ATTTTAGTTT	CTCCTTGAGA	AACAATGACA	AGACATAAAA	TTGGCAAGAA	4426
AGTCAGGAGT	GTATTCTAAT	AAGTGTGCT	TATCTCTTAT	TTTCTTCTAC	4476
AGTTGCAAAG	CCCAGAAGAA	AGAAATGGAC	AGCGGAAGAA	GTGGTTGTTT	4526
TTTTTTCCCC	TTCAATTAAT	TTCTAGTTT	TAGTAATCCA	GAAAATTTGA	4576
TTTTGTCTTA	AAGTTCATTA	TGCAAAGATG	TCACCAACAG	ACTTCTGACT	4626
GCATGGTGAA	CTTTCATATG	ATACATAGGA	TTACTCTTGT	ACCTGTTAAA	4676
AATAAAAGTT	TGACTTGCAT	AC			4698



Leu Pro Tyr Leu Gly Trp Leu Val Phe  
5

Leu Pro Tyr Leu Gly Trp Leu Val Phe  
5

- (2) INFORMATION FOR SEQUENCE ID NO: 7:  
 (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 2418 base pairs  
     (B) TYPE: nucleic acid  
     (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: genomic DNA  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

GGATCCAGGC	CCTGCCAGGA	AAAATATAAG	GGCCCTGCGT	GAGAACAGAG	50
GGGGTCATCC	ACTGCATGAG	AGTGGGGATG	TCACAGAGTC	CAGCCCACCC	100
TCCTGGTAGC	ACTGAGAAGC	CAGGGCTGTG	CTTGCGGTCT	GCACCCTGAG	150
GGCCCGTGGA	TTCCTCTTCC	TGGAGCTCCA	GGAACCAGGC	AGTGAGGCCT	200
TGGTCTGAGA	CAGTATCCTC	AGGTCACAGA	GCAGAGGATG	CACAGGGTGT	250
GCCAGCAGTG	AATGTTTGCC	CTGAATGCAC	ACCAAGGGCC	CCACCTGCCA	300
CAGGACACAT	AGGACTCCAC	AGAGTCTGGC	CTCACCTCCC	TACTGTCACT	350
CCTGTAGAAT	CGACCTCTGC	TGGCCGGCTG	TACCTGAGT	ACCTCTCAC	400
TTCCTCCTTC	AGGTTTTTTCAG	GGGACAGGCC	AACCCAGAGG	ACAGGATTCC	450
CTGGAGGCCA	CAGAGGAGCA	CCAAGGAGAA	GATCTGTAAG	TAGGCCTTTG	500
TTAGAGTCTC	CAAGGTTTCAG	TTCTCAGCTG	AGGCCCTCTCA	CACACTCCCT	550
CTCTCCCCAG	GCCTGTGGGT	CTTCATTGCC	CAGCTCCTGC	CCACACTCCT	600
GCCTGCTGCC	CTGACGAGAG	TCATCATGTC	TCTTGAGCAG	AGGAGTCTGC	650
ACTGCAAGCC	TGAGGAAGCC	CTTGAGGCC	AACAAGAGGC	CCTGGGCCTG	700
GTGTGTGTGC	AGGCTGCCAC	CTCCTCCTCC	TCTCCTCTGG	TCCTGGGCAC	750
CCTGGAGGAG	GTGCCCCACTG	CTGGGTCAAC	AGATCCTCCC	CAGAGTCCCT	800
AGGGAGCCTC	CGCCTTTCCC	ACTACCATCA	ACTTCACTCG	ACAGAGGCAA	850
CCCAGTGAGG	GTTCCAGCAG	CCGTGAAGAG	GAGGGGCCAA	GCACCTCTTG	900
TATCCTGGAG	TCCTTGTTCC	GAGCAGTAAT	CACTAAGAAG	GTGGCTGATT	950
TGGTTGGTTT	TCTGCTCCTC	AAATATCGAG	CCAGGGAGCC	AGTCACAAAG	1000
GCAGAAATGC	TGGAGAGTGT	CATCAAAAAT	TACAAGCACT	GTTTTCTCTGA	1050
GATCTTCGGC	AAAGCCTCTG	AGTCCTTGCA	GCTGGTCTTT	GGCATTGACG	1100
TGAAGGAAGC	AGACCCACC	GGCCACTCCT	ATGTCCTTGT	CACCTGCCTA	1150
GGTCTCTCCT	ATGATGGCCT	GCTGGGTGAT	AATCAGATCA	TGCCCAAGAC	1200
AGGCTTCCTG	ATAATTGTCC	TGGTCATGAT	TGCAATGGAG	GGCGGCCATG	1250
CTCCTGAGGA	GGAAATCTGG	GAGGAGCTGA	GTGTGATGGA	GGTGTATGAT	1300
GGGAGGGAGC	ACAGTGCCCTA	TGGGGAGCCC	AGGAAGCTGC	TCACCCAAGA	1350
TTTGGTGCAG	GAAAAGTACC	TGGAGTACGG	CAGGTGCCGG	ACAGTGATCC	1400
CGCACGCTAT	GAGTTCCTGT	GGGGTCCAAG	GGCCCTCGCT	GAAACCAGCT	1450
ATGTGAAAGT	CCTTGAGTAT	GTGATCAAGG	TCAGTGCAAG	AGTTCGCTTT	1500
TTCTTCCCAT	CCCTGCGTGA	AGCAGCTTTG	AGAGAGGAGG	AAGAGGGAGT	1550
CTGAGCATGA	GTTGCAGCCA	AGGCCAGTGG	GAGGGGGACT	GGGCCAGTGC	1600
ACCTTCCAGG	GCCGCGTCCA	GCAGCTTCCC	CTGCCTCGTG	TGACATGAGG	1650
CCCATTCTTC	ACTCTGAAGA	GAGCGGTCAG	TGTTCTCAGT	AGTAGGTTTC	1700
TGTTCTATTG	GGTGAATTGG	AGATTTATCT	TTGTTCTCTT	TTGGAATTGT	1750
TCAAATGTTT	TTTTTTTAAGG	GATGGTTGAA	TGAACTTCAG	CATCCAAGTT	1800
TATGAATGAC	AGCAGTCACA	CAGTTCCTGT	TATATAGTTT	AAGGGTAAGA	1850
GTCTTGTGTT	TTATTTCAGAT	TGGGAAATCC	ATTCTATTTT	GTGAATTGGG	1900
ATAATAACAG	CAGTGGAATA	AGTACTTAGA	AATGTGAAAA	ATGAGCAGTA	1950
AAATAGATGA	GATAAAGAAC	TAAAGAAATT	AAGAGATAGT	CAATTCTTGC	2000
CTTATACCTC	AGTCTATTCT	GTAAAATTTT	TAAAGATATA	TGCATACCTG	2050
GATTTCTCTG	GCTTCTTTGA	GAATGTAAGA	GAAATTAAAT	CTGAATAAAG	2100
AATTCTTCCT	GTTCACTGGC	TCTTTTCTTC	TCCATGCACT	GAGCATCTGC	2150
TTTTTTGGAAG	GCCCTGGGTT	AGTAGTGGAG	ATGCTAAGGT	AAGCCAGACT	2200
CATACCCACC	CATAGGGTCG	TAGAGTCTAG	GAGCTGCAGT	CACGTAATCG	2250
AGGTGGCAAG	ATGTCCTCTA	AAGATGTAGG	GAAAAGTGAG	AGAGGGGTGA	2300
GGGTGTGGGG	CTCCGGGTGA	GAGTGGTGGG	GTGTCAATGC	CCTGAGCTGG	2350
GGCATTTTTG	GCTTTGGGAA	ACTGCAGTTC	CTTCTGGGGG	AGCTGATTGT	2400
AATGATCTTG	GGTGGATCC				2418

- (2) INFORMATION FOR SEQUENCE ID NO: 8:  
 (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 5724 base pairs  
     (B) TYPE: nucleic acid  
     (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: genomic DNA  
 (ix) FEATURE:  
     (A) NAME/KEY: MAGE-1 gene  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

CCCGGGGCAC	CACTGGCATC	CCTCCCCCTA	CCACCCCCAA	TCCCTCCCTT	50
TACGCCACCC	ATCCAAACAT	CTTCACGCTC	ACCCCCAGCC	CAAGCCAGGC	100
AGAATCCGGT	TCCACCCCTG	CTCTCAACCC	AGGGAAGCCC	AGGTGCCCAG	150
ATGTGACGCC	ACTGACTTGA	GCATTAGTGG	TTAGAGAGAA	GCGAGGTTTT	200
CGGTCTGAGG	GGCGGCTTGA	GATCGGTGGA	GGGAAGCGGG	CCCAGCTCTG	250
TAAGGAGGCA	AGGTGACATG	CTGAGGGAGG	ACTGAGGACC	CACTTACCCC	300
AGATAGAGGA	CCCCAAATAA	TCCCTTCATG	CCAGTCCTGG	ACCATCTGGT	350
GGTGGACTTC	TCAGGCTGGG	CCACCCCCAG	CCCCCTTGCT	GCTTAAACCA	400
CTGGGGACTC	GAAGTCAGAG	CTCCGTGTGA	TCAGGGAAGG	GCTGCTTAGG	450
AGAGGGCAGC	GTCCAGGCTC	TGCCAGACAT	CATGCTCAGG	ATTCTCAAGG	500
AGGGCTGAGG	GTCCCTAAGA	CCCCACTCCC	GTGACCCAAC	CCCCACTCCA	550
ATGCTCACTC	CCGTGACCCA	ACCCCTCTTT	CATTGTCAAT	CCAACCCCCA	600
CCCCACATCC	CCCACCCCAT	CCCTCAACCC	TGATGCCCAT	CCGCCCAGCC	650
ATTCCACCTT	CACCCCCACC	CCCACCCCCA	CGCCCACTCC	CACCCCCACC	700
CAGGCAGGAT	CCGGTTCCCG	CCAGGAAACA	TCCGGGTGCC	CGGATGTGAC	750
GCCACTGACT	TGCGCATTGT	GGGGCAGAGA	GAAGCGAGGT	TTCCATTCTG	800
AGGGACGGCG	TAGAGTTCGG	CCGAAGGAAC	CTGACCCAGG	CTCTGTGAGG	850
AGGCAAGGTG	AGAGGCTGAG	GGAGGACTGA	GGACCCCGCC	ACTCCAAATA	900
GAGAGCCCCA	AATATTCCAG	CCCCGCCCTT	GCTGCCAGCC	CTGGCCCACC	950
CGCGGGAAGA	CGTCTCAGCC	TGGGCTGCCC	CCAGACCCCT	GCTCCAAAAG	1000
CCTTGAGAGA	CACCAGGTTT	TTCTCCCCAA	GCTCTGGAAT	CAGAGGTTGC	1050
TGTGACCAGG	GCAGGACTGG	TTAGGAGAGG	GCAGGGCACA	GGCTCTGCCA	1100
GGCATCAAGA	TCAGCACCCA	AGAGGGAGGG	CTGTGGGCCC	CCAAGACTGC	1150
ACTCCAATCC	CCACTCCCAC	CCCATTGCGA	TTCCCATTTT	CCACCCAACC	1200
CCCATCTCCT	CAGCTACACC	TCCACCCCCA	TCCCTACTCC	TACTCCGTCA	1250
CCTGACCACC	ACCCTCCAGC	CCCAGCACCA	GCCCCAACCC	TTCTGCCACC	1300
TCACCCTCAC	TGCCCCCAAC	CCCACCCTCA	TCTCTCTCAT	GTGCCCCACT	1350
CCCATCGCCT	CCCCCATTTT	GGCAGAATCC	GGTTTGCCCC	TGCTCTCAAC	1400
CCAGGGAAGC	CCCTGGTAGG	CCGATGTGAA	ACCACTGACT	TGAACCTCAC	1450
AGATCTGAGC	GAAGCCAGGT	TCATTTAATG	GTCTTGAGGG	GCGGCTTGAG	1500
ATCCACTGAG	GGGAGTGGTT	TTAGGCTCTG	TGAGGAGGCA	AGGTGAGATG	1550
CTGAGGGAGG	ACTGAGGAGG	CACACACCCC	AGGTAGATGG	CCCCAAAATG	1600
ATCCAGTACC	ACCCCTGCTG	CCAGCCCTGG	ACCACCCGGC	CAGGACAGAT	1650
GTCTCAGCTG	GACCACCCCC	CGTCCCGTCC	CAGTGCCACT	TAACCCACAG	1700
GGCAATCTGT	AGTCATAGCT	TATGTGACCG	GGGCAGGGTT	GGTCAGGAGA	1750
GGCAGGGCCC	AGGCATCAAG	GTCCAGCATC	CGCCCGGCAT	TAGGGTCAGG	1800
ACCCTGGGAG	GGAAGTGAGG	GTTCCCCACC	CACACCTGTC	TCCTCATCTC	1850
CACCGCCACC	CCACTCACAT	TCCCATACTT	ACCCCTTACC	CCCAACCTCA	1900
TCTTGTCAGA	ATCCCTGCTG	TCAACCCACG	GAAGCCACGG	GAATGGCGGC	1950
CAGGCACTCG	GATCTTGACG	TCCCCATCCA	GGGTCTGATG	GAGGGAAGGG	2000
GCTTGAACAG	GGCCTCAGGG	GAGCAGAGGG	AGGGCCCTAC	TGCGAGATGA	2050
GGGAGGCCTC	AGAGGACCCA	GCACCCTAGG	ACACCGCACC	CCTGTCTGAG	2100
ACTGAGGCTG	CCACTTCTGG	CCTCAAGAAT	CAGAACGATG	GGGACTCAGA	2150
TTGCATGGGG	GTGGGACCCA	GGCCTGCAAG	GCTTACGCGG	AGGAAGAGGA	2200
GGGAGGACTC	AGGGGACCTT	GGAATCCAGA	TCAGTGTGGA	CCTCGGCCCT	2250
GAGAGGTCCA	GGGCACGGTG	GCCACATATG	GCCCATATTT	CCTGCATCTT	2300
TGAGGTGACA	GGACAGAGCT	GTGGTCTGAG	AAGTGGGGCC	TCAGGTCAAC	2350
AGAGGGAGGA	GTTCCAGGAT	CCATATGGCC	CAGATGTGTC	CCCCCTCATG	2400
AGGACTGGGG	ATATCCCCGG	CTCAGAAAGA	AGGGACTCCA	CACAGTCTGG	2450
CTGTCCCCTT	TTAGTAGCTC	TAGGGGGACC	AGATCAGGGA	TGGCGGTATG	2500
TTCCATTCTT	ACTTGTACCA	CAGGCAGGAA	GTTGGGGGGC	CCTCAGGGAG	2550
ATGGGGTCTT	GGGGTAAAGG	GGGGATGTCT	ACTCATGTCA	GGGAATTGGG	2600
GGTTGAGGAA	GCACAGGCGC	TGGCAGGAAT	AAAGATGAGT	GAGACAGACA	2650
AGGCTATTGG	AATCCACACC	CCAGAACCAA	AGGGGTCAGC	CCTGGACACC	2700

TCACCCAGGA	TGTGGCTTCT	TTTTCACTCC	TGTTTCCAGA	TCTGGGGCAG	2750
GTGAGGACCT	CATTCTCAGA	GGGTGACTCA	GGTCAACGTA	GGGACCCCCA	2800
TCTGGTCTAA	AGACAGAGCG	GTCCCAGGAT	CTGCCATGCG	TTCGGGTGAG	2850
GAACATGAGG	GAGGACTGAG	GGTACCCCAG	GACCAGAACA	CTGAGGGGAGA	2900
CTGCACAGAA	ATCAGCCCTG	CCCCTGCTGT	CACCCCAGAG	AGCATGGGCT	2950
GGGCCGTCTG	CCGAGGTCCT	TCCGTTATCC	TGGGATCATT	GATGTCAGGG	3000
ACGGGGAGGC	CTTGGTCTGA	GAAGGCTGCG	CTCAGGTCAG	TAGAGGGAGC	3050
GTCCCAGGCC	CTGCCAGGAG	TCAAGGTGAG	GACCAAGCGG	GCACCTCACC	3150
CAGGACACAT	TAATTCCAAT	GAATTTTGAT	ATCTCTTGCT	GCCCTTCCCC	3200
AAGGACCTAG	GCACGTGTGG	CCAGATGTTT	GTCCCCTCCT	GTCCTTCCAT	3250
TCCTTATCAT	GGATGTGAAC	TCTTGATTTG	GATTTCCTCAG	ACCAGCAAAA	3300
GGGCAGGATC	CAGGCCCTGC	CAGGAAAAAT	ATAAGGGCCC	TGCGTGAGAA	3350
CAGAGGGGGT	CATCCACTGC	ATGAGAGTGG	GGATGTCACA	GAGTCCAGCC	3400
CACCCTCCTG	GTAGCACTGA	GAAGCCAGGG	CTGTGCTTGC	GGTCTGCACC	3450
CTGAGGGCCC	GTGGATTCCCT	CTTCCTGGAG	CTCCAGGAAC	CAGGCAGTGA	3500
GGCCTTGGTC	TGAGACAGTA	TCCTCAGGTC	ACAGAGCAGA	GGATGCACAG	3550
GGTGTGCCAG	CAGTGAATGT	TTGCCCTGAA	TGCACACCAA	GGGCCCCACC	3600
TGCCACAGGA	CACATAGGAC	TCCACAGAGT	CTGGCCTCAC	CTCCCTACTG	3650
TCAGTCTCTG	AGAATCGACC	TCTGCTGGCC	GGCTGTACCC	TGAGTACCCT	3700
CTCACTTCCT	CCTTCAGGTT	TTCAGGGGAC	AGGCCAACCC	AGAGGACAGG	3750
ATTCCCTGGA	GGCCACAGAG	GAGCACCAAG	GAGAAGATCT	GTAAGTAGGC	3800
CTTTGTTAGA	GTCTCCAAGG	TTCAGTTCTC	AGCTGAGGCC	TCTCACACAC	3850
TCCCTCTCTC	CCCAGGCCTG	TGGGTCTTCA	TTGCCCAGCT	CCTGCCCCACA	3900
CTCCTGCCTG	CTGCCCTGAC	GAGAGTCATC			3930
ATG TCT CTT	GAG CAG AGG	AGT CTG CAC	TGC AAG CCT	GAG GAA	3972
GCC CTT GAG	GCC CAA CAA	GAG GCC CTG	GGC CTG GTG	TGT GTG	4014
CAG GCT GCC	ACC TCC TCC	TCT CCT CTG	GTC CTG GGC	ACC	4056
CTG GAG GAG	GTG CCC ACT	GCT GGG TCA	ACA GAT CCT	CCC CAG	4098
AGT CCT CAG	GGA GCC TCC	GCC TTT CCC	ACT ACC ATC	AAC TTC	4140
ACT CGA CAG	AGG CAA CCC	AGT GAG GGT	TCC AGC AGC	CGT GAA	4182
GAG GAG GGG	CCA AGC ACC	TCT TGT ATC	CTG GAG TCC	TTG TTC	4224
CGA GCA GTA	ATC ACT AAG	AAG GTG GCT	GAT TTG GTT	GGT TTT	4266
CTG CTC CTC	AAA TAT CGA	GCC AGG GAG	CCA GTC ACA	AAG GCA	4308
GAA ATG CTG	GAG AGT GTC	ATC AAA AAT	TAC AAG CAC	TGT TTT	4350
CCT GAG ATC	TTC GGC AAA	GCC TCT GAG	TCC TTG CAG	CTG GTC	4392
TTT GGC ATT	GAC GTG AAG	GAA GCA GAC	CCC ACC GGC	CAC TCC	4434
TAT GTC CTT	GTC ACC TGC	CTA GGT CTC	TCC TAT GAT	GGC CTG	4476
CTG GGT GAT	AAT CAG ATC	ATG CCC AAG	ACA GGC TTC	CTG ATA	4518
ATT GTC CTG	GTC ATG ATT	GCA ATG GAG	GGC GGC CAT	GCT CCT	4560
GAG GAG GAA	ATC TGG GAG	GAG CTG AGT	GTG ATG GAG	GTG TAT	4602
GAT GGG AGG	GAG CAC AGT	GCC TAT GGG	GAG CCC AGG	AAG CTG	4644
CTC ACC CAA	GAT TTG GTG	CAG GAA AAG	TAC CTG GAG	TAC GGC	4686
AGG TGC CGG	ACA GTG ATC	CCG CAC GCT	ATG AGT TCC	TGT GGG	4728
GTC CAA GGG	CCC TCG CTG	AAA CCA GCT	ATG TGA		4761
AAGTCCTTGA	GTATGTGATC	AAGGTCAGTG	CAAGAGTTC		4800
GCTTTTTCTT	CCCATCCCTG	CGTGAAGCAG	CTTTGAGAGA	GGAGGAAGAG	4850
GGAGTCTGAG	CATGAGTTGC	AGCCAAGGCC	AGTGGGAGGG	GGACTGGGCC	4900
AGTGCACCTT	CCAGGGCCGC	GTCCAGCAGC	TTCCCCTGCC	TCGTGTGACA	4950
TGAGGGCCAT	TCTTCACTCT	GAAGAGAGCG	GTCAGTGTTT	TCAGTAGTAG	5000
GTTTCTGTTC	TATTGGGTGA	CTTGAGAGTT	TATCTTTGTT	CTCTTTTGGA	5050
ATTGTTCAAA	TGTTTTTTTT	TAAGGGATGG	TTGAATGAAC	TTCAGCATCC	5100
AAGTTTATGA	ATGACAGCAG	TCACACAGTT	CTGTGTATAT	AGTTTAAGGG	5150
TAAGAGTCTT	GTGTTTTTAT	CAGATTGGGA	AATCCATTCT	ATTTTGTGAA	5200
TTGGGATAAT	AACAGCAGTG	GAATAAGTAC	TTAGAAATGT	GAAAAATGAG	5250
CAGTAAATA	GATGAGATAA	AGAACTAAAG	AAATTAAGAG	ATAGTCAATT	5300
CTTGCCCTTAT	ACCTCAGTCT	ATTCTGTAAA	ATTTTTAAAG	ATATATGCAT	5350
ACCTGGATTT	CCTTGGCTTC	TTTGAGAAAT	TAAGAGAAAT	TAAATCTGAA	5400
TAAAGAATTC	TTCCTGTTCA	CTGGCTCTTT	TCTTCTCCAT	GCACTGAGCA	5450
TCTGCTTTTT	GGAAGGCCCT	GGGTTAGTAG	TGGAGATGCT	AAGGTAAGCC	5500
AGACTCATAC	CCACCCATAG	GGTCGTAGAG	TCTAGGAGCT	GCAGTCACGT	5550
AATCGAGTGC	GCAAGATGTC	CTCTAAAGAT	GTAGGGAAAA	GTGAGAGAGG	5600
GGTGAGGGTG	TGGGGCTCCG	GGTGAGAGTG	GTGGAGTGTC	AATGCCCTGA	5650
GCTGGGGCAT	TTTGGGCTTT	GGGAAACTGC	AGTTCCTTCT	GGGGGAGCTG	5700
ATTGTAATGA	TCTTGGGTGG	ATCC			5724

- (2) INFORMATION FOR SEQUENCE ID NO: 9:  
 (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 4157 base pairs  
     (B) TYPE: nucleic acid  
     (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: genomic DNA  
 (ix) FEATURE:  
     (A) NAME/KEY: MAGE-2 gene  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

CCCATCCAGA	TCCCCATCCG	GGCAGAATCC	GGTTCCACCC	TTGCCGTGAA	50
CCCAGGGAAG	TCACGGGGCC	GGATGTGACG	CCACTGACTT	GCACATTGGA	100
GGTCAGAGGA	CAGCGAGATT	CTCGCCCTGA	GCAACGGCCT	GACGTCGGCG	150
GAGGGAAGCA	GGCGCAGGCT	CCGTGAGGAG	GCAAGGTAAG	ACGCCGAGGG	200
AGGACTGAGG	CGGGCCTCAC	CCCAGACAGA	GGGCCCCCAA	TTAATCCAGC	250
GCTGCCTCTG	CTGCCGGGCC	TGGACCACCC	TGCAGGGGAA	GACTTCTCAG	300
GCTCAGTCG	CACCACCTCA	CCCCGCCACC	CCCCGCCGCT	TTAACCGCAG	350
GGAACTCTGG	CGTAAGAGCT	TTGTGTGACC	AGGGCAGGGC	TGGTTAGAAG	400
TGCTCAGGGC	CCAGACTCAG	CCAGGAATCA	AGGTCAGGAC	CCCAAGAGGG	450
GACTGAGGGC	AACCCACCCC	CTACCCTCAC	TACCAATCCC	ATCCCCCAAC	500
ACCAACCCCA	CCCCCATCCC	TCAAACACCA	ACCCACCCC	CAAACCCCAT	550
TCCCATCTCC	TCCCCACCA	CCATCCTGGC	AGAAATCCGG	TTTGCCCTG	600
CAATCAACCC	ACGGAAGCTC	CGGGAATGGC	GGCCAAGCAC	GCGGATCCTG	650
ACGTTACAT	GTACGGCTAA	GGGAGGGAAG	GGGTTGGGTC	TCGTGAGTAT	700
GGCCTTTGGG	ATGCAGAGGA	AGGGCCAGG	CCTCCTGGAA	GACAGTGGAG	750
TCCTTAGGGG	ACCCAGCATG	CCAGGACAGG	GGGCCCACTG	TACCCCTGTC	800
TCAAACCTGAG	CCACCTTTTC	ATTCAGCCGA	GGGAATCCTA	GGGATGCAGA	850
CCCACTTCAG	GGGGTTGGGG	CCCAGCCTGC	GAGGAGTCAA	GGGGAGGAAG	900
AAGAGGGAGG	ACTGAGGGGA	CCTTGGAGTC	CAGATCAGTG	GCAACCTTGG	950
GCTGGGGGAT	CCTGGGCACA	GTGGCCGAAT	GTGCCCCGTG	CTCATTGCAC	1000
CTTCAGGGTG	ACAGAGAGTT	GAGGGCTGTG	GTCTGAGGGC	TGGGACTTCA	1050
GGTCAGCAGA	GGGAGGAATC	CCAGGATCTG	CCGGACCCAA	GGTGTGCCCC	1100
CTTCATGAGG	ACTCCCCATA	CCCCCGGCC	AGAAAGAAGG	GATGCCACAG	1150
AGTCTGGAAG	TAAATTGTTT	TTAGCTCTGG	GGGAACCTGA	TCAGGGATGG	1200
CCCTAAGTGA	CAATCTCATT	TGTACCACAG	GCAGGAGGTT	GGGGAACCTT	1250
CAGGAGAGTA	AGGTGTTGGT	GTAAAGAGGA	GCTGTCTGCT	CATTTCAGGG	1300
GGTTCCCCCT	TGAGAAAGGG	CAGTCCCTGG	CAGGAGTAAA	GATGAGTAAC	1350
CCACAGGAGG	CCATCATAAC	GTTCAACCCTA	GAACCAAAGG	GGTCAGCCCT	1400
GGACAACGCA	CGTGGGGTAA	CAGGATGTGG	CCCCTCCTCA	CTTGTCTTTC	1450
CAGATCTCAG	GGAGTTGATG	ACCTTGTTTT	CAGAAGGTGA	CTCAGTCAAC	1500
ACAGGGGCC	CTCTGGTCGA	CAGATGCAGT	GGTTCTAGGA	TCTGCCAAGC	1550
ATCCAGGTGG	AGAGCCTGAG	GTAGGATTGA	GGGTACCCCT	GGGCCAGAAT	1600
GCAGCAAGGG	GGCCCCATAG	AAATCTGCCC	TGCCCTGCG	GTTACTTCAG	1650
AGACCCTGGG	CAGGGCTGTC	AGCTGAAGTC	CCTCCATTAT	CTGGGATCTT	1700
TGATGTCAGG	GAAAGGGAGG	CCTTGGTCTG	AAGGGGCTGG	AGTCAGGTCA	1750
GTAGAGGGAG	GGTCTCAGGC	CCTGCCAGGA	GTGGACGTGA	GGACCAAGCG	1800
GACTCGTCAC	CCAGGACACC	TGGACTCCAA	TGAATTTGAC	ATCTCTCGTT	1850
GTCCTTCGCG	GAGGACCTGG	TCACGTATGG	CCAGATGTGG	GTCCCCTCTA	1900
TCTCCTTCTG	TACCATATCA	GGGATGTGAG	TTCTTGACAT	GAGAGATTCT	1950
CAAGCCAGCA	AAAGGGTGGG	ATTAGGCCCT	ACAAGGAGAA	AGGTGAGGGC	2000
CCTGAGTGAG	CACAGAGGGG	ACCCTCCACC	CAAGTAGAGT	GGGGACCTCA	2050
CGGAGTCTGG	CCAACCCTGC	TGAGACTTCT	GGGAATCCGT	GGCTGTGCTT	2100
GCAGTCTGCA	CACTGAAGGC	CCGTGCATTG	CTCTCCCAGG	AATCAGGAGC	2150
TCCAGGAAC	AGGCAGTGAG	GCCTTGGTCT	GAGTCAGTGC	CTCAGGTCAC	2200
AGAGCAGAGG	GGACGCAGAC	AGTGCCAACA	CTGAAGGTTT	GCTTGGGAATG	2250
CACACCAAGG	GCCCCACCCG	CCCAGAACAA	ATGGGACTCC	AGAGGGCCTG	2300
GCCTCACCC	CCCTATTCTC	AGTCCTGCAG	CCTGAGCATG	TGCTGGCCGG	2350
CTGTACCCTG	AGGTGCCCTC	CCACTTCCTC	CTTCAGGTTT	TGAGGGGGAC	2400
AGGCTGACAA	GTAGGACCCG	AGGCATTGGA	GGAGCATTGA	AGGAGAAGAT	2450
CTGTAAGTAA	GCTTTGTCA	GAGCCTCCAA	GGTTCAGTTC	AGTTCTCACC	2500
TAAGGCCTCA	CACACGCTCC	TTCTCTCCCC	AGGCCTGTGG	GTCTTCATTG	2550
CCCAGCTCCT	GCCCGCACTC	CTGCCTGCTG	CCCTGACCAG	AGTCATC	2597
ATG CCT CTT	GAG CAG AGG	AGT CAG CAC	TGC AAG CCT	GAA GAA	2639
GGC CTT GAG	GCC CGA GGA	GAG GCC CTG	GCG CTG GTG	GGT GCG	2681
CAG GCT CTT	GCT ACT GAG	GAG CAG CAG	ACC GCT TCT	TCC TCT	2723

TCT ACT CTA GTG GAA GTT ACC CTG GGG GAG GTG CCT GCT GCC	2765
GAC TCA CCG AGT CCT CCC CAC AGT CCT CAG GGA GCC TCC AGC	2807
TTC TCG ACT ACC ATC AAC TAC ACT CTT TGG AGA CAA TCC GAT	2849
GAG GGC TCC AGC AAC CAA GAA GAG GAG GGG CCA AGA ATG TTT	2891
CCC GAC CTG GAG TCC GAG TTC CAA GCA GCA ATC AGT AGG AAG	2933
ATG GTT GAG TTG GTT CAT TTT CTG CTC CTC AAG TAT CGA GCC	2975
AGG GAG CCG GTC ACA AAG GCA GAA ATG CTG GAG AGT GTC CTC	3017
AGA AAT TGC CAG GAC TTC TTT CCC GTG ATC TTC AGC AAA GCC	3059
TCC GAG TAC TTG CAG CTG GTC TTT GGC ATC GAG GTG GTG GAA	3101
GTG GTC CCC ATC AGC CAC TTG TAC ATC CTT GTC ACC TGC CTG	3143
GGC CTC TCC TAC GAT GGC CTG CTG GGC GAC AAT CAG GTC ATG	3185
CCC AAG ACA GGC CTC CTG ATA ATC GTC CTG GCC ATA ATC GCA	3227
ATA GAG GGC GAC TGT GCC CCT GAG GAG AAA ATC TGG GAG GAG	3269
CTG AGT ATG TTG GAG GTG TTT GAG GGG AGG GAG GAC AGT GTC	3311
TTC GCA CAT CCC AGG AAG CTG CTC ATG CAA GAT CTG GTG CAG	3353
GAA AAC TAC CTG GAG TAC CGG CAG GTG CCC GGC AGT GAT CCT	3395
GCA TGC TAC GAG TTC CTG TGG GGT CCA AGG GCC CTC ATT GAA	3437
ACC AGC TAT GTG AAA GTC CTG CAC CAT ACA CTA AAG ATC GGT	3479
GGA GAA CCT CAC ATT TCC TAC CCA CCC CTG CAT GAA CGG GCT	3521
TTG AGA GAG GGA GAA GAG TGA	3542
GTCTCAGCAC ATGTTGCAGC CAGGGCCAGT GGGAGGGGGT CTGGGCCAGT	3592
GCACCTTCCA GGGCCCCATC CATTAGCTTC CACTGCCTCG TGTGATATGA	3642
GGCCCATTC TGCCTCTTTG AAGAGAGCAG TCAGCATTCT TAGCAGTGAG	3692
TTTCTGTTCT GTTGGATGAC TTTGAGATTT ATCTTTCTTT CCTGTTGGAA	3742
TTGTTCAAAT GTTCCTTTTA ACAAATGGTT GGATGAACTT CAGCATCCAA	3792
GTTTATGAAT GACAGTAGTC ACACATAGTG CTGTTTATAT AGTTTAGGGG	3842
TAAGAGTCCT GTTTTTTATT CAGATTGGGA AATCCATTCC ATTTTGTGAG	3892
TTGTCACATA ATAACAGCAG TGGAATATGT ATTTGCCTAT ATTGTGAACG	3942
AATTAGCAGT AAAATACATG ATACAAGGAA CTCAAAAGAT AGTTAATTCT	3992
TGCCTTATAC CTCAGTCTAT TATGTAAAAT TAAAAATATG TGTATGTTTT	4042
TGCTTCTTTG AGAATGCAAA AGAAATTAAA TCTGAATAAA TTCTTCCTGT	4092
TCACTGGCTC ATTTCTTTAC CATTCACCTCA GCATCTGCTC TGTGGAAGGC	4142
CCTGGTAGTA GTGGG	4157

- (2) INFORMATION FOR SEQUENCE ID NO: 10:  
 (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 662 base pairs  
     (B) TYPE: nucleic acid  
     (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: genomic DNA  
 (ix) FEATURE:  
     (A) NAME/KEY: MAGE-21 gene  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

GGATCCCCAT	GGATCCAGGA	AGAATCCAGT	TCCACCCCTG	CTGTGAACCC	50
AGGGAAGTCA	CGGGGCCCGA	TGTGACGCCA	CTGACTTGCG	CGTTGGAGGT	100
CAGAGAACAG	CGAGATTCTC	GCCCTGAGCA	ACGGCCTGAC	GTCGGCGGAG	150
GGAAGCAGGC	GCAGGCTCCG	TGAGGAGGCA	AGGTAAGATG	CCGAGGGAGG	200
ACTGAGGCGG	GCCTCACCCC	AGACAGAGGG	CCCCCAATAA	TCCAGCGCTG	250
CCTCTGCTGC	CAGGCCTGGA	CCACCCTGCA	GGGGAAGACT	TCTCAGGCTC	300
AGTCGCCACC	ACCTCACCCC	GCCACCCCCC	GCCGCTTTAA	CCGCAGGGAA	350
CTCTGGTGTA	AGAGCTTTGT	GTGACCAGGG	CAGGGCTGGT	TAGAAGTGCT	400
CAGGGCCCAG	ACTCAGCCAG	GAATCAAGGT	CAGGACCCCA	AGAGGGGACT	450
GAGGGTAACC	CCCCCGCACC	CCCACCACCA	TTCCCATCCC	CCAACACCAA	500
CCCCACCCCC	ATCCCCCAAC	ACCAAACCCA	CCACCATCGC	TCAAACATCA	550
ACGGCACCCC	CAAACCCCGA	TTCCCATCCC	CACCCATCCT	GGCAGAATCG	600
GAGCTTTGCC	CCTGCAATCA	ACCCACGGAA	GCTCCGGGAA	TGGCGGCCAA	650
GCACGCGGAT	CC				662

## (2) INFORMATION FOR SEQUENCE ID NO: 11:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1640 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

## (ix) FEATURE:

(A) NAME/KEY: cDNA MAGE-3

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

GCCGCGAGGG	AAGCCGGCCC	AGGCTCGGTG	AGGAGGCAAG	GTTCTGAGGG	50
GACAGGCTGA	CCTGGAGGAC	CAGAGGCCCC	CGGAGGAGCA	CTGAAGGAGA	100
AGATCTGCCA	GTGGGTCTCC	ATTGCCCAGC	TCCTGCCAC	ACTCCCGCCT	150
GTTGCCCTGA	CCAGAGTCAT	C			171
ATG CCT CTT	GAG CAG AGG	AGT CAG CAC	TGC AAG CCT	GAA GAA	213
GGC CTT GAG	GCC CGA GGA	GAG GCC CTG	GGC CTG GTG	GGT GCG	255
CAG GCT CCT	GCT ACT GAG	GAG CAG GAG	GCT GCC TCC	TCC TCT	297
TCT ACT CTA	GTT GAA GTC	ACC CTG GGG	GAG GTG CCT	GCT GCC	339
GAG TCA CCA	GAT CCT CCC	CAG AGT CCT	CAG GGA GCC	TCC AGC	381
CTC CCC ACT	ACC ATG AAC	TAC CCT CTC	TGG AGC CAA	TCC TAT	423
GAG GAC TCC	AGC AAC CAA	GAA GAG GAG	GGG CCA AGC	ACC TTC	465
CCT GAC CTG	GAG TCC GAG	TTC CAA GCA	GCA CTC AGT	AGG AAG	507
GTG GCC GAG	TTG GTT CAT	TTT CTG CTC	CTC AAG TAT	CGA GCC	549
AGG GAG CCG	GTC ACA AAG	GCA GAA ATG	CTG GGG AGT	GTC GTC	591
GGA AAT TGG	CAG TAT TTC	TTT CCT GTG	ATC TTC AGC	AAA GCT	633
TCC AGT TCC	TTG CAG CTG	GTC TTT GGC	ATC GAG CTG	ATG GAA	675
GTG GAC CCC	ATC GGC CAC	TTG TAC ATC	TTT GCC ACC	TGC CTG	717
GGC CTC TCC	TAC GAT GGC	CTG CTG GGT	GAC AAT CAG	ATC ATG	759
CCC AAG GCA	GGC CTC CTG	ATA ATC GTC	CTG GCC ATA	ATC GCA	801
AGA GAG GGC	GAC TGT GCC	CCT GAG GAG	AAA ATC TGG	GAG GAG	843
CTG AGT GTG	TTA GAG GTG	TTT GAG GGG	AGG GAA GAC	AGT ATG	885
TTG GGG GAT	CCC AAG AAG	CTG CTC ACC	CAA CAT TTC	GTG CAG	927
GAA AAC TAC	CTG GAG TAC	CGG CAG GTC	CCC GGC AGT	GAT CCT	969
GCA TGT TAT	GAA TTC CTG	TGG GGT CCA	AGG GCC CTC	GTT GAA	1011
ACC AGC TAT	GTG AAA GTC	CTG CAC CAT	ATG GTA AAG	ATC AGT	1053
GGA GGA CCT	CAC ATT TCC	TAC CCA CCC	CTG CAT GAG	TGG GTT	1095
TTG AGA GAG	GGG GAA GAG	TGA			1116
GTCTGAGCAC	GAGTTGCAGC	CAGGGCCAGT	GGGAGGGGGT	CTGGGCCAGT	1166
GCACCTTCCG	GGGCCGCATC	CCTTAGTTTC	CACTGCCTCC	TGTGACGTGA	1216
GGCCCATTCT	TCACTCTTTG	AAGCGAGCAG	TCAGCATTCT	TAGTAGTGGG	1266
TTTCTGTTCT	GTTGGATGAC	TTTGAGATTA	TTCTTTGTTT	CCTGTTGGAG	1316
TTGTTCAAAT	GTTCTTTTTA	ACGGATGGTT	GAATGAGCGT	CAGCATCCAG	1366
GTTTATGAAT	GACAGTAGTC	ACACATAGTG	CTGTTTATAT	AGTTTAGGAG	1416
TAAGAGTCTT	GtTTTTTACT	CAAATTgGGA	AATCCATTCC	ATTTTGTGAA	1466
TTGTGACATA	ATAATAGCAG	TGGTAAAAGT	ATTTGCTTAA	AATTGTGAGC	1516
GAATTAGCAA	TAACATACAT	GAGATAACTC	AAGAAATCAA	AAGATAGTTG	1566
ATTCTTGCCT	TGTACCTCAA	TCTATTCTGT	AAAATTAAAC	AAATATGCAA	1616
ACCAGGATTT	CCTTGACTTC	TTTG			1640



- (2) INFORMATION FOR SEQUENCE ID NO: 12:  
 (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 943 base pairs  
     (B) TYPE: nucleic acid  
     (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: genomic DNA  
 (ix) FEATURE:  
     (A) NAME/KEY: MAGE-31 gene  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

GGATCCTCCA	CCCCAGTAGA	GTGGGGACCT	CACAGAGTCT	GGCCAACCCCT	50
CCTGACAGTT	CTGGGAATCC	GTGGCTGCGT	TTGCTGTCTG	CACATTGGGG	100
GCCCGTGGAT	TCCTCTCCCA	GGAATCAGGA	GCTCCAGGAA	CAAGGCAGTG	150
AGGACTTGGT	CTGAGGCAGT	GTCCTCAGGT	CACAGAGTAG	AGGGGGCTCA	200
GATAGTGCCA	ACGGTGAAGG	TTTGCCTTGG	ATTCAAACCA	AGGGCCCCAC	250
CTGCCCCAGA	ACACATGGAC	TCCAGAGCGC	CTGGCCTCAC	CCTCAATACT	300
TTCAGTCCTG	CAGCCTCAGC	ATGCGCTGGC	CGGATGTACC	CTGAGGTGCC	350
CTCTCACTTC	CTCCTTCAGG	TTCTGAGGGG	ACAGGCTGAC	CTGGAGGACC	400
AGAGGCCCCC	GGAGGAGCAC	TGAAGGAGAA	GATCTGTAAG	TAAGCCTTTG	450
TTAGAGCCTC	CAAGGTTCCA	TTCAGTACTC	AGCTGAGGTC	TCTCACATGC	500
TCCCTCTCTC	CCCAGGCCAG	TGGGTCTCCA	TTGCCCAGCT	CCTGCCCCACA	550
CTCCCGCCTG	TTGCCCTGAC	CAGAGTCATC			580
ATG CCT CTT	GAG CAG AGG	AGT CAG CAC	TGC AAG CCT	GAA GAA	622
GGC CTT GAG	GCC CGA GGA	GAG GCC CTG	GGC CTG GTG	GGT GCG	664
CAG GCT CCT	GCT ACT GAG	GAG CAG GAG	GCT GCC TCC	TCC TCT	706
TCT AGT GTA	GTT GAA GTC	ACC CTG GGG	GAG GTG CCT	GCT GCC	748
GAG TCA CCA	GAT CCT CCC	CAG AGT CCT	CAG GGA GCC	TCC AGC	790
CTC CCC ACT	ACC ATG AAC	TAC CCT CTC	TGG AGC CAA	TCC TAT	832
GAG GAC TCC	AGC AAC GAA	GAG GAG GGG	CCA AGC ACC	TTC	874
CCT GAC CTG	GAG TCT GAG	TTC CAA GCA	GCA CTC AGT	AGG AAG	916
GTG GCC AAG	TTG GTT CAT	TTT CTG CTC			943

009250" 6456'550

- (2) INFORMATION FOR SEQUENCE ID NO: 13:  
 (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 2531 base pairs  
     (B) TYPE: nucleic acid  
     (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: genomic DNA  
 (ix) FEATURE:  
     (A) NAME/KEY: MAGE-4 gene  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

GGATCCAGGC	CCTGCCTGGA	GAAATGTGAG	GGCCCTGAGT	GAACACAGTG	50
GGGATCATCC	ACTCCATGAG	AGTGGGGACC	TCACAGAGTC	CAGCCTACCC	100
TCTTGATGGC	ACTGAGGGAC	CGGGGCTGTG	CTTACAGTCT	GCACCCTAAG	150
GGCCCATGGA	TTCCTCTCCT	AGGAGCTCCA	GGAACAAGGC	AGTGAGGCCT	200
TGGTCTGAGA	CAGTGTCTCT	AGGTTACAGA	GCAGAGGATG	CACAGGCTGT	250
GCCAGCAGTG	AATGTTTGCC	CTGAATGCAC	ACCAAGGGCC	CCACCTGCCA	300
CAAGACACAT	AGGACTCCAA	AGAGTCTGGC	CTCACCTCCC	TACCATCAAT	350
CCTGCAGAAT	CGACCTCTGC	TGGCCGGCTA	TACCCTGAGG	TGCTCTCTCA	400
CTTCCTCCTT	CAGGTTCTGA	GCAGACAGGC	CAACCGGAGA	CAGGATTCCC	450
TGGAGGCCAC	AGAGGAGCAC	CAAGGAGAAG	ATCTGTAAAT	AAGCCTTTGT	500
TAGAGCCTCT	AAGATTTGGT	TCTCAGCTGA	GGTCTCTCAC	ATGCTCCCTC	550
TCTCCGTAGG	CCTGTGGGTC	CCCATTGCCC	AGCTTTTGCC	TGCACTCTTG	600
CCTGCTGCCC	TGACCAGAGT	CATC			624
ATG TCT TCT	GAG CAG AAG	AGT CAG CAC	TGC AAG CCT	GAG GAA	666
GGC GTT GAG	GCC CAA GAA	GAG GCC CTG	GGC CTG GTG	GGT GCA	708
CAG GCT CCT	ACT ACT GAG	GAG CAG GAG	GCT GCT GTC	TCC TCC	750
TCC TCT CCT	CTG GTC CCT	GGC ACC CTG	GAG GAA GTG	CCT GCT	792
GCT GAG TCA	GCA GGT CCT	CCC CAG AGT	CCT CAG GGA	GCC TCT	834
GCC TTA CCC	ACT ACC ATC	AGC TTC ACT	TGC TGG AGG	CAA CCC	876
AAT GAG GGT	TCC AGC AGC	CAA GAA GAG	GAG GGG CCA	AGC ACC	918
TCG CCT GAC	GCA GAG TCC	TTG TTC CGA	GAA GCA CTC	AGT AAC	960
AAG GTG GAT	GAG TTG GCT	CAT TTT CTG	CTC CGC AAG	TAT CGA	1002
GCC AAG GAG	CTG GTC ACA	AAG GCA GAA	ATG CTG GAG	AGA GTC	1044
ATC AAA AAT	TAC AAG CGC	TGC TTT CCT	GTG ATC TTC	GGC AAA	1086
GCC TCC GAG	TCC CTG AAG	ATG ATC TTT	GGC ATT GAC	GTG AAG	1128
GAA GTG GAC	CCC GCC AGC	AAC ACC TAC	ACC CTT GTC	ACC TGC	1170
CTG GGC CTT	TCC TAT GAT	GGC CTG CTG	GGT AAT AAT	CAG ATC	1212
TTT CCC AAG	ACA GGC CTT	CTG ATA ATC	GTC CTG GGC	ACA ATT	1254
GCA ATG GAG	GGC GAC AGC	TCT TCT GAG	GAG GAA ATC	TGG GAG	1296
GAG CTG GGT	GTG ATG GGG	GTG TAT GAT	GGG AGG GAG	CAC ACT	1338
GTC TAT GGG	GAG CCC AGG	AAA CTG CTC	ACC CAA GAT	TGG GTG	1380
CAG GAA AAC	TAC CTG GAG	TAC CGG CAG	GTA CCC GGC	AGT AAT	1422
CCT GCG CGC	TAT GAG TTC	CTG TGG GGT	CCA AGG GCT	CTG GCT	1464
GAA ACC AGC	TAT GTG AAA	GTC CTG GAG	CAT GTG GTC	AGG GTC	1506
AAT GCA AGA	GTT CGC ATT	GCC TAC CCA	TCC CTG CGT	GAA GCA	1548
GCT TTG TTA	GAG GAG GAA	GAG GGA GTC	TGA		1578
GCATGAGTTG	CAGCCAGGGC	TGTGGGGAAG	GGGCAGGGCT	GGGCCAGTGC	1628
ATCTAACAGC	CCTGTGCAGC	AGCTTCCCTT	GCCTCGTGTA	ACATGAGGCC	1678
CATTCTTCAC	TCTGTTTGAA	GAAAATAGTC	AGTGTTCCTTA	GTAGTGGGTT	1728
TCTATTTTGT	TGGATGACTT	GGAGATTTAT	CTCTGTTTCC	TTTTACAATT	1778
GTTGAAATGT	TCCTTTTAAT	GGATGGTTGA	ATTAACTTCA	GCATCCAAGT	1828
TTATGAATCG	TAGTTAACGT	ATATTGCTGT	TAATATAGTT	TAGGAGTAAG	1878
AGTCTTGTTT	TTTATTTCAGA	TTGGGAAATC	CGTTCTATTT	TGTGAATTG	1928
GGACATAATA	ACAGCAGTGG	AGTAAGTATT	TAGAAGTGTG	AATTCACCGT	1978
GAAATAGGTG	AGATAAATTA	AAAGATACTT	AATTCCC GCC	TTATGCCTCA	2028
GTCTATTCTG	TAAAATTTAA	AAATATATAT	GCATACCTGG	ATTTCCCTTGG	2078
CTTCGTGAAT	GTAAGAGAAA	TTAAATCTGA	ATAAATAATT	CTTTCTGTTA	2128
ACTGGCTCAT	TTCTTCTCTA	TGCACTGAGC	ATCTGCTCTG	TGGAAGGCC	2178
AGGATTAGTA	GTGGAGATAC	TAGGGTAAGC	CAGACACACA	CCTACCGATA	2228
GGGTATTAAG	AGTCTAGGAG	CGCGGTCATA	TAATTAAGGT	GACAAGATGT	2278
CCTCTAAGAT	GTAGGGGAAA	AGTAACGAGT	GTGGGTATGG	GGCTCCAGGT	2328
GAGAGTGGTC	GGGTGTAAAT	TCCCTGTGTG	GGCCCTTTTG	GGCTTTGGGA	2378
AACTGCATTT	TCTTCTGAGG	GATCTGATTC	TAATGAAGCT	TGGTGGGTCC	2428
AGGGCCAGAT	TCTCAGAGGG	AGAGGGAAAA	GCCCAGATTG	GAAAAGTTGC	2478

TCTGAGCAGT TCCTTTGTGA CAATGGATGA ACAGAGAGGA GCCTCTACCT  
GGG

2528  
2531

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	2101	2102	2103	2104	2105	2106	2107	2108	2109	2110	2111	2112	2113	2114	2115	2116	2117	2118	2119	2120	2121	2122	2123	2124	2125	2126	2127	2128	2129	2130	2131	2132	2133	2134	2135	2136	2137	2138	2139	2140	2141	2142	2143	2144	2145	2146	2147	2148	2149	2150	2151	2152	2153	2154	2155	2156	2157	2158	2159	2160	2161	2162	2163	2164	2165	2166	2167	2168	2169	2170	2171	2172	2173	2174	2175	2176	2177	2178	2179	2180	2181	2182	2183	2184	2185	2186	2187	2188	2189	2190	2191	2192	2193	2194	2195	2196	2197	2198	2199	2200	2201	2202	2203	2204	2205	2206	2207	2208	2209	2210	2211	2212	2213	2214	2215	2216	2217	2218	2219	2220	2221	2222	2223	2224	2225	2226	2227	2228	2229	2230	2231	2232	2233	2234	2235	2236	2237	2238	2239	2240	2241	2242	2243	2244	2245	2246	2247	2248	2249	2250	2251	2252	2253	2254	2255	2256	2257	2258	2259	2260	2261	2262	2263	2264	2265	2266	2267	2268	2269	2270	2271	2272	2273	2274	2275	2276	2277	2278	2279	2280	2281	2282	2283	2284	2285	2286	2287	2288	2289	2290	2291	2292	2293	2294	2295	2296	2297	2298	2299	2300	2301	2302	2303	2304	2305	2306	2307	2308	2309	2310	2311	2312	2313	2314	2315	2316	2317	2318	2319	2320	2321	2322	2323	2324	2325	2326	2327	2328	2329	2330	2331	2332	2333	2334	2335	2336	2337	2338	2339	2340	2341	2342	2343	2344	2345	2346	2347	2348	2349	2350	2351	2352	2353	2354	2355	2356	2357	2358	2359	2360	2361	2362	2363	2364	2365	2366	2367	2368	2369	2370	2371	2372	2373	2374	2375	2376	2377	2378	2379	2380	2381	2382	2383	2384	2385	2386	2387	2388	2389	2390	2391	2392	2393	2394	2395	2396	2397	2398	2399	2400	2401	2402	2403	2404	2405	2406	2407	2408	2409	2410	2411	2412	2413	2414	2415	2416	2417	2418	2419	2420	2421	2422	2423	2424	2425	2426	2427	2428	2429	2430	2431	2432	2
--	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	---

## (2) INFORMATION FOR SEQUENCE ID NO: 14:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2531 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: genomic DNA

## (ix) FEATURE:

(A) NAME/KEY: MAGE-41 gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

GGATCCAGGC	CCTGCCTGGA	GAAATGTGAG	GGCCCTGAGT	GAACACAGTG	50
GGGATCATCC	ACTCCATGAG	AGTGGGGACC	TCACAGAGTC	CAGCCTACCC	100
TCTTGATGGC	ACTGAGGGAC	CGGGGCTGTG	CTTACAGTCT	GCACCCTAAG	150
GGCCCATGGA	TTCCTCTCCT	AGGAGCTCCA	GGAACAAGGC	AGTGAGGCCT	200
TGGTCTGAGA	CAGTGTCTCT	AGGTTACAGA	GCAGAGGATG	CACAGGCTGT	250
GCCAGCAGTG	AATGTTTGCC	CTGAATGCAC	ACCAAGGGCC	CCACCTGCCA	300
CAAGACACAT	AGGACTCCAA	AGAGTCTGGC	CTCACCCTCC	TACCATCAAT	350
CCTGCAGAAT	CGACCTCTGC	TGGCCGGCTA	TACCCTGAGG	TGCTCTCTCA	400
CTTCCTCCTT	CAGGTTCTGA	GCAGACAGGC	CAACCGGAGA	CAGGATTCCC	450
TGGAGGCCAC	AGAGGAGCAC	CAAGGAGAAG	ATCTGTAAGT	AAGCCTTTGT	500
TAGAGCCTCT	AAGATTTGGT	TCTCAGCTGA	GGTCTCTCAC	ATGCTCCCTC	550
TCTCCGTAGG	CCTGTGGGTC	CCCATTGCCC	AGCTTTTGCC	TGCACTCTTG	600
CCTGCTGCCC	TGAGCAGAGT	CATC			624
ATG TCT TCT	GAG CAG AAG	AGT CAG CAC	TGC AAG CCT	GAG GAA	666
GGC GTT GAG	GCC CAA GAA	GAG GCC CTG	GGC CTG GTG	GGT GCG	708
CAG GCT CCT	ACT ACT GAG	GAG CAG GAG	GCT GCT GTC	TCC TCC	750
TCC TCT CCT	CTG GTC CCT	GGC ACC CTG	GAG GAA GTG	CCT GCT	792
GCT GAG TCA	GCA GGT CCT	CCC CAG AGT	CCT CAG GGA	GCC TCT	834
GCC TTA CCC	ACT ACC ATC	AGC TTC ACT	TGC TGG AGG	CAA CCC	876
AAT GAG GGT	TCC AGC AGC	CAA GAA GAG	GAG GGG CCA	AGC ACC	918
TCG CCT GAC	GCA GAG TCC	TTG TTC CGA	GAA GCA CTC	AGT AAC	960
AAG GTG GAT	GAG TTG GCT	CAT TTT CTG	CTC CGC AAG	TAT CGA	1002
GCC AAG GAG	CTG GTC ACA	AAG GCA GAA	ATG CTG GAG	AGA GTC	1044
ATC AAA AAT	TAC AAG CGC	TGC TTT CCT	GTG ATC TTC	GGC AAA	1086
GCC TCC GAG	TCC CTG AAG	ATG ATC TTT	GGC ATT GAC	GTG AAG	1128
GAA GTG GAC	CCC ACC AGC	AAC ACC TAC	ACC CTT GTC	ACC TGC	1170
CTG GGC CTT	TCC TAT GAT	GGC CTG CTG	GGT AAT AAT	CAG ATC	1212
TTT CCC AAG	ACA GGC CTT	CTG ATA ATC	GTC CTG GGC	ACA ATT	1254
GCA ATG GAG	GGC GAC AGC	GCC TCT GAG	GAG GAA ATC	TGG GAG	1296
GAG CTG GGT	GTG ATG GGG	GTG TAT GAT	GGG AGG GAG	CAC ACT	1338
GTC TAT GGG	GAG CCC AGG	AAA CTG CTC	ACC CAA GAT	TGG GTG	1380
CAG GAA AAC	TAC CTG GAG	TAC CGG CAG	GTA CCC GGC	AGT AAT	1422
CCT GCG CGC	TAT GAG TTC	CTG TGG GGT	CCA AGG GCT	CTG GCT	1464
GAA ACC AGC	TAT GTG AAA	GTC CTG GAG	CAT GTG GTC	AGG GTC	1506
AAT GCA AGA	GTT CGC ATT	GCC TAC CCA	TCC CTG CGT	GAA GCA	1548
GCT TTG TTA	GAG GAG GAA	GAG GGA GTC	TGA		1578
GCATGAGTTG	CAGCCAGGGC	TGTGGGGAAG	GGGCAGGGCT	GGGCCAGTGC	1628
ATCTAACAGC	CCTGTGCAGC	AGCTTCCCTT	GCCTCGTGTA	ACATGAGGCC	1678
CATTCTTCAC	TCTGTTTGAA	GAAAATAGTC	AGTGTTCTTA	GTAGTGGGTT	1728
TCTATTTTGT	TGGATGACTT	GGAGATTTAT	CTCTGTTTCC	TTTTACAATT	1778
GTTGAAATGT	TCCTTTTAAT	GGATGGTTGA	ATTAACCTCA	GCATCCAAGT	1828
TTATGAATCG	TAGTTAACGT	ATATTGCTGT	TAATATAGTT	TAGGAGTAAG	1878
AGTCTTGTTT	TTTATTCAGA	TTGGGAAATC	CGTTCTATTT	TGTGAATTTG	1928
GGACATAATA	ACAGCAGTGG	AGTAAGTATT	TAGAAGTGTG	AATTCACCGT	1978
GAAATAGGTG	AGATAAATTA	AAAGATACTT	AATTCCC GCC	TTATGCCTCA	2028
GTCTATTCTG	TAAATTTTAA	AAATATATAT	GCATACCTGG	ATTTCCCTGG	2078
CTTCGTGAAT	GTAAGAGAAA	TTAAATCTGA	ATAAATAATT	CTTTCTGTTA	2128
ACTGGCTCAT	TTCTTCTCTA	TGCACTGAGC	ATCTGCTCTG	TGGAAGGCCC	2178
AGGATTAGTA	TGGAGATAC	TAGGGTAAGC	CAGACACACA	CCTACCGATA	2228
GGGTATTAAG	AGTCTAGGAG	CGCGGTCATA	TAATTAAGGT	GACAAGATGT	2278
CCTCTAAGAT	GTAGGGGAAA	AGTAACGAGT	GTGGGTATGG	GGCTCCAGGT	2328
GAGAGTGGTC	GGGTGTAAAT	TCCCTGTGTG	GGGCCTTTTG	GGCTTTGGGA	2378
AACTCCATTT	TCTTCTGAGG	GATCTGATTC	TAATGAAGCT	TGGTGGGTCC	2428

2478  
2528  
2531

## (2) INFORMATION FOR SEQUENCE ID NO: 15:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1068 base pairs  
 (B) TYPE: nucleic acid  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

## (ix) FEATURE:

(A) NAME/KEY: cDNA MAGE-4

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

G GGG CCA AGC ACC TCG CCT GAC GCA GAG TCC TTG TTC CGA	40
GAA GCA CTC AGT AAC AAG GTG GAT GAG TTG GCT CAT TTT CTG	82
CTC CGC AAG TAT CGA GCC AAG GAG CTG GTC ACA AAG GCA GAA	124
ATG CTG GAG AGA GTC ATC AAA AAT TAC AAG CGC TGC TTT CCT	166
GTG ATC TTC GGC AAA GCC TCC GAG TCC CTG AAG ATG ATC TTT	208
GGC ATT GAC GTG AAG GAA GTG GAC CCC GCC AGC AAC ACC TAC	250
ACC CTT GTC ACC TGC CTG GGC CTT TCC TAT GAT GGC CTG CTG	292
GGT AAT AAT CAG ATC TTT CCC AAG ACA GGC CTT CTG ATA ATC	334
GTC CTG GGC ACA ATT GCA ATG GAG GGC GAC AGC GCC TCT GAG	376
GAG GAA ATC TGG GAG GAG CTG GGT GTG ATG GGG GTG TAT GAT	418
GGG AGG GAG CAC ACT GTC TAT GGG GAG CCC AGG AAA CTG CTC	460
ACC CAA GAT TGG GTG CAG GAA AAC TAC CTG GAG TAC CGG CAG	502
GTA CCC GGC AGT AAT CCT GCG CGC TAT GAG TTC CTG TGG GGT	544
CCA AGG GCT CTG GCT GAA ACC AGC TAT GTG AAA GTC CTG GAG	586
CAT GTG GTC AGG GTC AAT GCA AGA GTT CGC ATT GCC TAC CCA	628
TCC CTG CGT GAA GCA GCT TTG TTA GAG GAG GAA GAG GGA GTC	670
TGAGCATGAG TTGCAGCCAG GGCTGTGGGG AAGGGGCAGG GCTGGGCCAG	720
TGCATCTAAC AGCCCTGTGC AGCAGCTTCC CTTGCCCTCGT GTAACATGAG	770
GCCCATTCTT CACTCTGTTT GAAGAAAATA GTCAGTGTTT TTAGTAGTGG	820
GTTTCTATTT TGTTGGATGA CTTGGAGATT TATCTCTGTT TCCTTTTACA	870
ATTGTTGAAA TGTTTCCTTTT AATGGATGGT TGAATTAACT TCAGCATCCA	920
AGTTTATGAA TCGTAGTTAA CGTATATTGC TGTTAATATA GTTTAGGAGT	970
AAGAGTCTTG TTTTTTATTC AGATTGGGAA ATCCGTTCTA TTTTGTGAAT	1020
TTGGGACATA ATAACAGCAG TGGAGTAAGT ATTTAGAAGT GTGAATTC	1068

- (2) INFORMATION FOR SEQUENCE ID NO: 16:  
 (i) SEQUENCE CHARACTERISTICS:  
   (A) LENGTH: 2226 base pairs  
   (B) TYPE: nucleic acid  
   (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: genomic DNA  
 (ix) FEATURE:  
   (A) NAME/KEY: MAGE-5 gene  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

GGATCCAGGC CTTGCCAGGA GAAAGGTGAG GGCCCTGTGT GAGCACAGAG 50  
 GGGACCATTC ACCCCAAGAG GGTGGAGACC TCACAGATTC CAGCCTACCC 100  
 TCCTGTTAGC ACTGGGGGCC TGAGGCTGTG CTTGCAGTCT GCACCCCTGAG 150  
 GGCCCATGCA TTCCTCTTCC AGGAGCTCCA GGAAACAGAC ACTGAGGCCT 200  
 TGGTCTGAGG CCGTGCCCTC AGGTACAGAG GCAGAGGAGA TGCAGACGTC 250  
 TAGTGCCAGC AGTGAACGTT TGCCTTGAAT GCACACTAAT GGCCCCCATC 300  
 GCCCCAGAAC ATATGGGACT CCAGAGCACC TGGCCTCACC CTCTCTACTG 350  
 TCAGTCCCTGC AGAATCAGCC TCTGCTTGCT TGTGTACCCT GAGGTGCCCT 400  
 CTCACCTTTT CCTTCAGGTT CTCAGGGGAC AGGCTGACCA GGATCACCAG 450  
 GAAGCTCCAG AGGATCCCCA GGAGGCCCTA GAGGAGCACC AAAGGAGAAG 500  
 ATCTGTAAGT AAGCCTTTGT TAGAGCCTCC AAGGTTTCA GTTTTAGCTGA 550  
 GGCTTCTCAC ATGCTCCCTC TCTCTCCAGG CCAGTGGGTC TCCATTGCCC 600  
 AGCTCCTGCC CACACTCCTG CCTGTTGCGG TGACCAGAGT CGTC 644  
 ATG TCT CTT GAG CAG AAG AGT CAG CAC TGC AAG CCT GAG GAA 684  
 CTC CTC TGG TCC CAG GCA CCC TGG GGG AGG TGC CTG CTG CTG 728  
 GGT CAC CAG GTC CTC TCA AGA GTC CTC AGG GAG CCT CCG CCA 770  
 TCC CCA CTG CCA TCG ATT TCA CTC TAT GGA GGC AAT CCA TTA 812  
 AGG GCT CCA GCA ACC AAG AAG AGG AGG GGC CAA GCA CCT CCC 854  
 CTG ACC CAG AGT CTG TGT TCC GAG CAG CAC TCA GTA AGA AGG 896  
 TGG CTG ACT TGA 908  
 TTCATTTTCT GCTCCTCAAG TATTAAGTCA AGGAGCTGGT CACAAAGGCA 958  
 GAAATGCTGG AGAGCGTCAT CAAAAATTAC AAGCGCTGCT TTCCTGAGAT 1008  
 CTTCCGCAAA GCCTCCGAGT CCTTGACAGT GGTCTTTGGC ATTGACGTGA 1058  
 AGGAAGCGGA CCCCACCAGC AACACCTACA CCCTTGTCAC CTGCCTGGGA 1108  
 CTCCTATGAT GGCTGCTGG TTGATAATAA TCAGATCATG CCCAAGACGG 1158  
 GCCTCCTGAT AATCGTCTTG GGCATGATTG CAATGGAGGG CAAATGCGTC 1208  
 CCTGAGGAGA AAATCTGGGA GGAGCTGAGT GTGATGAAGG TGTATGTTGG 1258  
 GAGGGAGCAC AGTGTCTGTG GGGAGCCCAG GAAGCTGCTC ACCCAAGATT 1308  
 TGGTGCAGGA AAATACCTG GAGTACCGGC AGGTGCCAG CAGTGATCCC 1358  
 ATATGCTATG AGTTACTGTG GGGTCCAAGG GCACTCGCTG CTTGAAAGTA 1408  
 CTGGAGCACG TGGTCAGGGT CAATGCAAGA GTTCTCATTT CCTACCCATC 1458  
 CCTGCGTGAA GCAGCTTTGA GAGAGGAGGA AGAGGGAGTC TGAGCATGAG 1508  
 CTGCAGCCAG GGCCACTGCG AGGGGGGCTG GGCCAGTGCA CCTTCCAGGG 1558  
 CTCCGTCCAG TAGTTTCCCC TGCCTTAATG TGACATGAGG CCCATTCTTC 1608  
 TCTCTTTGAA GAGAGCAGTC AACATTCTTA GTAGTGGGT TCTGTTCTAT 1658  
 TGGATGACTT TGAGATTTGT CTTTGTTCCT TTTTGGAAAT GTTCAAATGT 1708  
 TTCTTTTAAT GGGTGGTTGA ATGAACCTCA GCATTCAAAT TTATGAATGA 1758  
 CAGTAGTCAC ACATAGTGCT GTTTATATAG TTTAGGAGTA AGAGTCTTGT 1808  
 TTTTTATTCA GATTGGGAAA TCCATTCCAT TTTGTGAATT GGGACATAGT 1858  
 TACAGCAGTG GAATAAGTAT TCATTTAGAA ATGTGAATGA GCAGTAAAC 1908  
 TGATGACATA AAGAAATTAA AAGATATTTA ATTCTTGCTT ATACTCAGTC 1958  
 TATTCGGTAA AATTTTTTTT AAAAAATGTG CATACCTGGA TTTCTTGGC 2008  
 TTCTTTGAGA ATGTAAGACA AATTAAATCT GAATAAATCA TTCTCCCTGT 2058  
 TCACTGGCTC ATTTATTCTC TATGCACTGA GCATTTGCTC TGTGGAAGGC 2108  
 CCTGGGTTAA TAGTGAGAT GCTAAGGTAA GCCAGACTCA CCCCTACCCA 2158  
 CAGGGTAGTA AAGTCTAGGA GCAGCAGTCA TATAATTAAG GTGGAGAGAT 2208  
 GCCCTCTAAG ATGTAGAG 2226

- (2) INFORMATION FOR SEQUENCE ID NO: 17:  
 (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 2305 base pairs  
     (B) TYPE: nucleic acid  
     (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: genomic DNA  
 (ix) FEATURE:  
     (A) NAME/KEY: MAGE-51 gene  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

GGATCCAGGC CTTGCCAGGA GAAAGGTGAG GGCCCTGTGT GAGCACAGAG 50  
 GGGACCATTC ACCCCAAGAG GGTGGAGACC TCACAGATTC CAGCCTACCC 100  
 TCCTGTTAGC ACTGGGGGCC TGAGGCTGTG CTTGCAGTCT GCACCCTGAG 150  
 GGCCCATGCA TTCCTCTTCC AGGAGCTCCA GGAAACAGAC ACTGAGGCCT 200  
 TGGTCTGAGG CCGTGCCCTC AGGTCACAGA GCAGAGGAGA TGCAGACGTC 250  
 TAGTGCCAGC AGTGAACGTT TGCCTTGAAT GCACACTAAT GGCCCCCATC 300  
 GCCCCAGAAC ATATGGGACT CCAGAGCACC TGGCCTCACC CTCTCTACTG 350  
 TCAGTCCTGC AGAATCAGCC TCTGCTTGCT TGTGTACCCT GAGGTGCCCT 400  
 CTCACTTTTT CCTTCAGGTT CTCAGGGGAC AGGCTGACCA GGATCACCAG 450  
 GAAGCTCCAG AGGATCCCCA GGAGGCCCTA GAGGAGCACC AAAGGAGAAG 500  
 ATCTGTAAGT AAGCCTTTGT TAGAGCCTCC AAGGTTCACT TTTTAGCTGA 550  
 GGCTTCTCAC ATGCTCCCTC TCTCTCCAGG CCAGTGGGTC TCCATTGCCC 600  
 AGCTCCTGCC CACACTCCTG CCTGTTGCGG TGACCAGAGT CGTC 644  
 ATG TCT CTT GAG CAG AAG AGT CAG CAC TGC AAG CCT GAG GAA 686  
 GGC CTT GAC ACC CAA GAA GAG CCC TGG GCC TGG TGG GTG TGC 728  
 AGG CTG CCA CTA CTG AGG AGC AGG AGG CTG TGT CCT CCT CCT 770  
 CTC CTC TGG TCC CAG GCA CCC TGG GGG AGG TGC CTG CTG CTG 812  
 GGT CAC CAG GTC CTC TCA AGA GTC CTC AGG GAG CCT CCG CCA 854  
 TCC CCA CTG CCA TCG ATT TCA CTC TAT GGA GGC AAT CCA TTA 896  
 AGG GCT CCA GCA ACC AAG AAG AGG AGG GGC CAA GCA CCT CCC 938  
 CTG ACC CAG AGT CTG TGT TCC GAG CAG CAC TCA GTA AGA AGG 980  
 TGG CTG ACT TGA 992  
 TTCATTTTCT GCTCCTCAAG TATTAAGTCA AGGAGCCGGT CACAAAGGCA 1042  
 GAAATGCTGG AGAGCGTCAT CAAAAATTAC AAGCGCTGCT TTCCTGAGAT 1092  
 CTTCCGGCAA GCCTCCGAGT CCTTGCAGCT GGTCTTTGGC ATTGACGTGA 1142  
 AGGAAGCGGA CCCCACCAGC AACACCTACA CCCTTGTCAC CTGCCTGGGA 1192  
 CTCCTATGAT GGCCTGGTGG TTTAATCAGA TCATGCCCAA GACGGGCCTC 1242  
 CTGATAATCG TCTTGGGCAT GATTGCAATG GAGGGCAAAT GCGTCCCTGA 1292  
 GGAGAAAATC TGGGAGGAGC TGGGTGTGAT GAAGGTGTAT GTTGGGAGGG 1342  
 AGCACAGTGT CTGTGGGGAG CCCAGGAAGC TGCTCACCCA AGATTTGGTG 1392  
 CAGGAAAACCT ACCTGGAGTA CCGCAGGTGC CCAGCAGTGA TCCCATATGC 1442  
 TATGAGTTAC TGTGGGGTCC AAGGGCACTC GCTGCTTGAA AGTACTGGAG 1492  
 CACGTGGTCA GGGTCAATGC AAGAGTTCTC ATTCCTACC CATCCCTGCA 1542  
 TGAAGCAGCT TTGAGAGAGG AGGAAGAGGG AGTCTGAGCA TGAGCTGCAG 1592  
 CCAGGGCCAC TGCGAGGGGG GCTGGGCCAG TGCACCTTCC AGGGCTCCGT 1642  
 CCAGTAGTTT CCCCTGCCTT AATGTGACAT GAGGCCCATT CTTCTCTCTT 1692  
 TGAAGAGAGC AGTCAACATT CTTAGTAGTG GGTTCCTGTT CTATTGGATG 1742  
 ACTTTGAGAT TTGTCTTTGT TTCCTTTTGG AATTGTTCAA ATGTTCCCTT 1792  
 TAATGGGTGG TTGAATGAAC TTCAGCATTC AAATTTATGA ATGACAGTAG 1842  
 TCACACATAG TGCTGTTTAT ATAGTTTAGG AGTAAGAGTC TTGTTTTTTA 1892  
 TTCAGATTGG GAAATCCATT CCATTTTGTG AATTGGGACA TAGTTACAGC 1942  
 AGTGGAATAA GTATTCATTT AGAAATGTGA ATGAGCAGTA AAACCTGATGA 1992  
 GATAAAGAAA TTAAAAGATA TTTAATTCTT GCCTTATACT CAGTCTATTC 2042  
 GGTAAAATTT TTTTTTAAAA ATGTGCATAC CTGGATTTCC TTGGCTTCTT 2092  
 TGAGAATGTA AGACAAATTA AATCTGAATA AATCATTCTC CCTGTTCACT 2142  
 GGCTCATTTA TTCTCTATGC ACTGAGCATT TGCTCTGTGG AAGGCCCTGG 2192  
 GTTAATAGTG GAGATGCTAA GGTAAGCCAG ACTCACCCCT ACCCACAGGG 2242  
 TAGTAAAGTC TAGGAGCAGC AGTCATATAA TTAAGGTGGA GAGATGCCCT 2292  
 CTAAGATGTA GAG 2305



## (2) INFORMATION FOR SEQUENCE ID NO: 18:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 225 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (ix) FEATURE:

(A) NAME/KEY: MAGE-6 gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

TAT	TTC	TTT	CCT	GTG	ATC	TTC	AGC	AAA	GCT	TCC	GAT	TCC	TTG	42
CAG	CTG	GTC	TTT	GGC	ATC	GAG	CTG	ATG	GAA	GTG	GAC	CCC	ATC	84
GGC	CAC	GTG	TAC	ATC	TTT	GCC	ACC	TGC	CTG	GGC	CTC	TCC	TAC	126
GAT	GGC	CTG	CTG	GGT	GAC	AAT	CAG	ATC	ATG	CCC	AGG	ACA	GGC	168
TTC	CTG	ATA	ATC	ATC	CTG	GCC	ATA	ATC	GCA	AGA	GAG	GGC	GAC	210
TGT	GCC	CCT	GAG	GAG										225

009250" 8462560

- (2) INFORMATION FOR SEQUENCE ID NO: 19:  
 (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 1947 base pairs  
     (B) TYPE: nucleic acid  
     (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: genomic DNA  
 (ix) FEATURE:  
     (A) NAME/KEY: *MAGE-7 gene*  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

TGAATGGACA	ACAAGGGCCC	CACACTCCCC	AGAACACAAG	GGACTCCAGA	50
GAGCCCAGCC	TCACCTTCCC	TACTGTCAGT	CCTGCAGCCT	CAGCCTCTGC	100
TGGCCGGCTG	TACCCTGAGG	TGCCCTCTCA	CTTCCTCCTT	CAGGTTCTCA	150
GCGGACAGGC	CGGCCAGGAG	GTCAGAAGCC	CCAGGAGGCC	CCAGAGGAGC	200
ACCGAAGGAG	AAGATCTGTA	AGTAGGCCTT	TGTTAGGGCC	TCCAGGGCGT	250
GGTTCACAAA	TGAGGCCCCCT	CACAAGCTCC	TTCTCTCCCC	AGATCTGTGG	300
GTTCCTCCCC	ATCGCCCAGC	TGCTGCCCGC	ACTCCAGCCT	GCTGCCCTGA	350
CCAGAGTCAT	CATGTCTTCT	GAGCAGAGGA	GTCAGCACTG	CAAGCCTGAG	400
GATGCCTTGA	GGCCCAAGGA	CAGGAGGCTC	TGGGCCTGGT	GGGTGCGCAG	450
GCTCCCGCCA	CCGAGGAGCA	CGAGGCTGCC	TCCTCCTTCA	CTCTGATTGA	500
AGGCACCCTG	GAGGAGGTGC	CTGCTGCTGG	GTCCCCCAGT	CCTCCCCTGA	550
GTCTCAGGGT	TCCTCCTTTT	CCCTGACCAT	CAGCAACAAC	ACTCTATGGA	600
GCCAATCCAG	TGAGGGCACC	AGCAGCCGGG	AAGAGGAGGG	GCCAACCACC	650
TAGACACACC	CCGCTCACCT	GGCGTCCTTG	TTCCA		685
ATG GGA AGG	TGG CTG AGT	TGG TTC GCT	TCC TGC	TGC ACA AGT	727
ATC GAG TCA	AGG AGC TGG	TCA CAA AGG	CAG AAA	TGC TGG ACA	769
GTG TCA TCA	AAA ATT ACA	AGC ACT AGT	TTC CTT	GTG ATC TAT	811
GGC AAA GCC	TCA GAG TGC	ATG CAG GTG	ATG TTT	GGC ATT GAC	853
ATG AAG GAA	GTG GAC CCC	GCG GCC ACT	CCT ACG	TCC TTG TCA	895
CCT GCT TGG	GCC TCT CCT	ACA ATG GCC	TGC TGG	GTG ATG ATC	937
AGA GCA TGC	CCG AGA CCG	GCC TTC TGA			964
TTATGGTCTT	GACCATGATC	TTAATGGAGG	GCCACTGTGC	CCCTGAGGAG	1014
GCAATCTGGG	AAGCGTTGAG	TGTAATGGTG	TATGATGGGA	TGGAGCAGTT	1064
TCTTTGGGCA	GCTGAGGAAG	CTGCTCACCC	AAGATTGGGT	GCAGGAAAAC	1114
TACCTGCAAT	ACCGCCAGGT	GCCCAGCAGT	GATCCCCCGT	GCTACCAGTT	1164
CCTGTGGGGT	CCAAGGGCCC	TCATTGAAAC	CAGCTATGTG	AAAGTCCTGG	1214
AGTATGCAGC	CAGGGTCAGT	ACTAAAGAGA	GCATTTCCCTA	CCCATCCCTG	1264
CATGAAGAGG	CTTTGGGAGA	GGAGGAAGAG	GGAGTCTGAG	CAGAAGTTGC	1314
AGCCAGGGCC	AGTGGGGCAG	ATTGGGGGAG	GGCCTGGGCA	GTGCACGTTT	1364
CACACATCCA	CCACCTTCCC	TGTCCTGTTA	CATGAGGCCC	ATTCTTCACT	1414
CTGTGTTTGA	AGAGAGCAGT	CAATGTTCTC	AGTAGCGGGG	AGTGTGTTGG	1464
GTGTGAGGGA	ATACAAGGTG	GACCATCTCT	CAGTTCCTGT	TCTCTTGGGC	1514
GATTTGGAGG	TTTATCTTTG	TTTCCTTTTG	CAGTCGTTCA	AATGTTCTCT	1564
TTAATGGATG	GTGTAATGAA	CTTCAACATT	CATTTCATGT	ATGACAGTAG	1614
GCAGACTTAC	TGTTTTTTAT	ATAGTTAAAA	GTAAGTGCAT	TGTTTTTTAT	1664
TTATGTAAGA	AAATCTATGT	TATTTCTTGA	ATTGGGACAA	CATAACATAG	1714
CAGAGGATTA	AGTACCTTTT	ATAATGTGAA	AGAACAAGAG	GGTAAAATGG	1764
GTGAGATAAA	GAAATAAAGA	AATTAAATTG	GCTGGGCACG	GTGGCTCACG	1814
CCTGTAATCC	CAGCACTTTA	GGAGGCAGAG	GCACGGGGAT	CACGAGGTCA	1864
GGAGATCGAG	ACCATTCTGG	CTAACACAGT	GAAACACCAT	CTCTATTAAA	1914
AATACAAAAC	TTAGCCGGGC	GTGGTGGCGG	GTG		1947

- (2) INFORMATION FOR SEQUENCE ID NO: 20:  
 (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 1810 base pairs  
     (B) TYPE: nucleic acid  
     (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: genomic DNA  
 (ix) FEATURE:  
     (A) NAME/KEY: MAGE-8 gene  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

GAGCTCCAGG	AACCAGGCTG	TGAGGTCTTG	GTCTGAGGCA	GTATCTTCAA	50
TCACAGAGCA	TAAGAGGCC	AGGCAGTAGT	AGCAGTCAAG	CTGAGGTGGT	100
GTTTTCCCTG	TATGTATACC	AGAGGCCCT	CTGGCATCAG	AACAGCAGGA	150
ACCCACAGT	TCCTGGCCCT	ACCAGCCCTT	TTGTCAGTCC	TGGAGCCTTG	200
GCCTTTGCCA	GGAGGCTGCA	CCCTGAGATG	CCCTCTCAAT	TTCTCCTTCA	250
GGTTCGCAGA	GAACAGGCCA	GCCAGGAGGT	CAGGAGGCC	CAGAGAAGCA	300
CTGAAGAAGA	CCTGTAAGTA	GACCTTTGTT	AGGGCATCCA	GGGTGTAGTA	350
CCCAGCTGAG	GCCTCTCACA	CGCTTCCTCT	CTCCCCAGGC	CTGTGGGTCT	400
CAATTGCCCA	GCTCCGGCCC	ACACTCTCCT	GCTGCCCTGA	CCTGAGTCAT	450
C					451
ATG CTT CTT	GGG CAG AAG	AGT CAG CGC	TAC AAG GCT	GAG GAA	493
GGC CTT CAG	GCC CAA GGA	GAG GCA CCA	GGG CTT ATG	GAT GTG	535
CAG ATT CCC	ACA GCT GAG	GAG CAG AAG	GCT GCA TCC	TCC TCC	577
TCT ACT CTG	ATC ATG GGA	ACC CTT GAG	GTG ACT GAT	TCT	619
GGG TCA CCA	AGT CCT CCC	CAG AGT CCT	GAG GGT GCC	TCC TCT	661
TCC CTG ACT	GTC ACC GAC	AGC ACT CTG	TGG AGC CAA	TCC GAT	703
GAG GGT TCC	AGC AGC AAT	GAA GAG GAG	GGG CCA AGC	ACC TCC	745
CCG GAC CCA	GCT CAC CTG	GAG TCC CTG	TTC CGG GAA	GCA CTT	787
GAT GAG AAA	GTG GCT GAG	TTA GTT CGT	TTC CTG CTC	CGC AAA	829
TAT CAA ATT	AAG GAG CCG	GTC ACA AAG	GCA GAA ATG	CTT GAG	871
AGT GTC ATC	AAA AAT TAC	AAG AAC CAC	TTT CCT GAT	ATC TTC	913
AGC AAA GCC	TCT GAG TGC	ATG CAG GTG	ATC TTT GGC	ATT GAT	955
GTG AAG GAA	GTG GAC CCT	GCC GGC CAC	TCC TAC ATC	CTT GTC	997
ACC TGC CTG	GGC CTC TCC	TAT GAT GGC	CTG CTG GGT	GAT GAT	1039
CAG AGT ACG	CCC AAG ACC	GGC CTC CTG	ATA ATC GTC	CTG GGC	1081
ATG ATC TTA	ATG GAG GGC	AGC CGC GCC	CCG GAG GAG	GCA ATC	1123
TGG GAA GCA	TTG AGT GTG	ATG GGG GCT	GTA TGA		1156
TGGGAGGGAG	CACAGTGTCT	ATTGGAAGCT	CAGGAAGCTG	CTCACCCAAG	1206
AGTGGGTGCA	GGAGAACTAC	CTGGAGTACC	GCCAGGCGCC	CGGCAGTGAT	1256
CCTGTGCGCT	ACGAGTTCCT	GTGGGGTCCA	AGGGCCCTTG	CTGAAACCAG	1306
CTATGTGAAA	GTCCTGGAGC	ATGTGGTCAG	GGTCAATGCA	AGAGTTCGCA	1356
TTTCCTACCC	ATCCCTGTCAT	GAAGAGGCTT	TGGGAGAGGA	GAAAGGAGTT	1406
TGAGCAGGAG	TTGCAGCTAG	GGCCAGTGGG	GCAGGTTGTG	GGAGGGCCTG	1456
GGCCAGTGCA	CGTTCCAGGG	CCACATCCAC	CACCTTCCCT	GCTCTGTTAC	1506
ATGAGGCCCA	TTCTTCACTC	TGTGTTTGAA	GAGAGCAGTC	ACAGTTCTCA	1556
GTAGTGGGGA	GCATGTTGGG	TGTGAGGGAA	CACAGTGTGG	ACCATCTCTC	1606
AGTTCCTGTT	CTATTGGGCG	ATTTGGAGGT	TTATCTTTGT	TTCTTTTGG	1656
AATTGTTCCA	ATGTTCTTTC	TAATGGATGG	TGTAATGAAC	TTCAACATTC	1706
ATTTTATGTA	TGACAGTAGA	CAGACTTACT	GCTTTTATA	TAGTTTAGGA	1756
GTAAGAGTCT	TGCTTTTCAT	TTATACTGGG	AAACCCATGT	TATTTCTTGA	1806
ATTC					1810

009250-4562560

- (2) INFORMATION FOR SEQUENCE ID NO: 21:  
 (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 1412 base pairs  
     (B) TYPE: nucleic acid  
     (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: genomic DNA  
 (ix) FEATURE:  
     (A) NAME/KEY: MAGE-9 gene  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

TCTGAGACAG TGTCCTCAGG TCGCAGAGCA GAGGAGACCC AGGCAGTGTG 50  
 AGCAGTGAAG GTGAAGTGTT CACCCTGAAT GTGCACCAAG GGCCCCACCT 100  
 GCCCCAGCAC ACATGGGACC CCATAGCACC TGGCCCCATT CCCCCTACTG 150  
 TCACTCATAG AGCCTTGATC TCTGCAGGCT AGCTGCACGC TGAGTAGCCC 200  
 TCTCACTTCC TCCCTCAGGT TCTCGGGACA GGCTAACCAG GAGGACAGGA 250  
 GCCCCAAGAG GCCCCAGAGC AGCACTGACG AAGACCTGTA AGTCAGCCTT 300  
 TGTTAGAACC TCCAAGGTTT GGTTCCTCAGC TGAAGTCTCT CACACACTCC 350  
 CTCTCTCCCC AGGCCTGTGG GTCTCCATCG CCCAGCTCCT GCCCAGCTC 400  
 CTGACTGCTG CCCTGACCAG AGTCATC 427  
 ATG TCT CTC GAG CAG AGG AGT CCG CAC TGC AAG CCT GAT GAA 469  
 GAC CTT GAA GCC CAA GGA GAG GAC TTG GGC CTG ATG GGT GCA 511  
 CAG GAA CCC ACA GGC GAG GAG GAG GAG ACT ACC TCC TCC TCT 553  
 GAC AGC AAG GAG GAG GAG GTG TCT GCT GCT GGG TCA TCA AGT 595  
 CCT CCC CAG AGT CCT CAG GGA GGC GCT TCC TCC TCC ATT TCC 637  
 GTC TAC TAC ACT TTA TGG AGC CAA TTC GAT GAG GGC TCC AGC 679  
 AGT CAA GAA GAG GAA GAG CCA AGC TCC TCG GTC GAC CCA GCT 721  
 CAG CTG GAG TTC ATG TTC CAA GAA GCA CTG AAA TTG AAG GTG 763  
 GCT GAG TTG GTT CAT TTC CTG CTC CAC AAA TAT CGA GTC AAG 805  
 GAG CCG GTC ACA AAG GCA GAA ATG CTG GAG AGC GTC ATC AAA 847  
 AAT TAC AAG CGC TAC TTT CCT GTG ATC TTC GGC AAA GCC TCC 889  
 GAG TTC ATG CAG GTG ATC TTT GGC ACT GAT GTG AAG GAG GTG 931  
 GAC CCC GCC GGC CAC TCC TAC ATC CTT GTC ACT GCT CTT GGC 973  
 CTC TCG TGC GAT AGC ATG CTG GGT GAT GGT CAT AGC ATG CCC 1015  
 AAG GCC GCC CTC CTG ATC ATT GTC CTG GGT GTG ATC CTA ACC 1057  
 AAA GAC AAC TGC GCC CCT GAA GAG GTT ATC TGG GAA GCG TTG 1099  
 AGT GTG ATG GGG GTG TAT GTT GGG AAG GAG CAC ATG TTC TAC 1141  
 GGG GAG CCC AGG AAG CTG CTC ACC CAA GAT TGG GTG CAG GAA 1183  
 AAC TAC CTG GAG TAC CGG CAG GTG CCC GGC AGT GAT CCT GCG 1225  
 CAC TAC GAG TTC CTG TGG GGT TCC AAG GCC CAC GCT GAA ACC 1267  
 AGC TAT GAG AAG GTC ATA AAT TAT TTG GTC ATG CTC AAT GCA 1309  
 AGA GAG CCC ATC TGC TAC CCA TCC CTT TAT GAA GAG GTT TTG 1351  
 GGA GAG GAG CAA GAG GGA GTC TGA 1375  
 GCACCAGCCG CAGCCGGGGC CAAAGTTTGT GGGGTCA 1412

009250" E4562650

## (2) INFORMATION FOR SEQUENCE ID NO: 22:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 920 base pairs

(B) TYPE: nucleic acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: genomic DNA

## (ix) FEATURE:

(A) NAME/KEY: MAGE-10 gene

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

ACCTGCTCCA	GGACAAAGTG	GACCCCACTG	CATCAGCTCC	ACCTACCCTA	50
CTGTCACTCC	TGGAGCCTTG	GCCTCTGCCG	GCTGCATCCT	GAGGAGCCAT	100
CTCTCACTTC	CTTCTTCAGG	TTCTCAGGGG	ACAGGGAGAG	CAAGAGGTCA	150
AGAGCTGTGG	GACACCACAG	AGCAGCACTG	AAGGAGAAGA	CCTGTAAGTT	200
GGCCTTTGTT	AGAACCTCCA	GGGTGTGGTT	CTCAGCTGTG	GCCACTTACA	250
CCCTCCCTCT	CTCCCCAGGC	CTGTGGGTCC	CCATCGCCCA	AGTCCTGCCC	300
ACACTCCCAC	CTGCTACCCT	GATCAGAGTC	ATC		333
ATG CCT CGA	GCT CCA AAG	CGT CAG CGC	TGC ATG CCT	GAA GAA	375
GAT CTT CAA	TCC CAA AGT	GAG ACA CAG	GGC CTC GAG	GGT GCA	417
CAG GCT CCC	CTG GCT GTG	GAG GAG GAT	GCT TCA TCA	TCC ACT	459
TCC ACC AGC	TCC TCT TTT	CCA TCC TCT	TTT CCC TCC	TCC TCC	501
TCT TCC TCC	TCC TCC TGC	TAT CCT CTA	ATA CCA AGC	ACC	543
CCA GAG GAG	GTT TCT GCT	GAT GAT GAG	ACA CCA AAT	CCT CCC	585
CAG AGT GCT	CAG ATA GCC	TGC TCC TCC	CCC TCG GTC	GTT GCT	627
TCC CTT CCA	TTA GAT CAA	TCT GAT GAG	GGC TCC AGC	AGC CAA	669
AAG GAG GAG	AGT CCA AGC	ACC CTA CAG	GTC CTG CCA	GAC AGT	711
GAG TCT TTA	CCC AGA AGT	GAG ATA GAT	GAA AAG GTG	ACT GAT	753
TTG GTG CAG	TTT CTG CTC	TTC AAG TAT	CAA ATG AAG	GAG CCG	795
ATC ACA AAG	GCA GAA ATA	CTG GAG AGT	GTC ATA AAA	AAT TAT	837
GAA GAC CAC	TTC CCT TTG	TTG TTT AGT	GAA GCC TCC	GAG TGC	879
ATG CTG CTG	GTC TTT GGC	ATT GAT GTA	AAG GAA GTG	GAT CC	920

- (2) INFORMATION FOR SEQUENCE ID NO: 23:
- (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 1107 base pairs
    - (B) TYPE: nucleic acid
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: genomic DNA
  - (ix) FEATURE:
    - (A) NAME/KEY: MAGE-11 gene
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

AGAGAACAGG	CCAACCTGGA	GGACAGGAGT	CCCAGGAGAA	CCCAGAGGAT	50
CACTGGAGGA	GAACAAGTGT	AAGTAGGCCT	TTGTTAGATT	CTCCATGGTT	100
CATATCTCAT	CTGAGTCTGT	TCTCACGCTC	CCTCTCTCCC	CAGGCTGTGG	150
GGCCCCATCA	CCCAGATATT	TCCCACAGTT	CGGCCTGCTG	ACCTAACCAG	200
AGTCATCATG	CCTCTTGAGC	AAAGAAGTCA	GCACTGCAAG	CCTGAGGAAG	250
CCTTCAGGCC	CAAGAAGAAG	ACCTGGGCCT	GGTGGGTGCA	CAGGCTCTCC	300
AAGCTGAGGA	GCAGGAGGCT	GCCTTCTTCT	CCTCTACTCT	GAATGTGGGC	350
ACTCTAGAGG	AGTTGCCTGC	TGCTGAGTCA	CCAAGTCCTC	CCCAGAGTCC	400
TCAGGAAGAG	TCCTTCTCTC	CCACTGCCAT	GGATGCCATC	TTTGGGAGCC	450
TATCTGATGA	GGGCTCTGGC	AGCCAAGAAA	AGGAGGGGCC	AAGTACCTCG	500
CCTGACCTGA	TAGACCCTGA	GTCCTTTTCC	CAAGATATAC	TACATGACAA	550
GATAATTGAT	TTGGTTCATT	TATTCTCCGC	AAGTATCGAG	TCAAGGGGCT	600
GATCACAAAG	GCAGAA				616
ATG CTG GGG	AGT GTC ATC	AAA AAT TAT	GAG GAC TAC	TTT CCT	658
GAG ATA TTT	AGG GAA GCC	TCT GTA TGC	ATG CAA CTG	CTC TTT	700
GGC ATT GAT	GTG AAG GAA	GTG GAC CCC	ACT AGC CAC	TCC TAT	742
GTC CTT GTC	ACC TCC CTC	AAC CTC TCT	TAT GAT GGC	ATA CAG	784
TGT AAT GAG	CAG AGC ATG	CCC AAG TCT	GGC CTC CTG	ATA ATA	826
GTC CTG GGT	GTA ATC TTC	ATG GAG GGG	AAC TGC ATC	CCT GAA	868
GAG GTT ATG	TGG GAA GTC	CTG AGC ATT	ATG GGG GTG	TAT GCT	910
GGA AGG GAG	CAC TTC CTC	TTT GGG GAG	CCC AAG AGG	CTC CTT	952
ACC CAA AAT	TGG GTG CAG	GAA AAG TAC	CTG GTG TAC	CGG CAG	994
GTG CCC GGC	ACT GAT CCT	GCA TGC TAT	GAG TTC CTG	TGG GGT	1036
CCA AGG GCC	CAC GCT GAG	ACC AGC AAG	ATG AAA GTT	CTT GAG	1078
TAC ATA GCC	AAT GCC AAT	GGG AGG GAT	CC		1107

009250 "E4562560

- (2) INFORMATION FOR SEQUENCE ID NO: 24:  
 (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 2150 base pairs  
     (B) TYPE: nucleic acid  
     (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: genomic DNA  
 (ix) FEATURE:  
     (A) NAME/KEY: smage-I  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

TCTGTCTGCA TATGCCTCCA CTTGTGTGTA GCAGTCTCAA ATGGATCTCT 50  
 CTCTACAGAC CTCTGTCTGT GTCTGGCACC CTAAGTGGCT TTGCATGGGC 100  
 ACAGGTTTCT GCCCCTGCAT GGAGCTTAAA TAGATCTTTC TCCACAGGCC 150  
 TATACCCCTG CATTGTAAGT TTAAGTGGCT TTATGTGGAT ACAGGTCTCT 200  
 GCCCTTGTAT GCAGGCCTAA GTTTTCTGT CTGCTTAACC CCTCCAAGTG 250  
 AAGCTAGTGA AAGATCTAAC CCACTTTTGG AAGTCTGAAA CTAGACTTTT 300  
 ATGCAGTGGC CTAACAAGTT TTAATTTCTT CCACAGGGTT TGCAGAAAAG 350  
 AGCTTGATCC ACGAGTTCAG AAGTCCTGGT ATGTTCTTAG AAAG 394  
 ATG TTC TCC TGG AAA GCT TCA AAA GCC AGG TCT CCA TTA AGT 436  
 CCA AGG TAT TCT CTA CCT GGT AGT ACA GAG GTA CTT ACA GGT 478  
 TGT CAT TCT TAT CCT TCC AGA TTC CTG TCT GCC AGC TCT TTT 520  
 ACT TCA GCC CTG AGC ACA GTC AAC ATG CCT AGG GGT CAA AAG 565  
 AGT AAG ACC CGC TCC CGT GCA AAA CGA CAG CAG TCA CGC AGG 604  
 GAG GTT CCA GTA GTT CAG CCC ACT GCA GAG GAA GCA GGG TCT 646  
 TCT CCT GTT GAC CAG AGT GCT GGG TCC AGC TTC CCT GGT GGT 688  
 TCT GCT CCT CAG GGT GTG AAA ACC CCT GGA TCT TTT GGT GCA 730  
 GGT GTA TCC TGC ACA GGC TCT GGT ATA GGT GGT AGA AAT GCT 772  
 GCT GTC CTG CCT GAT ACA AAA AGT TCA GAT GGC ACC CAG GCA 814  
 GGG ACT TCC ATT CAG CAC ACA CTG AAA GAT CCT ATC ATG AGG 856  
 AAG GCT AGT GTG CTG ATA GAA TTC CTG CTA GAT AAA TTT AAG 898  
 ATG AAA GAA GCA GTT ACA AGG AGT GAA ATG CTG GCA GTA GTT 940  
 AAC AAG AAG TAT AAG GAG CAA TTC CCT GAG ATC CTC AGG AGA 982  
 ACT TCT GCA CGC CTA GAA TTA GTC TTT GGT CTT GAG TTG AAG 1024  
 GAA ATT GAT CCC AGC ACT CAT TCC TAT TTG CTG GTA GGC AAA 1066  
 CTG GGT CTT TCC ACT GAG GGA AGT TTG AGT AGT AAC TGG GGG 1108  
 TTG CCT AGG ACA GGT CTC CTA ATG TCT GTC CTA GGT GTG ATC 1150  
 TTC ATG AAG GGT AAC CGT GCC ACT GAG CAA GAG GTC TGG CAA 1192  
 TTT CTG CAT GGA GTG GGG GTA TAT GCT GGG AAG AAG CAC TTG 1234  
 ATC TTT GGC GAG CCT GAG GAG TTT ATA AGA GAT GTA GTG CGG 1276  
 GAA AAT TAC CTG GAG TAC CGC CAG GTA CCT GGC AGT GAT CCC 1314  
 CCA AGC TAT GAG TTC CTG TGG GGA CCC AGA GCC CAT GCT GAA 1360  
 ACA ACC AAG ATG AAA GTC CTG GAA GTT TTA GCT AAA GTC AAT 1402  
 GGC ACA GTC CCT AGT GCC TTC CCT AAT CTC TAC CAG TTG GCT 1444  
 CTT AGA GAT CAG GCA GGA GGG GTG CCA AGA AGG AGA GTT CAA 1486  
 GGC AAG GGT GTT CAT TCC AAG GCC CCA TCC CAA AAG TCC TCT 1528  
 AAC ATG TAG 1537  
 TTGAGTCTGT TCTGTTGTGT TTGAAAAACA GTCAGGCTCC TAATCAGTAG 1587  
 AGAGTTCATA GCCTACCAGA ACCAACATGC ATCCATTCTT GGCCTGTTAT 1637  
 ACATTAGTAG AATGGAGGCT ATTTTGTGTTA CTTTTCAAAT GTTTGTTTAA 1687  
 CTAAACAGTG CTTT'TTGCCA TGCTTCTTGT TAACTGCATA AAGAGGTAAC 1737  
 TGTCAC TTGT CAGATTAGGA CTTGTTTGT TATTTGCAAC AAAGTGGAAA 1787  
 ACATTATTTT GTTTTACTA AAACATTGTG TAACATTGCA TTGGAGAAGG 1837  
 GATTGTCATG GCAATGTGAT ATCATA CAGT GGTGAAACAA CAGTGAAGTG 1887  
 GGAAAGTTTA TATTGTTAAT TTTGAAAATT TTATGAGTGT GATTGCTGTA 1937  
 TACTTTTTTC TTTTTGTAT AATGCTAAGT GAAATAAAGT TGGATTTGAT 1987  
 GACTTTACTC AAATTCATTA GAAAGTAAAT CGTAAACTC TATTACTTTA 2037  
 TTATTTTCTT CAATTATGAA TTAAGCATTG GTTATCTGGA AGTTTCTCCA 2087  
 GTAGCACAGG ATCTAGTATG AAATGTATCT AGTATAGGCA CTGACAGTGA 2137  
 GTTATCAGAG TCT 2150

- (2) INFORMATION FOR SEQUENCE ID NO: 25:  
 (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 2099 base pairs  
     (B) TYPE: nucleic acid  
     (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: genomic DNA  
 (ix) FEATURE:  
     (A) NAME/KEY: smage-II  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

ACCTTATTGG	GTCTGTCTGC	ATATGCCTCC	ACTTGTGTGT	AGCAGTCTCA	50
AATGGATCTC	TCTCTACAGA	CCTCTGTCTG	TGTCTGGCAC	CCTAAGTGGC	100
TTTGCATGGG	CACAGGTTTC	TGCCCCTGCA	TGGAGCTTAA	ATAGATCTTT	150
CTCCACAGGC	CTATACCCCT	GCATTGTAAG	TTTAAGTGGC	TTTATGTGGA	200
TACAGGTCTC	TGCCCTTGTA	TGCAGGCCTA	AGTTTTTCTG	TCTGCTTAGC	250
CCCTCCAAGT	GAAGCTAGTG	AAAGATCTAA	CCCACTTTTG	GAAGTCTGAA	300
ACTAGACTTT	TATGCAGTGG	CCTAACAAGT	TTTAATTTCT	TCCACAGGGT	350
TTGCAGAAAA	GAGCTTGATC	CACGAGTTCG	GAAGTCCTGG	TATGTTCCCTA	400
GAAAGATGTT	CTCCTGGAAA	GCTTCAAAAAG	CCAGGTCTCC	ATTAAGTCCA	450
AGGTATTCTC	TACCTGGTAG	TACAGAGGTA	CTTACAGGTT	GTCATTCTTA	500
TCTTTCCAGA	TTCTGTCTG	CCAGCTCTTT	TACTTCAGCC	CTGAGCACAG	550
TCAACATGCC	TAGGGGTCAA	AAGAGTAAGA	CCCGCTCCCG	TGCAAAACGA	600
CAGCAGTCAC	GCAGGGAGGT	TCCAGTAGTT	CAGCCCACTG	CAGAGGAAGC	650
AGGGTCTTCT	CCTGTTGACC	AGAGTGCTGG	GTCCAGCTTC	CCTGGTGGTT	700
CTGCTCCTCA	GGGTGTGAAA	ACCCCTGGAT	CTTTTGGTGC	AGGTGTATCC	750
TGCACAGGCT	CTGGTATAGG	TGGTAGAAAT	GCTGCTGTCC	TGCCTGATAC	800
AAAAAGTTCA	GATGGCACCC	AGGCAGGGAC	TTCCATTGAG	CACACACTGA	850
AAGATCCTAT	CATGAGGAAG	GCTAGTGTGC	TGATAGAATT	CCTGCTAGAT	900
AAGTTTAAAG	TGAAAGAAGC	AGTTACAAGG	AGTGAAATGC	TGGCAGTAGT	950
TAACAAGAAG	TATAAGGAGC	AATTCCCTGA	GATCCTCAGG	AGAACTTCTG	1000
CACGCCTAGA	ATTAGTCTTT	GGTCTTGAGT	TGAAGGAAAT	TGATCCCAGC	1050
ACTCATTCCT	ATTTGCTGGT	AGGCAAACTG	GGTCTTTCCA	CTGAGGGAAG	1100
TTTGAGTAGT	AACTGGGGGT	TGCCTAGGAC	AGGTCTCCTA	ATGTCTGTCC	1150
TAGGTGTGAT	CTTCATGAAG	GGTAACCGTG	CCACTGAGCA	AGAGGTCTGG	1200
CAATTTCTGC	ATGGAGTGGG	GGTATATGCT	GGGAAGAAGC	ACTTGATCTT	1250
TGGCGAGCCT	GAGGAGTTTA	TAAGAGATGT	AGTGCGGGAA	AATTACCTGG	1300
AGTACCGCCA	GGTACCTGGC	AGTGATCCCC	CAAGCTATGA	GTTCTGTGG	1350
GGACCCAGAG	CCCATGCTGA	AACAACCAAG	ATGAAAGTCC	TGGAAGTTTT	1400
AGCTAAAGTC	AATGGCACAG	TCCCTAGTGC	CTTCCCTAAT	CTCTACCAGT	1450
TGGCTCTTAG	AGATCAGGCA	GGAGGGGTGC	CAAGAAGGAG	AGTTCAAGGC	1500
AAGGGTGTTC	ATTCCAAGGC	CCCATCCCAA	AAGTCCTCTA	ACATGTAGTT	1550
GAGTCTGTTT	TGTTGTGTTT	GAAAAACAGT	CAGGCTCCTA	ATCAGTAGAG	1600
AGTTCATAGC	CTACCAGAAC	CAACATGCAT	CCATTCTTGG	CCTGTTATAC	1650
ATTAGTAGAA	TGGAGGCTAT	TTTTGTGTTT	TTTCAAATGT	TTGTTTAACT	1700
AAACAGTGCT	TTTTGCCATG	CTTCTTGTTA	ACTGCATAAA	GAGGTAAGTG	1750
TCACCTTGTC	GATTAGGACT	TGTTTGTGTT	TTTGCAACAA	ACTGGAAAAC	1800
ATTATTTTGT	TTTTACTAAA	ACATTGTGTA	ACATTGCATT	GGAGAAGGGA	1850
TTGTCATGGC	AATGTGATAT	CATACAGTGG	TGAAACAACA	GTGAAGTGGG	1900
AAAGTTTATA	TTGTTAGTTT	TGAAAATTTT	ATGAGTGTGA	TTGCTGTATA	1950
CTTTTTTCTT	TTTTGTATAA	TGCTAAGTGA	AATAAAGTTG	GATTTGATGA	2000
CTTTACTCAA	ATTCAATTAGA	AAGTAAATCA	TAAAACCTCTA	TTACTTTTATT	2050
ATTTTCTTCA	ATTATTAATT	AAGCATTGGT	TATCTGGAAG	TTTCTCCAG	2099





**We claim:**

1. Isolated nucleic acid molecule which codes for or is complementary to a nucleic acid molecule which codes for tumor rejection antigen precursor MAGE-3.
2. The isolated nucleic acid molecule of claim 1, which codes for tumor rejection antigen precursor MAGE-3.
3. The nucleic acid molecule of claim 2, wherein said molecule is cDNA.
4. The nucleic acid molecule of claim 3, wherein said molecule has the nucleotide sequence set forth in SEQ ID NO: 1 (MAGE-3) or SEQ ID NO: 2 (MAGE-31).
5. Expression vector comprising the nucleic acid molecule of claim 2 operably linked to a promoter.
6. The expression vector of claim 5, further comprising a nucleic acid molecule which codes for HLA-A1.
7. Cell line transfected with the nucleic acid molecule of claim 2.
8. The cell line of claim 7, wherein said cell line expresses HLA-A1.
9. The cell line of claim 7, wherein said cell line is further transfected with a nucleic acid molecule which codes for HLA-A1.
10. Isolated tumor rejection antigen precursor coded for by the nucleic acid molecule of claim 2.
11. Vaccine comprising the isolated tumor rejection antigen precursor of claim 10 and an adjuvant.

12. Isolated tumor rejection antigen derived from the tumor rejection antigen precursor of claim 10, wherein said tumor rejection antigen is antigen D.
- 5 13. Isolated complex of the tumor rejection antigen of claim 12 and HLA-A1.
- 10 14. Method for treating a disorder characterized by expression of tumor rejection antigen precursor MAGE-3, comprising administering to a subject an amount of a cytolytic T cell specific for complexes of a tumor rejection antigen derived from MAGE-3 and a human leukocyte antigen molecule, sufficient to generate an immune response against said complexes.
- 15 15. The method of claim 14, wherein said human leukocyte antigen is HLA-A1.
- 20 16. The method of claim 15, wherein said tumor rejection antigen is antigen D.
- 25 17. Method for treating a disorder characterized by expression of tumor rejection antigen precursor MAGE-3, comprising administering an agent sufficient to provoke an immune response to complexes of a tumor rejection antigen derived from MAGE-3 and a human leukocyte antigen, to a subject in need thereof.
- 30 18. The method of claim 17, wherein said human leukocyte antigen is HLA-A1.
- 35 19. The method of claim 18, wherein said tumor rejection antigen is antigen D.
20. Method for determining a disorder characterized by expression of tumor rejection antigen precursor MAGE-3, comprising contacting a sample taken from a subject with an agent which identifies said tumor rejection antigen

precursor to determine expression of said tumor rejection antigen precursor as a determination of said disorder.

21. Method for determining a disorder characterized by expression of tumor rejection antigen precursor MAGE-3 and presentation of a tumor rejection antigen derived therefrom by a cell, comprising contacting a sample taken with a subject with an agent which identifies said tumor rejection antigen to determine said tumor rejection antigen as a determination of said disorder.

009250" E4967660

5

The invention relates to nucleic acid molecules which code for the tumor rejection antigen precursor MAGE-3. Also disclosed are vectors, cell lines, and so forth, which utilize the nucleic acid molecule, and optionally, molecules coding for human leukocyte antigen HLA-A1. Uses of these materials in therapeutic and diagnostic contexts are also a part of the invention.

009250" E4552550

FIG. 1A





FIG. 1B



09579343.052500

# FIG. 2







FIG. 3



009250-44562560

# FIG. 4






FIG. 5





009250" E4662560

FIG. 6



# FIG. 7



# FIG. 8

AAGTCTCTCT  
 AAGTCTCTCT  
 AAGTCTCTCT  
 ,  
 UCCCTCCCC  
 AtGTTCCCC  
 UCCCTCTGG  
 TTACACAAAA  
 TTACACAAAA  
 TTACACAAAA  
 CATCGAGG  
 CATCGAGG  
 CATTGAC  
 CCCAAGG  
 CCCAAGA  
 CCCAAGA

09579543-053600




FIG. 10

# FIG. 11

Expression of  
antigen MZ2-E  
after transfection\*\*

		EXPRESSION OF MAGE GENE FAMILY				RECOGNITION BY ANI-E CTL		
		Northern blot probed with cross-reactive MAGE-1 probe*	cDNA-PCR product probed with oligonucleotide specific for:			tested by:		
			MAGE-1	MAGE-2	MAGE-3†	TNF release‡	Lysis§	
Cells of patient MZ2	melanoma cell line MZ2-MEL3.0	+	++++	++++	++++	+	+	
	tumor sample MZ2 (1982)	+	+++	+++	+++			
	antigen-loss variant MZ2-MEL2.2	+	-	+++	+++	-	-	
	CTL clone MZ2-CTL82/30	-	-	-	-			
	PHA-activated blood lymphocytes	-	-	-	-			
Normal tissues	Liver	-	-	-	-			
	Muscle	-	-	-	-			
	Skin	-	-	-	-			
	Lung	-	-	-	-			
	Brain	-	-	-	-			
	Kidney	-	-	-	-			
Melanoma cell lines of HLA-A1 patients	LB34-MEL	+	++	++++	++++	+	+-	
	M6652-MEL	-	-	-	-	-	-	+
	M110221-MEL	+	-	++	+++	-	-	+
	M113443-MEL	+	+++	++++	++++	+	+	
	SK33-MEL	+	-	++++	++++	-	-	-
	SK23-MEL	+	-	++++	++++	-	-	+
Melanoma cell lines of other patients	LB17-MEL	+	+	++++	++++	-	-	-
	LB33-MEL	+	-	+++	+++	-	-	-
	LB4-MEL	-	-	-	-	-	-	
	LB41-MEL	-	-	-	-	-	-	
	M4024-MEL	+	+++	++++	++++	-	-	
	SK29-MEL	-	-	-	-	-	-	
	MZ3-MEL	+	+	++++	++++	-	-	
	MZ5-MEL	+	-	++++	++++	-	-	
Melanoma tumor sample	B85-MEL	+	+++	++	+++			
Other tumor cell lines	small cell lung cancer H209	+	-	++++	++++			
	small cell lung cancer H345	+	-	++++	++++			
	small cell lung cancer H510	+	-	++++	++++			
	small cell lung cancer LB11	+	+	++++	++++			
	bronchial squamous cell carcinoma LB37	+	-	-	+++			
	thyroid medullary carcinoma TT	+	++++	+++	++++			
	colon carcinoma LB31	+	-	+++	++++	-		
	colon carcinoma LS411	-	-	-	-			
Other tumor samples	chronic myeloid leukemia LLC5	-	-	-	-			
	acute myeloid leukemia TA	-	-	-	-			

\* Data obtained in the conditions of figure 5.

† Data obtained as described in figure 6.

‡ TNF release by CTL 82/30 after stimulation with the tumor cells as described in (11).

§ Lysis of 51 Cr labelled target by CTL 82/30 in the conditions of figure 1.

\*\* Cells transfected with the 2.4 kb fragment of gene MAGE-1 were tested for their ability to stimulate TNF release by CTL 82/30

009250" 54562560



FIG. 12





FIG. 13



009250" 64552560




Fig. 14

009250" 54562560




Fig. 15

009250-ET562560




Fig. 16

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My resident, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled ISOLATED NUCLEIC ACID MOLECULES CODING FOR TUMOR REJECTION ANTIGEN PRECURSOR MAGE-3 AND USES THEREOF, the specification of which

( ) is attached hereto.

(X) was filed on March 26, 1993 as Application Serial No. 08/037,230 and was amended on (1) \_\_\_\_\_, (2) \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56(a).

Foreign Priority Applications

I hereby claim foreign priority benefits under Title 35, United States Code §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Priority Claimed

<u>(Number)</u>	<u>(Country)</u>	<u>(Day/Month/Year Filed)</u>	<u>Yes ( ) No ( )</u>
-----------------	------------------	-------------------------------	-----------------------

U.S. Priority Applications

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulation, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

<u>PCT/US92/04354</u> (Applic. Serial No.)	<u>May 22, 1992</u> (Filing Date)	<u>Pending</u> (Status-patented/pending/abandoned)
<u>07/807,043</u> (Applic. Serial No.)	<u>December 12, 1991</u> (Filing Date)	<u>Pending</u> (Status-patented/pending/abandoned)

<u>07/764,364</u>	<u>September 23, 1991</u>	<u>Pending</u>
(Applic. Serial No.)	(Filing Date)	(Status-patented/pending/abandoned)
<u>07/728,838</u>	<u>July 9, 1991</u>	<u>Pending</u>
(Applic. Serial No.)	(Filing Date)	(Status-patented/pending/abandoned)
<u>07/705,702</u>	<u>May 23, 1991</u>	<u>Pending</u>
(Applic. Serial No.)	(Filing Date)	(Status-patented/pending/abandoned)


Power of Attorney

I hereby appoint the following attorneys to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: John E. Lynch, Reg. No. 20,940; Peter F. Felfe, Reg. No. 20,297; Alfred H. Hemingway, Jr., Reg. No. 26,736; Vincent M. Fazzari, Reg. No. 26,879; Frederick H. Rabin, Reg. No. 24,488; Hallie R. Levie, Reg. No. 31,116; Charles A. Blank, Reg. No. 17,419; Norman D. Hanson, Reg. No. 30,946; Walter G. Weissenberger, Reg. No. 17,344; F. Brice Faller, Reg. No. 29,532; Andrew L. Tiajoloff, Reg. No. 31,575; John P. Luther, Reg. No. 32,261; Christine H. Tsai, Reg. No. 34,266 and John A. Bauer, Reg. No. 32,554, my attorneys with full power of substitution and revocation. Address all telephone calls to Norman D. Hanson, Esq., at (212) 688-9200. Address all correspondence to:

FELFE & LYNCH  
805 Third Avenue  
New York, New York 10022

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(1) <sup>au</sup> Béatrice Guagler  
Full Name/Sole or First Inventor

  
Signature

7 april 93  
Date

Residence: Avenue Hippocrate 74, UCL 7459  
1200 Brussels, Belgium

French Belgian  
Citizenship

Post Office Address: Avenue Hippocrate 74, UCL 7459  
1200 Brussels, Belgium

(2) Benoit Van den Eynde  
Full Name/Second Inventor

*Benoit Eynde*

Signature

7 April 93  
Date

Residence: Avenue Hippocrate 74, UCL 7459  
1200 Brussels, Belgium

Belgian  
Citizenship

Post Office Address: Avenue Hippocrate 74, UCL 7459  
1200 Brussels, Belgium

(3) Pierre van <sup>der</sup> Bruggen  
Full Name/Third Inventor

*Pierre Bruggen*

Signature

19 April 93  
Date

Residence: Avenue Hippocrate 74, UCL 7459  
1200 Brussels, Belgium

Belgian  
Citizenship

Post Office Address: Avenue Hippocrate 74, UCL 7459  
1200 Brussels, Belgium

(4) Thierry Boon-Falleur  
Full Name/Fourth Inventor

*Thierry Boon-Falleur*

Signature

7 April 93  
Date

Residence: Avenue Hippocrate 74, UCL 7459  
1200 Brussels, Belgium

Belgian  
Citizenship

Post Office Address: Avenue Hippocrate 74, UCL 7459  
1200 Brussels, Belgium



VIA EXPRESS MAIL

"Express Mail" mailing label Number EL227321857US

Date of Deposit May 26, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under CFR 1.10 on the date indicated above, and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

FULBRIGHT & JAWORSKI L.L.P.

By: *Denise Jones*

LUD 5353.5 DIV (10016355)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Boon, et al

Serial No. : TO BE ASSIGNED

Filed : HEREWITH

For : Isolated Nucleic Acid Molecules Coding For Tumor Rejection Antigen Precursor Mage-2 And Uses Thereof

Group Art Unit : NOT YET ASSIGNED

Examiner : NOT YET ASSIGNED

May 26, 2000

Hon. Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

LETTER RE CHANGE IN ATTORNEYS ADDRESS

Sir:

The USPTO is asked to correct the mailing address in the above referenced applicaiton.

The attorneys of record in this application are:

FULBRIGHT & JAWORSKI LLP


666 Fifth Avenue  
New York, New York 10103  
Attn: Norman D. Hanson

The telephone number is 212-318-3000, and the facsimile number is 212-318-3400.

Respectfully submitted,

FULBRIGHT & JAWORSKI L.L.P.

By

A handwritten signature in black ink, appearing to read "Norman D. Hanson", written over a horizontal line.

Norman D. Hanson

Reg. No. 30,946

666 Fifth Avenue  
New York, New York 10103  
(212) 318-3000

009250" E-4562560